These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results 2004-000025-29 A randomized, double-blind, placebo-controlled, parallel group, multi-center, multiple dose (7 days) dose-ranging study, to assess the efficacy and safety of 4 doses of QAB149 (50, 100, 200 & 400 µg)... bad-data
Completed, but no date, and reported results 2004-000113-18 A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2000 mg/d as adjunctive therapy to an atypical antipsychotic in... bad-data
Reported results 2004-000114-40 A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2000 mg/d as adjunctive therapy to lithium or valproate in the ... 2007-06-29 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-000185-12 A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo in patients with Parkinson's disease 2008-11-11 bad-data
Reported results 2004-000186-35 A randomized, double blind, active controlled, parallel group study to evaluate the effectiveness of valsartan 320 mg in combination with lisinopril 20 mg versus monotherapy with lisinopril 40 mg or v... 2007-05-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-000240-25 An 8 week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hy... 2005-06-27 bad-data
Reported results 2004-000248-25 A multinational, multicenter, randomized, double-blind, double-dummy, stratified, active controlled parallel group study comparing the efficacy and safety of intravenous zoledronic acid, 5 mg once yea... 2007-04-04 due-trials
Completed, but no date, and reported results 2004-000376-14 A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY TO COMPARE THE EFFECT OF 52 WEEKS TREATMENT WITH LAF237 50 MG BID TO METFORMIN UP TO 1000 MG BID IN DRUG NAIVE PATIENTS WITH TYPE 2 DIA... bad-data
Reported results 2004-000539-27 A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg qd to Placebo in Drug-Naïve Patients with Type 2 Diabetes and Mild Hyperglyc... 2007-07-11 due-trials
Reported results 2004-000540-24 A multicenter, double-blind, randomized, active controlled study to compare the effect of long term treatment with LAF237 50 mg bid to gliclazide up to 320 mg daily in drug naïve patients with type 2 ... 2008-04-17 due-trials
Completed, but no date, and reported results 2004-000541-38 A Six-month, Multicenter, Randomized, Open-label Study of the Safety, Tolerability and Efficacy of Two Neoral Doses in addition to Certican 61668; and Steroids in de novo Heart Transplant Recipients. bad-data
Listed as ongoing, but also has a completion date and reported results 2004-000542-20 A Multicenter, Double-Blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily as Add-On Therapy in Patients with T... 2009-03-02 bad-data
Reported results 2004-000587-26 A 24-month Extension to a one-year, multicentre, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral and steroids v... 2005-09-17 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-000597-31 A one year open label, non comparative extension to a randomised, multicentre, phase II study to evaluate the asfety, tolerability, pharmacokinetics and effects on iron concentration of repeated doses... 2009-07-31 bad-data
Reported results 2004-000638-35 A 2-year randomized, multicenter, double-blind, placebocontrolled study to determine the efficacy and safety of intravenous zoledronic acid 5 mg administered either annually at randomization and 12 mo... 2008-01-23 due-trials
Ongoing, reported early 2004-000655-41 A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients maintaine... not-yet-due
Ongoing, reported early 2004-000664-27 A 34 week, open label, single cohort, exploratory study to evaluate the effect of FTY720 on chronic Hepatitis C in patients who are non-responsive to, or intolerant of Interferon-based antiviral thera... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2004-000671-34 A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/5 mg or 160/10 mg versus valsartan ... 2005-06-27 bad-data
Reported results 2004-000677-62 A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/10 mg versus amlodipine 10 mg alo... 2005-06-28 due-trials
Completed, but no date 2004-000686-35 A 52-week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2000 mg/d in the treatment of manic episodes of bipolar I disorder bad-data
Ongoing 2004-000687-27 A 52-week, opem- label extension study to evaluate the sahety and tolerability of licarbazepine 750-2500 mg/d in the treatment of manic episodes of bipolar I disorder not-yet-due
Reported results 2004-000701-21 A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to letrozole Femara as preoperative therapy of primary breast cancer in postmenopaus... 2007-11-15 due-trials
Completed, but no date 2004-000782-35 EVALUATION OF THE QUALITY OF LIFE AND GASTROINTESTINAL SYMPTOMS AFTER CONVERSION TO MYFORTIC (ERL080) and CELLCEPT WITHDRAWAL IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS TREATED WITH TACROLIMUS. bad-data
Not reported 2004-000829-30 Project on the promotion of cardiovascular risk evaluation in clinical practice and the assessment of cardiovascular risk evolution after the introduction of a preventive multifactorial strategy aimed... 2007-07-24 due-trials
Reported results 2004-000849-38 A Phase 3, randomized, double-blind, placebo-controlled multi-center study of RAD001 in combination with letrozole (Femara®) to investigate the value of adding RAD001 to letrozole as a first-line ther... 2011-03-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-000895-16 A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of aliskiren on proteinuria when added to standardized losartan therapy and optimal antihypert... 2007-04-04 bad-data
Reported results 2004-000940-26 A 22-week randomized, multicenter, parallel-group, double-blind study to compare a pimecrolimus 1 % (Elidel) twice daily (b.i.d.) maintenance dosing regimen to a once daily (o.d.) maintenance dosing r... 2005-10-14 due-trials
Reported results 2004-001036-23 A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the safety and efficacy of Elid... 2005-07-18 due-trials
Reported results 2004-001052-36 A 12-month, multi-center, randomized, open-label non-inferiority study of renal function and efficacy comparing concentration-controlled Certican® (1.5 mg/day starting dose) with reduced Neoral® dose ... 2007-05-30 due-trials
Completed, but no date, and reported results 2004-001060-50 An eight-week, randomized, double-blind, multi-center, active-controlled, parallel group study to evaluate the safety and efficacy of an aliskiren based regimen compared to a lisinopril based regimen ... bad-data
Reported results 2004-001061-17 A 26 week, double-blind, randomized, multicenter, parallel group, active-controlled study comparing aliskiren to ramipril with optional addition of hydrochlorothiazide (HCTZ), followed by a 4 week dou... 2006-03-23 due-trials
Reported results 2004-001062-40 An eight-week, randomized, double-blind, parallel group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with ramipril in pati... 2005-08-30 due-trials
Completed, but no date, and reported results 2004-001069-17 A double-blind, active-controlled, randomized, multicenter, parallel-group 2 day comparison of 1000 mg propyphenazone / 80 mg codeine (applied as two suppositories) combination therapy versus a 1000 m... bad-data
Reported results 2004-001101-10 A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying of progression or recurrences in patients with stage III non-small cell lung can... 2010-05-12 due-trials
Completed, but no date 2004-001132-23 A 52-week, international, multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial to compare retention on treatment, safety, tolerability and efficacy of lumiracoxib 100mg o... bad-data
Completed, but no date, and reported results 2004-001197-10 A double-blind, randomized, multi-center active-controlled, parallel-group study comparing the combination of valsartan 320 mg plus hydrochlorothiazide 12.5 mg and valsartan 320 mg plus hydrochloroth... bad-data
Completed, but no date 2004-001273-26 A 3 weeks study randomized, multicenter, double blind, vehicle controlled , parallel-group to evaluate the efficacy and safety of Pimecrolimus cream 1% in children between 2 – 11 years with mild to mo... bad-data
Reported results 2004-001361-18 Conversion trial from Cellcept® (MMF) to myfortic® (enteric-coated MPA) in stable transplanted patients suffering from GI adverse events while on Cellcept® therapy. 2006-08-22 due-trials
Reported results 2004-001362-40 PHASE II STUDY OF IMATINIB MESYLATE IN CHORDOMA 2008-05-05 due-trials
Completed, but no date 2004-001369-17 An open-label, randomized, multicenter study to evaluate the use of Zoledronic Acid in the prevention of cancer treatment-related bone loss in postmenopausal women with ER+ and/or PgR+ breast cancer r... bad-data
Ongoing 2004-001396-19 An extension to a phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive leukemia including acute lymphoblastic leukaemia, acute m... not-yet-due
Ongoing 2004-001397-92 An extension to a phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha not-yet-due
Reported results 2004-001453-28 Open-label, Multicenter, Phase II Study Assessing the Safety of Lucentis (ranibizumab) Administered in Conjunction with Photodynamic Therapy with Visudyne in Patients with Occult or Predominantly Clas... 2007-10-15 due-trials
Not reported 2004-001473-25 A facilitated access program to provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation. 2014-02-24 due-trials
Reported results 2004-001483-51 A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant CML in accelerated phase or blast crisis, rela... 2012-09-20 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-001546-32 A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50 mg qd or bid) to placebo as add-on therapy to glimepiride in patients with typ... 2006-04-27 bad-data
Reported results 2004-001666-40 An international, multicenter, randomized, open-label, safety and efficacy trial of intravenous zoledronic acid administered either once or twice yearly in children with severe osteogenesis imperfecta... 2007-05-01 due-trials
Reported results 2004-001754-92 A phase II, 12-month, double-blind, placebo-controlled, dose-finding, multicenter study to evaluate the safety, tolerability, and disease modifying efficacy of daily oral AAE581 (10, 25 and 50 mg tabl... 2006-07-27 due-trials
Completed, but no date, and reported results 2004-001979-18 Extensión de 28 semanas de duración del estudio multicéntrico, doble ciego, aleatorizado, de grupos paralelos que compara el efecto de 24 semanas de tratamiento con 50 mg bid de LAF237 frente a placeb... bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002089-39 A randomized, multi-center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler™ 10µg b.i.d., tiotropium HandiHaler® 18µg o.d. and tiotropium HandiHaler® 18µg... 2005-11-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002136-25 A 52-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to metformin up to 1000 mg bid in drug naïve p... 2006-08-02 bad-data
Reported results 2004-002252-33 A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in pati... 2006-08-16 due-trials
Reported results 2004-002267-24 Assessment of Everolimus in addition to Calcineurin Inhibitors Reduction in Mainteinance Renal Transplant Recipients ? ASCERTAIN 2009-10-05 due-trials
Reported results 2004-002407-32 Extension to a multicenter, open label study to assess the safety and efficacy of 600 micrograms SOM230, administered subcutaneously, b.i.d. in patients with Cushing's disease 2013-07-08 due-trials
Reported results 2004-002410-11 A six-week, randomized, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of the combination of aliskiren 150 mg and amlodipine 5 mg compared to amlodipine 5 mg and 1... 2005-10-24 due-trials
Reported results 2004-002418-12 An open-label, randomised, multicentre safety study to evaluate the skeletal and lipid profile effects of letrozole and tamoxifen in postmenopausal women with resected, receptor positive early breast ... 2011-03-17 due-trials
Ongoing, reported early 2004-002466-38 A multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA... not-yet-due
Completed, but no date, and reported results 2004-002534-18 An open, multicenter study to evaluate the efficacy and safety of a 4 week therapy with CoDiovan 160/25 (fixed dose combination of valsartan 160 mg plus HCTZ 25 mg) in patients not adequately respondi... bad-data
Reported results 2004-002612-28 A one year, open label, multi-center, extension study to CHTF919D2301 to assess the long term safety of tegaserod 6 mg bid given orally in female patients with symptoms of dyspepsia 2006-08-04 due-trials
Completed, but no date, and reported results 2004-002644-10 A 28-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug naïve patient... bad-data
Ongoing, reported early 2004-002661-21 A multicenter, randomized, double-blind active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to acarbose up to 100 mg tid in drug naïve patients with type 2 diabet... not-yet-due
Reported results 2004-002688-25 A 4-week, randomized, multicenter, parallel-group, placebo-controlled study to investigate the effect of Elidel (pimecrolimus) cream 1% on the Quality of Life (QoL) of patients with moderate facial At... 2006-01-03 due-trials
Ongoing, reported early 2004-002757-31 A 28-Week Extension to a Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy in Patients ... not-yet-due
Reported results 2004-002831-14 Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor negative breast cancer and adjuvant chemotherapeutic treatment 2013-12-02 due-trials
Reported results 2004-002832-24 Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine or... 2014-05-19 due-trials
Reported results 2004-002849-12 Extension to a multicenter, randomized, crossover, open label, dose finding study to compare the safety, efficacy and PK/PD relationship of multiple doses of SOM230 (200, 400 and 600 µg b.i.d.) and do... 2013-12-06 due-trials
Reported results 2004-002855-15 A long term extension to a randomised, double-blind, placebo-controlled, stratified, paralle-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 1.0, 2.5, 7.5 and 15 mg admin... 2005-01-11 due-trials
Reported results 2004-002888-24 An open-label, multi-center trial to evaluate the feasibility and safety of short-term treatment with subcutaneously injected certoparin (8000 U anti-Xa twice daily) in patients with persistent nonval... 2006-08-14 due-trials
Reported results 2004-002894-21 A 12-week, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety and tolerability of darifenacin (7.5 mg o.d. with voluntary up-titration to... 2006-08-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-002940-82 A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Combination Therapy of LAF237 and Pioglitazone to LAF237 Monotherapy or Pioglitazone M... 2006-01-06 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002952-33 A 2-year extension to study 2203, partially randomized, double-blind, placebo-controlled in the first year and open label in the second year, to assess the safety of the dose of AAE581 selected for p... 2006-05-17 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002980-26 An open-label, phase II dose titration study of ACZ885 (human anti-IL-1beta monoclonal antibody) to assess the clinical efficacy, safety, pharmacokinetics and pharmacodynamics in patients with NALP3 m... 2008-07-17 bad-data
Completed, reported early 2004-003017-16 A combined phase 1 and 2 study investigating the combination of RAD001 and erlotinib in patients with advanced NSCLC previously treated only with chemotherapy 2011-03-30 not-yet-due
Reported results 2004-003018-41 Open label, non-randomized, phase 2 Study investigating the effect of RAD001 monotherapy in patients with advanced NSCLC previously treated with either chemotherapy only or with chemotherapy and EGFR ... 2007-10-24 due-trials
Reported results 2004-003798-94 A randomized, open-label, parallel-group study to investigate blood concentrations, safety and tolerability of 2 ointment formulations of ASM981 in adult patients with atopic dermatitis treated topica... 2006-04-15 due-trials
Other 2004-003886-34 Phase II study on letrozole in patients with advanced or recurrent hormone receptor positive endometrial cancer. not-yet-due
Reported results 2004-003888-71 An open phase III trial with Letrozole (Femara®) alone or in combination with Zoledronic acid (Zometa®) as extended adjuvant treatment of postmenopausal patients with primary breast cancer 2010-08-19 due-trials
Reported results 2004-003889-15 An open phase III trial with Letrozole (Femara®) as Early Adjuvant treatment of postmenopausal patients with primary breast cancer 2010-07-15 due-trials
Reported results 2004-003905-26 A 12-week, double-blind, parallel group study to evaluate the efficacy and safety of the combination of aliskiren with HCTZ compared to irbesartan or amlodipine with HCTZ or HCTZ alone in hypertensive... 2006-03-27 due-trials
Reported results 2004-003913-18 A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the safety and efficacy of SAB378 (15 mg t.i.d.) administered orally for 4 weeks to patients with postherp... 2006-06-05 due-trials
Reported results 2004-003953-16 A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients diagnosed with transfusion-dependent iron overload 2010-06-22 due-trials
Reported results 2004-003972-12 A 2 week multiple ascending dose, double-blind placebo controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of twice daily administration of oral AEB071 and to explore the p... 2007-02-05 due-trials
Completed, but no date, and reported results 2004-004007-37 Neoadjuvant therapy for postmenopausal women with ER and/or PgR positive breast cancer. A randomized open phase II trial evaluating the efficacy of a 6 months preoperative treatment with Letrozole ... bad-data
Reported results 2004-004014-16 A twelve-week, randomized, double-blind, multi-center, placebo controlled, parallel group study to evaluate the safety and efficacy of aliskiren 150 mg when added to standard therapy in hypertensive p... 2007-03-12 due-trials
Reported results 2004-004015-38 A twenty six-week, randomized, double-blind, parallel group, multicenter, active controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional ad... 2006-07-27 due-trials
Reported results 2004-004063-29 Glivec (imatinib mesylate) in combination with hydroxyurea or hydroxyurea alone as an oral therapy in temozolomide resistant progressive glioblastoma patients 2008-08-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-004095-37 An exploratory, multi-center, randomized, open-label, single dose, crossover study to assess the safety and tolerability of 200µg of QAB149, delivered via a MDDPI, with or without the co-administratio... 2005-04-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-004131-57 A two year multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the fracture efficacy and safety of intravenous zoledronic acid 5 mg annually for the treatment o... 2010-11-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-004208-19 A 12-week multicentre, double blind, double dummy, randomized, parallel group, active controlled study to evaluate the efficacy and tolerability of fluvastatin extended release (Lescol XL® 80 mg) alon... 2006-01-19 bad-data
Completed, but no date, and reported results 2004-004252-40 An open-label, Phase I/II, dose escalating study evaluating the safety and efficacy of EPO906, q3w, in patients with non-small cell lung cancer bad-data
Listed as ongoing, but also has a completion date and reported results 2004-004255-18 An 8-week, randomized, double-blind, parallel-group, multicenter study assessing the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in patients 65 years of age with essential hypertens... 2006-02-21 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-004274-87 An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies 2010-05-27 bad-data
Completed, reported early 2004-004275-11 An open-label study to investigate blood concentrations, safety, tolerability and efficacy of Elidel® Cream 1% in patients with moderate or severe seborrheic dermatitis treated topically for 3 weeks. 2006-05-18 not-yet-due
Reported results 2004-004346-40 Full title of the trial : Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic® and Certican® in comparison to standard therapy with M... 2012-09-12 due-trials
Reported results 2004-004377-28 A two-year extension to a one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral and cort... 2006-05-27 due-trials
Reported results 2004-004559-21 A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Long-Term Effect of Treatment with LAF237 50 mg bid to Glimepiride up to 6 mg Daily as Add-On Therapy in Patients with T... 2008-07-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-004696-11 An open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy ... 2006-03-16 bad-data
Completed, but no date, and reported results 2004-004776-37 An 8-week, multi-center, randomized, double-blind, placebo-controlled, parallel group trial of Diclofenac Sodium Gel 1% in patients with primary osteoarthritis of the hand bad-data
Reported results 2004-004794-28 A 12-week, randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy and safety of aliskiren in patients with diabetes and hypertension not adequately responsive to th... 2007-05-07 due-trials
Reported results 2004-004865-14 A 2 x 5 weeks open label, multicenter, randomized cross-over study to compare the reduction of predialysis systolic blood pressure with valsartan (Diovan) 80 mg compared to irbesartan150 mg in patient... 2006-03-16 due-trials
Completed, but no date, and reported results 2004-004958-63 A two-year extension to a one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral and cort... bad-data
Reported results 2004-005045-35 A multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug naïve patients with type 2 diabetes 2005-09-28 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-005071-42 A study of the effect of conversion to Myfortic on quality of life in patients with gastrointestinal (GI) symptoms related to MMF therapy after renal transplantation (MYQOL). 2008-03-25 bad-data
Reported results 2004-005088-17 A multicenter, Open-label Study to Determine the Effect of I.V. Zometa on Pain and Quality of Life in Patients with Bone Metastases with or without Skeletal Related Events (SREs) Resulting from Breast... 2008-04-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-005181-20 A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/resi... 2010-02-26 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000039-73 An 8-week randomized, double-blind, parallel group, multi-center, placebo and active controlled dose escalation study to evaluate the efficacy and safety of aliskiren (150 mg and 300 mg) administered ... 2006-09-05 bad-data
Completed, reported early 2005-000048-10 A 52-week, multi-center, randomized, double-blind, placebo-controlled, time-lagged, parallel group study in patients with mild to moderate Alzheimer's Disease (AD) to investigate the safety, tolerabil... 2010-03-03 not-yet-due
Reported results 2005-000229-51 A 1-week, multi-center, randomized, double-blind, double-dummy, active-controlled, parallel trial of lumiracoxib (400 mg od) in patients with acute flares of gout, using indomethacin (50 mg tid) as a ... 2005-11-11 due-trials
Reported results 2005-000286-19 A randomized, double-blind, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients w... 2008-04-22 due-trials
Completed, but no date, and reported results 2005-000350-69 A two-year extension to a one-year, multicenter, open-label, randomized study to evaluate the safety and efficacy of FTY720 combined with tacrolimus and steroids versus MMF (Cellcept) combined with ta... bad-data
Reported results 2005-000361-19 An open-label, one-period, one-treatment study which objective is to evaluate the time course of the antiproteinuric and blood pressure lowering effect of renin inhibition with Aliskiren in patients w... 2006-11-16 due-trials
Reported results 2005-000362-39 A randomized, double-blind, parallel-group, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the renoprotective effect of renin inhibition with Aliskiren as an alte... 2008-03-06 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-000365-19 A 24A 24-month, double-blind, randomized, multicenter, placebocontrolled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo ... 2009-07-29 bad-data
Ongoing, reported early 2005-000380-26 A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3 mo... not-yet-due
Completed, but no date, and reported results 2005-000473-22 A multicenter, randomized, double-blind study to compare the effects of 24 weeks treatment with LAF237 (50 mg qd, 50 mg bid or 100 mg qd) to placebo in drug naïve patients with type 2 diabetes bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000487-11 A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the tr... 2008-07-17 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000517-36 RESCUE Study (Certican in Liver Transplant Recipients with Renal Insufficiency) A 6-month, multicenter, randomized, open-label study of safety and efficacy of Certican-based regimen versus CNI-base... 2007-11-09 bad-data
Completed, but no date, and reported results 2005-000561-18 A phaseI dose escalation study of AMN107 in combination with Imatinib on a continous daily dosing schedule in adult patients with Imatinib-resistent gastrointestinal stromal tumours (GIST). bad-data
Reported results 2005-000657-29 A randomized open-label study of 400 mg versus 800 mg of Gleevec/Glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) us... 2010-11-05 due-trials
Reported results 2005-000661-19 Neoadjuvant hormone therapy for postmenopausal women with ER and/or PgR positive primary breast cancer: A multi-center study to determine the optimum length of treatment with Femara (letrozole 2.5mg d... 2010-10-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-000668-17 A 3 year, double-blind extension to CZOL446H2301 to evaluate the long term safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. 2009-11-27 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000684-26 A randomized, double blind, parallel group, active-controlled, multi-center, 14 week study to evaluate the effectiveness of a valsartan versus an amlodipine treatment strategy in achieving blood press... 2007-04-18 bad-data
Reported results 2005-000839-17 A 16-week, randomized, multi-center, parallel-group, pimecrolimus-blinded, controlled study (4-week treatment period followed by 12-week observational period) to evaluate the safety of concomitant use... 2007-01-24 due-trials
Reported results 2005-000856-34 A 36 week, randomized, double-blind, multi-center, parallel group study comparing the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of left ventr... 2007-11-28 due-trials
Reported results 2005-000864-16 Multicenter, randomized, open-label trial to evaluate the safety, tolerability and efficacy of two regimens of Everolimus plus Neoral, given according different blood target levels, in de novo renal t... 2007-07-24 due-trials
Reported results 2005-001013-18 Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic® and Certican® in comparison to standard therapy with Myfortic® and a calcineurin... 2013-03-25 due-trials
Reported results 2005-001032-72 A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 t.i.d. vs. immediate release carbidopa/levodopa t.i.d. in Parkinsons disease ... 2007-09-25 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-001099-11 A randomized, open label, parallel-group, international, multicenter study evaluating persistency of response to omalizumab during 32 weeks treatment given as add on to optimized asthma therapy in adu... 2008-09-25 bad-data
Reported results 2005-001144-23 Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Simultaneous Pancreas-Kidney Transplant Recipients 2008-01-23 due-trials
Completed, but no date 2005-001148-22 A 12-Months, Randomized, Double-Blind, Parallel-Group, Multicenter, Proof of Concept Study of the Efficacy of Oral RAD001 (6 mg/day) versus Azathioprine and Placebo in Crohn’s Disease bad-data
Reported results 2005-001176-12 A randomized, double-blind, double-dummy, parallel-group study to compare the effects of multiple dose administration of aliskiren and irbesartan on biomarkers of inflammation and cardiovascular risk ... 2007-05-11 due-trials
Reported results 2005-001221-28 A multicenter, randomized, open label study to compare the development of liver fibrosis after transplantation for hepatitis C cirrhosis in patients receiving either Neoral or tacrolimus. 2010-09-17 due-trials
Completed, but no date, and reported results 2005-001252-21 An open-label, multiple-dose study to evaluate the pharmacokinetics, safety and tolerability of SPP100 (Aliskiren) and Atenolol (Tenormin®) administered alone and in combination in healthy subjects bad-data
Listed as ongoing, but also has a completion date and reported results 2005-001258-26 An 8 week extension to a randomized, double-blind, parallel group, active-controlled, multi-center, 14 week study to evaluate the effectiveness of a valsartan versus anamlodipine treatment strategy i... 2007-03-14 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-001290-10 A study to provide expanded access of Exjade deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated w... 2008-10-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-001349-40 A multicentre, Randomised, Assesor-Blind Study to Evaluate Efficacy and Safety of Daptomycin versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (cSSTI) Estud... 2008-05-06 bad-data
Reported results 2005-001380-61 An extension to a phase II open label study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast cris... 2013-04-22 due-trials
Reported results 2005-001381-14 An extension to a phase II study to determine the safety and the anti- leukemic effects of STI571 in adults patients with Philadelphia chromosome positive leukemia including acute lymphoblastic leuke... 2013-09-23 due-trials
Ongoing, reported early 2005-001382-33 An extension to a phase II study to determine the efficacy and the safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha not-yet-due
Reported results 2005-001518-42 A six-month, prospective, multicenter, open label, parallel, randomized study of the safety, tolerability and efficacy of myfortic® (ERL080) with Simulect®, corticosteroids and two different levels of... 2007-03-26 due-trials
Reported results 2005-001537-15 Open-label trial of imatinib mesylate (Glivec, formerly known as STI571) in combination with vinorelbine (Navelbine) for patients with advanced breast carcinoma 2012-07-05 due-trials
Reported results 2005-001614-41 OPEN-LABEL TRIAL OF GLIVEC IMATINIB MESYLATE IN PATIENTS WITH REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMORS DSRCT EXPRESSING A MOLECULAR TARGET OF GLIVEC PDGF-R AND/OR C-KIT 2009-06-23 due-trials
Reported results 2005-001650-25 A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the efficacy and safety of Elide... 2006-08-25 due-trials
Reported results 2005-001714-41 A twelve-month, prospective, multicenter, open-label, randomized study of the safety, tolerability and efficacy of Certican™ with an IL-2 receptor antagonist, corticosteroids and two different exposur... 2008-12-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-001818-41 An open label multicenter expanded access study of oral AMN107 in adult patients with imatinib Glivec/Gleevec resistant or intolerant chronic myeloid leukemia in blast crisis, accelerated phase or ch... 2008-11-12 bad-data
Reported results 2005-002035-28 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects 2007-02-28 due-trials
Reported results 2005-002058-23 A 4 week, randomized, vehicle-controlled, multicenter evaluation of the efficacy and safety of 1% pimecrolimus cream in adult patients with perioral dermatitis followed by a 8 week treatment free obse... 2006-07-06 due-trials
Reported results 2005-002060-28 Nordic Certican trial in heart and lung transplantation ("NOCTET") 2010-02-26 due-trials
Reported results 2005-002132-94 „Effect of intravenous Zoledronic Acid on Bone Metabolism given over 4 month in patients with prostate cancer or breast cancer and bone metastasis. A prospective, single-arm multicenter study” (ZoTe... 2009-07-20 due-trials
Reported results 2005-002199-14 A Multicenter, Double-blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with Vidagliptin 50 mg bid to Pioglitazone 30 mg Daily as Add-On Therapy in Patients with T... 2007-10-19 due-trials
Reported results 2005-002233-12 Measurement and Analysis of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Patients with Autoimmune Diseases treated with Mycophenolic Acid 2009-06-02 due-trials
Reported results 2005-002234-35 Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients 2008-09-19 due-trials
Completed, but no date, and reported results 2005-002372-16 Multicenter, open-label, single-arm, safety, tolerability, efficacy and pharmacokinetic study of RAD001 in pediatric de novo renal transplant patients bad-data
Reported results 2005-002382-36 A 12-week treatment, randomized, double-blind, parallel group, multicenter study to evaluate the efficacy of the valsartan/simvastatin combinations 160/20mg up titrated to 320/20mg versus 160/40mg up ... 2006-09-07 due-trials
Reported results 2005-002600-41 A phase II, open-label, multi-centre, single-arm study, evaluating the efficacy of Glivec® plus Hydroxyurea (HU) in patients with progressive glioblastoma multiforme (GBM), not receiving enzyme induc... 2008-07-24 due-trials
Reported results 2005-002603-16 A phase II, open-label, multi-centre, single-arm study, evaluating the efficacy of Glivec® plus Hydroxyurea (HU) in patients with progressive glioblastoma multiforme (GBM), receiving enzyme inducing a... 2008-08-19 due-trials
Reported results 2005-002635-27 An eight week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / valsartan / HCTZ (300/320/25 mg), compared to the combi... 2007-01-11 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-002772-14 A 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial of lumiracoxib COX189 100 mg o.d. in patients with primary hip osteoarthritis using celecoxib... 2006-10-16 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-002778-30 A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of 12 Week Treatment with Vildagliptin (LAF237) 50 mg QD in Subjects with Impaired G... 2006-07-06 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-002854-22 A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing concentration-controlled Certican® in two doses (1,5 and 3,0 mg/day starting doses) with reduced ... 2009-08-18 bad-data
Reported results 2005-002919-24 A multicenter, single arm, proof of concept study to investigate in a first stage the efficacy of a combination therapy of Sandostatin® LAR® and Cabergoline, optionally followed by a combination of Sa... 2010-01-12 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-002920-32 PRESERVATION OF RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS WITH CERTICAN THERAPY: PROTECT Study A twelve-month, multicenter, randomized, open-label study of safety, tolerability and efficacy of Cer... 2013-01-22 bad-data
Not reported 2005-003002-28 A 7 week multicenter, double-blind, randomized, placebo-controlled cross-over evaluation of the efficacy and safety of a modified-release oral dosage form of methylphenidate-HCl, Ritalin LA® (20 mg, q... 2006-02-04 due-trials
Ongoing, reported early 2005-003070-19 A randomized, multicenter, parallel-group, open-label study to assess the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic®) versus continuation of previous therapy in pati... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2005-003286-17 A 4-week, multicentre, randomized, double-blind, double-dummy, parallel group ambulatory blood pressure monitoring study to demonstrate that treatment with lumiracoxib 100 mg o.d. results in a 24-hour... 2006-09-29 bad-data
Reported results 2005-003376-37 A 6-week, multicenter, randomized, double-blind, parallel-group study to evaluate the combination of valsartan/HCTZ (160/12.5 mg with forced titration to a maximum dose of 320/25 mg) compared to valsa... 2006-08-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-003413-32 A 24-month, multi-center, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0 g MMF with sta... 2011-07-11 bad-data
Reported results 2005-003444-53 A randomised, open label, multicenter study comparing the efficacy and safety of medical treatment with Sandostatin LAR 30 mg administered every 21 days for 6 months with that of Sandostatin LAR 60 mg... 2007-10-23 due-trials
Reported results 2005-003494-25 12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic after 3 months), vs. myfortic plus tacrolimus i... 2008-05-20 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-003517-33 A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety of ranibizumab (0.3 mg and 0.5 mg) administered as two dosing regimens in patients with subfoveal ch... 2008-03-21 bad-data
Reported results 2005-003605-82 A randomized, open-label, multicentric parallel group study to assess the impact of supportive measures on the drug adherence of patients with essential hypertension treated with Valsartan or Valsarta... 2007-06-01 due-trials
Reported results 2005-003606-28 A 12 week treatment, open-label, multicenter study to investigate the efficacy and safety of valsartan 160-320 mg with regard to effects on lipid subfractions in hypertensive patients with metabolic s... 2007-06-18 due-trials
Completed, reported early 2005-003670-26 A phase IA/II, two-arm, multi-center, open-label, dose-escalation study of LBH589 administered orally via different dosing schedules in adult patients with advanced hematological malignancies 2009-12-02 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2005-003772-37 A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis Subjects 2009-03-12 bad-data
Completed, but no date, and reported results 2005-003860-47 A randomized, 20 week, double-blind, placebo-controlled, parallel-group, multiple-dose, multicenter study to assess the efficacy and safety of Omalizumab in combination with Depigoid, versus Depigoid ... bad-data
Completed, report not yet due 2005-003944-68 A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab based Systemic Therapy and Cranial Radiotherapy 2018-03-15 not-yet-due
Reported results 2005-003958-94 A randomized, open-label, multicenter, cross-over trial to evaluate the efficacy of a 20 week treatment of Valsartan 320 mg (Diovan) versus Atenolol 100 mg in combination with Hydrochlorothiazide on m... 2007-12-24 due-trials
Reported results 2005-003976-39 An open-label, multicenter study to evaluate the efficacy and safety of a 5 week therapy with the combination of valsartan 160 mg plus amlodipine 10 mg in hypertensive patients not adequately respondi... 2006-07-07 due-trials
Reported results 2005-004024-39 Ensaio clínico multicêntrico, randomizado, aberto, de 12 semanas, para determinar o efeito do tratamento com Myfortic® (micofenolato de sódio) em termos de qualidade de vida em doentes com sintomas ga... 2008-09-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-004168-21 A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 & 400 µg o.d.) in... 2008-01-31 bad-data
Reported results 2005-004169-41 A 52-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 & 400 µg o.d) in patients with ... 2006-01-31 due-trials
Reported results 2005-004259-37 An uncontrolled, multicenter 12 month long term study on skin reconstitution with Elidel® (pimecrolimus) 1% cream in adult patients with atopic eczema and corticosteroid induced skin damage 2007-12-20 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-004263-35 A randomised multi-center Phase IIIb, open label, study of letrozole vs anastrazole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer 2014-09-08 bad-data
Completed, but no date, and reported results 2005-004566-16 Part 1: An open Label Pilot Study to Determine Interstitial and Tissue Concentrations of Aliskiren and Effects on the Renin-Angiotensin System (RAS) in Fat and Skeletal Muscle of Hypertensive Patients... bad-data
Reported results 2005-004579-39 An eight-week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in comparison with ... 2007-07-03 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-004580-40 An eight-week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / HCTZ (150/25 mg and 300/25 mg) in comparison with HCTZ ... 2007-08-20 bad-data
Ongoing 2005-004765-42 An Open label Randomised, multicentre study to evaluate the efficacy of two Zometa (Zoledronic acid) schedules on bone mineral density in prostrate cancer patients undergoing Androgen deprivation Ther... not-yet-due
Reported results 2005-004774-24 An open-label multicenter phase II study of Imatinib mesylate (Glivec) treatment of patients with malignant peripheral nerve sheath tumors 2009-01-21 due-trials
Reported results 2005-004837-16 Multicenter, single-arm, two-stage phase II trial of RAD001 (everolismus) with Glivec® in Glivec®-resistant patients with progressive GIST 2012-11-28 due-trials
Ongoing, reported early 2005-004908-36 Extension E-03 al Protocolo nº RAD001AB253 Estudio de seguimiento de 2 años para obtener datos especificos de la evolución de los pacientes de novo trasplantados cardíacos que discontinuaron la medica... not-yet-due
Completed, but no date 2005-004913-14 An open-label Phase I/II dose escalation study evaluating the safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer bad-data
Completed, but no date, and reported results 2005-004942-15 A prospective, randomized, multi-center comparative 2-arm trial on efficacy and safety of zoledronic acid every 3-months vs. every 4 weeks beyond approximately 1 year of treatment with zoledronic ac... bad-data
Reported results 2005-004993-26 A nine-week, randomized, double-blind, parallel group study to evaluate the efficacy and safety of aliskiren 300 mg compared to irbesartan 300 mg and ramipril 10 mg in the setting of a missed dose in ... 2007-05-03 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-005010-20 A double-blind, randomized, multicenter study to evaluate the effectiveness of the combination of valsartan and amlodipine in hypertensive patients not controlled on monotherapy 2007-01-05 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-005047-26 A phase III multi-center, open-label, randomized study of nilotinib versus imatinib in adult patients with Philadelphia chromosome positive (Ph+ ) chronic myelogenous leukemia in chronic phase (CML ... 2008-07-07 bad-data
Ongoing, reported early 2005-005422-31 A 16-day, randomized, double-blind, double-dummy, placebo-controlled, parallel-group trial comparing lumiracoxib 100mg o.d. with naproxen 500 mg b.i.d. plus omeprazole 20mg o.d. and placebo in healthy... not-yet-due
Reported results 2005-005569-12 A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hy... 2014-01-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-005852-42 An open-label, two-step, multicenter European study to evaluate the efficacy and safety of Sandostatin LAR at High Dose or in combination either with GH-receptor antagonist or dopamine-agonist in a... 2010-01-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-005921-73 A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 and/or 0.5 mg) in patients with subfoveal choroidal neovascularization secon... 2008-04-18 bad-data
Reported results 2005-005949-19 A multicenter, randomized, double-blind, placebo controlled, parallel group study to compare efficacy of a single dose of lumiracoxib 400 mg given preemptively versus post-operatively, in reducing pai... 2006-12-15 due-trials
Reported results 2005-006138-14 Multi-center, open-label, prospective, randomized, parallel group study investigating an intensified Myfortic® dosing regimen in comparison to a standard dosing regimen of Myfortic® in combination wit... 2008-05-29 due-trials
Reported results 2006-000207-42 A 24-weeks , national, multicenter, double blind controlled vs placebo trial to evaluate the efficacy of Neoral ciclosporine 5mg/kg/day , twice a week administered in reduction of the rate of relaps... 2007-11-14 due-trials
Reported results 2006-000218-19 A single stage phase II, multi-centre, open label study of Glivec in combination with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfane for anti-inflammatory and angiostatic treatment i... 2015-06-01 due-trials
Ongoing 2006-000336-28 A 52-week open-label, single-arm, multi-center study to evaluate the long term safety of pimecrolimus 1% cream intermittent treatment of seborrhoeic dermatitis in patients 12 years of age and older not-yet-due
Ongoing 2006-000562-36 ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study. A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combina... not-yet-due
Ongoing 2006-000564-81 A randomised, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer not-yet-due
Completed, but no date, and reported results 2006-000680-28 Estudio multicéntrico, doble ciego, aleatorizado y de tres meses de seguimiento para evaluar la eficacia de levodopa/carbidopa/entacapona frente a levodopa/carbidopa en pacientes con enfermedad de Par... bad-data
Listed as ongoing, but also has a completion date and reported results 2006-000704-17 A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ver... 2011-07-26 bad-data
Reported results 2006-000774-70 An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodip... 2007-08-02 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-000850-33 A double-blind, randomized, multicenter 8 weeks study to evaluate the efficacy and safety of of valsartan / amlodipine combination based therapy versus amlodipine monotherapy based therapy in patient... 2007-04-24 bad-data
Reported results 2006-000861-12 A one-year partial double-blinded, randomized, multi-center, multi-national study to assess the effects of combination therapy of annual zoledronic acid (5 mg) and daily subcutaneous teriparatide (20 ... 2009-02-02 due-trials
Reported results 2006-000880-27 A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell Lymphoma 2013-06-24 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-000881-35 A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors 2008-07-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-001138-42 A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inad... 2007-11-20 bad-data
Reported results 2006-001218-34 A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on glucagon counterregulatory response during hypoglycemia in patients with type 2 ... 2007-11-20 due-trials
Reported results 2006-001219-31 A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on the incretin effect in patients with type 2 diabetes treated with metformin 2007-10-02 due-trials
Reported results 2006-001247-64 An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy 2012-04-13 due-trials
Reported results 2006-001311-30 An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of valsartan 160 mg plus HCTZ 25 mg in hypertensive patients not adequate... 2006-12-27 due-trials
Reported results 2006-001484-39 An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the combination of valsartan 160 mg plus amlodipine 5 mg in hypertensive patients not adequately res... 2007-02-22 due-trials
Reported results 2006-001485-16 A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant... 2013-10-11 due-trials
Reported results 2006-001550-27 A 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1 beta monoclonal... 2008-09-24 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-001553-10 A 26-week, phase II, multi-center, randomized, double-blind, placebo-controlled study to assess the response to treatment (ACR50) and to determine a biomarker profile in responders to ACZ885 (anti-int... 2008-12-19 bad-data
Completed, but no date, and reported results 2006-001595-20 A phase Ib study investigating the combination of RAD001 with trastuzumab and vinorelbine in patients with HER2- overexpressing metastatic breast cancer bad-data
Completed, reported early 2006-001596-37 A phase Ib/II study investigating the combination of RAD001 with 2014-03-20 not-yet-due
Reported results 2006-001703-11 A multi-center, randomized, open-label, controlled, one-year trial to measure the effect of zoledronic acid and alendronate on bone metabolism in post menopausal women with osteopenia and osteoporosis 2008-11-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-001704-37 A 36 week, multicenter, randomized, double-blind, placebo- controlled, parallel-group, pilot study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in ... 2009-11-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-001763-36 A randomized, double-blind, parallel-group, placebo-controlled, multinational clinical trial to evaluate the efficacy of Aliskiren and valsartan versus placebo in lowering levels on NT-proBNP in stabi... 2009-06-11 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-001787-23 A 12-week, open label, multicenter, titration study, with a 9- month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels ... 2010-08-27 bad-data
Ongoing, reported early 2006-001812-65 A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the effect of valsartan on proteinuria and glomerular filtration rate in children with Chronic Kidney Dise... not-yet-due
Reported results 2006-001822-23 A Randomized Multicenter Phase II Trial of Patupilone (EPO906) plus Prednisone versus Docetaxel (Taxotere) plus Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer 2012-09-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-001834-42 A Multi-Center, Open label, Repeated Dose Range Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Efficacy of an Anti-IL-1 946; Monoclonal Antibody ACZ885 Gi... 2010-03-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-001954-28 A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (300 & 600 µg o.d.) in... 2008-07-22 bad-data
Reported results 2006-001955-37 A 26-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (7... 2008-08-23 due-trials
Reported results 2006-001977-17 An open-label, randomized, parallel group study comparing the efficacy and safety of Amlodipine in combination with Valsartan compared to Losartan in combination with Hydrochlorothiazide given for 52 ... 2010-03-29 due-trials
Reported results 2006-001980-41 Glivec® (imatinib mesylate)/Litalir® (hydroxyurea) plus initial radiotherapy after surgery in patients with newly diagnosed glioblastoma multiforme followed by Glivec® and Litalir® – A phase I/II safe... 2008-04-03 due-trials
Reported results 2006-002007-13 A randomized, active-controlled, open-label, multicenter cross-over study with two 6-week treatment periods to investigate the effect of the combination of Lescol XL (fluvastatin) 80 mg and fenofibrat... 2007-03-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-002011-27 A phase II, multicentre study of oral LBH589 in patients with accelerated phase or blast phase (blast crisis) chronic myeloid leukemia with resistant disease following treatment with at least two B... 2008-07-21 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-002070-21 A randomized, double-blind, placebo-controlled, multicenter phase III study to compare the safety and efficacy of RAD001 plus Best Supportive Care (BSC) versus BSC plus Placebo in patients with met... 2011-10-27 bad-data
Reported results 2006-002102-57 A phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis 2009-03-19 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-002107-13 A randomized, multicenter, open-label, 6-month study to explore the efficacy and safety of enteric-coated mycophenolate sodium myfortic in combination with two corticosteroid regimens for the treat... 2009-11-18 bad-data
Ongoing, reported early 2006-002262-19 Angiotensin II receptor blockers in patients with systemic right ventricle. not-yet-due
Reported results 2006-002267-11 A randomized, open-label, multi-center study to evaluate the efficacy of nilotinib versus best supportive care with or without a tyrosine kinase inhibitor (investigator´s choice) in adult patients wit... 2011-06-20 due-trials
Reported results 2006-002289-21 An open label study to assess the utility of measuring markers of inflammation, to detect transition from optimal to sub-optimal Inhaled corticosteroid therapy in moderatesevere bronchial asthma 2006-12-08 due-trials
Reported results 2006-002466-19 A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd or Metformin 1500 mg daily in Elderly Drug Naïve Patients with ... 2008-07-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-002621-23 A 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300mg/ valsartan 320 mg in patients with essential hypertension. 2008-01-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-002766-20 A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in pa... 2012-04-20 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-002794-51 A randomized, double-blind, active-controlled, multicenter study to compare the effect of 24 weeks treatment with a fixed combination therapy of vildagliptin and metformin to the individual monotherap... 2008-06-06 bad-data
Reported results 2006-002877-30 An open label, multicenter, pilot phase II study of SOM230 s.c. in patients with duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonメs syndrome, non-functioning adeno... 2007-02-09 due-trials
Reported results 2006-003225-87 A randomized, multi-centre, double-blind, double dummy placebo controlled single-dose cross-over study to demonstrate that 12 and 24 µg of formoterol delivered by Concept1 has a bronchodilator efficac... 2007-05-21 due-trials
Reported results 2006-003255-20 A single arm, multicenter phase II study of RAD001 in patients with metastatic colorectal adenocarcinoma whose cancer has progressed despite prior therapy with an anti-EGFR antibody (if appropriate), ... 2009-07-15 due-trials
Reported results 2006-003337-32 ?Estudio Fase II, multicéntrico, abierto y no comparativo para evaluar la eficacia y la seguridad de ICL670 administrado durante 1 año ajustando la dosis en función de los niveles de ferritina en suer... 2012-02-02 due-trials
Completed, reported early 2006-003403-39 Combination of antiangiogenic therapy using the mTOR-inhibitor RAD001 and low dose chemotherapy for locally advanced and/or metastatic pancreatic cancer – a dose finding study 2011-07-01 not-yet-due
Completed, but no date, and reported results 2006-003501-71 Studio multicentrico controllato, randomizzato, per gruppi paralleli, per valutare l’efficacia e la tollerabilita' di Myfortic a dose piena, insieme a ciclosporina in microemulsione a dose ridotta, in... bad-data
Reported results 2006-003506-25 A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or ... 2008-06-26 due-trials
Reported results 2006-003508-21 A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or ... 2008-06-27 due-trials
Reported results 2006-003570-10 A randomized, open-label, active-controlled, multicenter, parallel group study to assess the efficacy, safety and tolerability of topical 10% terbinafine hydrogen chloride (HCl) formulation versus 5% ... 2009-06-09 due-trials
Reported results 2006-003629-98 A 54-week, open label, multi-center study to assess the long-term safety and tolerability of the combination of aliskiren 300 mg/ amlodipine 10 mg in patients with essential hypertension 2008-03-08 due-trials
Reported results 2006-003633-32 A randomized, multi-center, parallel-group, open-label study to evaluate the therapeutical benefit of an initially intensified dosing regimen of Myfortic® vs. a standard dosing regimen of Myfortic® i... 2009-07-30 due-trials
Reported results 2006-003634-15 An exploratory, double-blind comparison of inspiratory capacity (IC) and FEV1 in COPD patients following single dose administration of indacaterol and placebo and open-label b.i.d. administration of f... 2006-10-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-003771-12 A multicenter, double-blind, randomized parallel-group study to demonstrate the effect of 24 weeks treatment with vildagliptin 100 mg qd as add-on to metformin 500 mg bid compared to metformin up t... 2008-08-15 bad-data
Reported results 2006-003970-89 A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients three to six months after allogeneic hematopoietic cell transplantat... 2012-01-30 due-trials
Reported results 2006-003971-11 A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 in patients diagnosed with Low and INT-1 risk Myelodysplastic Syndrome (MDS) and transfusion-de... 2010-09-06 due-trials
Reported results 2006-003984-30 A multicenter, randomized, double-blind, two-arm, vehicle-controlled, parallel-group, two stage study to evaluate and demonstrate the efficacy and to evaluate the safety of pimecrolimus 1% cream in th... 2007-01-18 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-004003-18 A randomized, open-label, controlled, multi-center two-year study comparing efficacy and safety of telbivudine LDT600 600 mg PO in combination with peg alpha-2a sq 180 g with peg alpha-2a monothera... 2009-02-03 bad-data
Completed, but no date, and reported results 2006-004069-33 A randomized, double-blind, double-dummy, active (formoterol 12 µg b.i.d) and placebo controlled, multi-center, 5 period crossover, dose-ranging study to assess the bronchodilatory efficacy and safety... bad-data
Listed as ongoing, but also has a completion date and reported results 2006-004087-31 A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy 2009-12-25 bad-data
Reported results 2006-004110-40 A Single Centre, Single Arm, Exploratory, Open Label Study to Determine the Early Bone Formation and Bone Resorption Biomarker Response Profile of a Potent Bone Anabolic Treatment (PTH-1-34) with Dail... 2007-04-05 due-trials
Reported results 2006-004111-22 A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurre... 2014-05-21 due-trials
Reported results 2006-004128-35 A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus tacrolimus® in combination with myfortic®,... 2008-05-20 due-trials
Reported results 2006-004172-12 A 12-month randomized, double -masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin Visudyne photodynamic therapy administered in conjunction with Lucentis ve... 2009-07-15 due-trials
Reported results 2006-004177-95 A single center, randomized, partially blind, placebo controlled, crossover, single oral dose study to assess the effect of concomitant antacid (calcium carbonate) on the pharmacokinetics and pharmaco... 2006-11-29 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-004507-18 A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR and RAD001 10 mg/d or Sandostatin LAR and placebo 2013-06-13 bad-data
Ongoing, reported early 2006-004524-36 A randomized, double-blind, vehicle controlled, single center, intra-individual comparative study of the efficacy and safety of diclofenac sodium 1 mg/g (0.1%) gel in subjects with painful UV-induced ... not-yet-due
Reported results 2006-004540-23 A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus Neoral® in combination with Certican®, Sim... 2011-07-12 due-trials
Reported results 2006-004586-34 A A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlod... 2007-11-07 due-trials
Completed, but no date 2006-004664-31 Not available bad-data
Completed, but no date, and reported results 2006-004666-14 An exploratory, open label pharmacokinetic – pharmacodynamic study to compare subcutaneous versus intravenous administration of ACZ885 in adult patients with established rheumatoid arthritis. bad-data
Completed, but no date, and reported results 2006-004669-32 Estudio multicéntrico, de fase II, aleatorizado, doble ciego, controlado con placebo, de 12 semanas de duración, para evaluar la respuesta al tratamiento (ACR20) y para determinar un perfil de biomarc... bad-data
Reported results 2006-004676-12 A randomized, double-blind, multi-center comparison of the efficacy and safety of certoparin (3000 U anti-Xa o.d.) with unfractionated heparin (5000 IU t.i.d.) in the prophylaxis of thromboembolic eve... 2009-06-15 due-trials
Reported results 2006-004722-82 An exploratory study of the effects of Imatinib on allergic inflammation following out of allergy season repeated nasal allergen challenge in subjects with seasonal allergic rhinitis sensitive to Timo... 2007-04-04 due-trials
Reported results 2006-005010-12 A multicenter, open-label, single-arm study to evaluate the single-dose pharmacokinetics, acceptability and safety of famciclovir oral pediatric formulation in infants 1 month to <1 year of age with h... 2008-11-17 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-005260-88 A multicenter, randomized, double-blind, parallel-group, evaluation of 12 weeks of valsartan compared to enalapril on sitting systolic blood pressure in children 6 to 17 years of age with hypertensio... 2009-02-17 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-005261-19 A randomized, multicenter, double-blind, 6 week study to evaluate the dose response of valsartan on blood pressure reduction in children 1-5 years old with hypertension, followed by a 2 week placebo... 2009-01-21 bad-data
Reported results 2006-005404-13 A randomized, 24-week, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of Omalizumab in adult patients with chronic urticaria who exhibit IgE agai... 2009-05-03 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-005408-14 A 14 week extension to a randomized, double-blind, multicenter, parallel-group, active-controlled study to evaluate the long term safety, tolerability and efficacy of valsartan and enalapril combine... 2009-06-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-005455-15 A three-part multicenter study, with a randomized, doubleblind, placebo controlled, withdrawal design in Part II to assess efficacy, safety, and tolerability of ACZ885 (antiinterleukin-1β monoclonal a... 2008-10-29 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-005473-21 An open label extension study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension. 2009-05-25 bad-data
Reported results 2006-005588-24 Multi-center, open-label, multiple dose study in mild to moderate asthmatics (with IgE/body weight combinations above that in the SmPC dosing table) to determine safety, tolerability, pharmacokinetics... 2008-08-07 due-trials
Completed, but no date, and reported results 2006-005893-37 A one year multicenter, randomized, double-blind, placebocontrolled, parallel group study to evaluate the efficacy and safety of a single intravenous 5 mg dose zoledronic acid for the treatment of ... bad-data
Reported results 2006-005917-36 An open label, single arm study to assess the safety and immunogenicity of omalizumab liquid administered subcutaneously in a pre-filled safety syringe (75 mg or 150 mg) over a period of 6 months to m... 2008-09-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-005969-18 A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Demonstrate the Effect of 12 Weeks Treatment with Initial Combination of Vildagliptin 100 mg qd plus Metformin 1000 mg bid as compared ... 2008-01-28 bad-data
Reported results 2006-006066-42 A randomized, eight-week double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / amlodipine (300/5 mg and 300/10 mg) in comparison with... 2009-05-29 due-trials
Reported results 2006-006068-44 A randomized, eight week double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / amlodipine (150/10 mg and 300/10 mg) in comparison with a... 2009-06-05 due-trials
Completed, but no date, and reported results 2006-006182-16 Estudio multicéntrico, aleatorizado, abierto, para evaluar la conveniencia, en base a la seguridad, del cambio en la vía de administración de Rivastigmina (paso de la administración en forma de cápsul... bad-data
Other 2006-006410-15 A multi-center, randomized, double-blinded, placebo-controlled, multiple dose study to assess the efficacy of intravenously administered RSV604 in immunocompromised adults with evidence of RSV infecti... not-yet-due
Reported results 2006-006441-14 A randomized, rater-blinded cross-over multicenter study comparing the clinical efficacy of Ritalin® LA (methylphenidate) treatment (20 or 40 mg orally o.d.) in children with ADHD under different brea... 2007-12-18 due-trials
Reported results 2006-006638-16 A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 and IV bortezomib in adult patients with multiple myeloma 2013-10-07 due-trials
Ongoing, reported early 2006-006690-25 A Double-Blind, Randomized, Parallel Group, Placebo Controlled Study, Evaluating the Decongestant Effect, Time to Onset, Duration of Effect and Impact on Sleep and General Well-being of Otrivin F2 in ... not-yet-due
Reported results 2006-006719-66 Efficacité d’un traitement par l’association amlodipine et valsartan en monoprise vespérale ou matinale, chez des Patients présentant une HTA Essentielle moyenne à modérée, non contRôlée par amlodipin... 2008-08-15 due-trials
Completed, but no date, and reported results 2006-006733-41 Effet de l’association fixe amlodipine/valsartan sur la Pression artérielle centrale chez des hypertendus essentiels non contrôlés par amlodipine 5mg bad-data
Completed, but no date 2006-006803-35 An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon alfa-... bad-data
Listed as ongoing, but also has a completion date and reported results 2006-006819-75 A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumo... 2014-03-05 bad-data
Completed, but no date, and reported results 2006-006838-17 Phase I study to examine the effect of deferasirox on renal hemodynamics in &#946;-thalassemia patients with transfusional iron overload bad-data
Ongoing 2006-006852-37 A phase III randomized, double-blind study of induction(daunorubicin/cytarabine)and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412)(IND-101261) or placebo in newly diagnosed p... not-yet-due
Reported results 2006-007021-32 Multi-center, open-label, prospective, randomized, parallel group, long-term study investigating a standard regimen in de novo kidney transplant patients versus a CNI-free regimen and a CNI-low dose r... 2015-06-04 due-trials
Completed, but no date 2006-007030-35 A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 when administered in combination with oral lenalidomide & dexamethasone in adult patients with multiple myeloma bad-data
Reported results 2007-000180-13 A Randomized, Open-label, 104-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Conce... 2015-12-10 due-trials
Ongoing 2007-000208-34 A phase III multi-center, open label, randomised study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chroni... not-yet-due
Reported results 2007-000213-11 A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon 10 and 15 cm2 Patch in Patients with Alzheimer’s Disease S... 2011-05-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-000350-31 A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mil... 2010-11-02 bad-data
Reported results 2007-000491-16 A 76-week open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1β monoclonal antibody) in patients with active rheumatoid arthritis 2009-10-19 due-trials
Reported results 2007-000538-37 A multicenter, randomized, double-blind, parallel-group study to investigate the glucose lowering effect, safety and tolerability of a 24 week treatment with Vildagliptin 100 mg o.a.d. versus placebo ... 2008-07-07 due-trials
Completed, but no date, and reported results 2007-000642-13 A randomized, double-blind, placebo-controlled, 4 period incomplete block cross-over, multi-center, multiple dose (7 days) dose-ranging study to assess the efficacy and safety of 4 doses of NVA237 in ... bad-data
Reported results 2007-000643-95 A randomized, double-blind, placebo controlled, parallel group, multi-center study, to assess the safety and tolerability of 28 days treatment with NVA237 (100 or 200µg once a day) in patients with mo... 2008-01-11 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-000739-25 A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlle... 2012-04-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-000743-95 A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-rel... 2010-01-28 bad-data
Listed as ongoing, but also has a completion date 2007-000766-20 A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions 2013-03-05 bad-data
Reported results 2007-000771-42 A controlled randomized open-label multicentre study evaluatiing if early conversion to everolimus (Certican) from cyclosporine (Neoral) in de novo renal transplant receipients can improve long-term r... 2013-05-07 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-000860-25 A randomized, double-blind, placebo-controlled, parallel-group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, aliskiren, on top of conve... 2013-02-06 bad-data
Reported results 2007-001005-16 A 26 week treatment, multi center, randomized, double-blind, double dummy, parallel group study with to assess the safety of indacaterol (300 and 600 ug o.d.) in patients with persistent asthma, using... 2008-08-20 due-trials
Reported results 2007-001013-41 A randomized, double-blind, placebo-controlled study to demonstrate the efficacy of Xolair in an allergen bronchoprovocation study in two asthmatic populations defined by serum IgE concentrations 2009-01-09 due-trials
Ongoing, reported early 2007-001049-16 A multi-centre, randomised, double blind, parallel group study to investigate the efficacy and tolerability of treatment (24 weeks double blind phase followed by open-label extension) with either v... not-yet-due
Reported results 2007-001051-19 A double-blind, randomized, cross-over, placebo-controlled, 2-part study to compare the effect of exercise and high-dose salbutamol on maximal heart-rate in patients with COPD following therapeutic do... 2008-06-16 due-trials
Reported results 2007-001360-76 A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose range study to evaluate the efficacy and safety of LCZ696 comparatively to valsartan, and to evaluate AHU3... 2008-07-23 due-trials
Reported results 2007-001361-15 An open-label, two-period, multi-center, single dose study to assess the pharmacokinetics of AEB071 in de novo liver transplant patients 2008-02-17 due-trials
Reported results 2007-001374-87 An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not ad... 2007-12-19 due-trials
Reported results 2007-001383-70 A 24 week, multicenter, open evaluation of the clinical effectiveness of the once-daily 10 cm2 Exelon® patch formulation in patients with probable Alzheimer’s disease (MMSE10-26) 2008-10-24 due-trials
Reported results 2007-001665-15 A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1&#61538; monoclonal antibody) in patients with rheumatoid a... 2009-08-13 due-trials
Ongoing, reported early 2007-001714-16 A double-blind, randomized, placebo-controlled, parallel, time-lagged, ascending, multi-centre, multiple-dose study to measure the magnitude and time course of the effect of FTY720 on FEV1 and other p... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-001776-36 A 24-month randomized, multicenter study, evaluating efficacy, safety, tolerability and pharmacokinetics of sotrastaurin (STN) combined with tacrolimus (TAC) vs a tacrolimus / mycophenolate mofetil (M... 2012-07-26 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-001821-85 A 24 month, multi-center, open-label, randomized, controlled study to evaluate the efficacy and safety of concentration-controlled everolimus to eliminate or to reduce tacrolimus compared to tacrol... 2012-04-12 bad-data
Ongoing, reported early 2007-001846-42 A 4-week, parallel-group, randomized, double-blind, placebo-controlled, adaptive proof of concept study of AQW051 at up to three dose levels for the treatment of patients with findings consistent with... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-001972-36 A multicenter, randomized, blinded study to assess safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly 2016-03-11 bad-data
Reported results 2007-002243-25 An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosis 2008-10-25 due-trials
Reported results 2007-002360-10 An exploratory, multi-centre, double-blind, placebo-controlled crossover study, to investigate the bronchodilatory efficacy of a single dose of indacaterol in fixed combination with mometasone furoate... 2008-04-10 due-trials
Reported results 2007-002376-34 A 26-week treatment, multi center, randomized, double blind, double dummy, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 &#956;g o.d.) in patients with... 2009-01-29 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-002449-19 A phase Ib/IIa, trial of LBH589 in combination with trastuzumab in adult female patients with HER2 positive metastatic breast cancer whose disease has progressed during or following therapy with tr... 2011-05-02 bad-data
Reported results 2007-002469-11 A 10 week, randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of once daily dosing of aliskiren (300 mg qd) to twice daily dosing of aliskiren (150 mg bid)... 2008-11-21 due-trials
Reported results 2007-002542-38 A randomized, double blind, placebo controlled, parallel group design study to explore the efficacy, safety and tolerability of AEB071 in patients with active, moderate to severe ulcerative colitis. 2012-04-03 due-trials
Completed, but no date, and reported results 2007-002552-42 Estudio de fase I/II, multicéntrico, abierto de BGT226, administrado por vía oral a pacientes adultos con tumores sólidos avanzados, incluyendo pacientes con cáncer de mama avanzado bad-data
Listed as ongoing, but also has a completion date and reported results 2007-002627-32 A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients with... 2014-12-18 bad-data
Reported results 2007-002671-14 A 15-month, multi-center, randomized, open-label, parallel group study investigating the renal tolerability, efficacy and safety of a CNI-free regimen (Certican® and MPA) versus a low-dose CNI- regime... 2017-03-06 due-trials
Reported results 2007-002900-16 A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration study in patients with Parkinson’s disease to assess the efficacy of AFQ056 in reducing L-dop... 2008-05-14 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-002986-11 A 24 month extension to a 12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic after 3 months), vs. ... 2008-05-20 bad-data
Reported results 2007-003037-17 A randomized, double-blind, double-dummy, active-controlled, parallel group study of single doses of ACZ885 in hospitalized patients with acute gout 2009-10-23 due-trials
Reported results 2007-003134-42 A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of Event-Related Potentia... 2008-08-27 due-trials
Reported results 2007-003189-16 A randomized, multi center, parallel group, double-blind, placebo and formoterol controlled 14 day dose ranging trial 4 doses of indacaterol delivered via Twisthaler®, in patients with COPD. 2008-05-09 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-003191-19 A randomized, multi-center, parallel group, double-blind, placebo and formetrol controlled 14 day dose ranging trial of 4 doses of indacaterol delivered via Twisthaler®, in adult and adolescent patie... 2008-04-18 bad-data
Completed, but no date, and reported results 2007-003192-39 A multicenter, randomized, double-blind, double dummy, placebo controlled crossover study, to investigate the 24 hour FEV1 profile of a single dose of QMF Twisthaler® (500/400 μg o.d.) delivered in th... bad-data
Completed, but no date, and reported results 2007-003360-22 Estudio prospectivo exploratorio para describir en pacientes naïve y no naïve la cinética del virus de la hepatitis B durante las primeras 24 semanas en tratamiento con telbivudina. bad-data
Reported results 2007-003403-13 A proof of concept study of the effects of QAX576 (an interleukin-13 monoclonal antibody) on allergic inflammation following out of allergy season repeated nasal allergen challenge in subjects with se... 2008-08-07 due-trials
Ongoing, reported early 2007-003405-27 Etude ouverte, multicentrique, de 24 semaines, évaluant l'efficience clinique de la forme Exelon patch 10 cm2 chez des patients avec une maladie d'Alzheimer (MMSE 10-26) not-yet-due
Reported results 2007-003655-36 A randomized, double-blind, placebo controlled, multicentre study to determine the effect of QVA149 on lung function in patients with Chronic Obstructive Pulmonary Disease (COPD) 2008-09-19 due-trials
Reported results 2007-003670-25 A randomized, double blind, placebo controlled, multicenter study to determine the effect of QVA149 on mean 24-hours heart rate in patients with Chronic Obstructive Pulmonary Disease (COPD) 2008-07-15 due-trials
Reported results 2007-003677-10 A twelve week, randomized, double-blind, parallel-group multicentre study to evaluate the efficacy and safety of the combination of aliskiren/ramipril/amlodipine (300/10/10mg), compared to the combin... 2009-07-14 due-trials
Reported results 2007-003703-13 A phase III randomized, double-blind, double dummy, placebo controlled, multicenter, 4 treatments, 3 period incomplete block crossover study to assess the effect on FEV1 of indacaterol 300 µg o.d. dos... 2008-07-29 due-trials
Reported results 2007-003723-21 A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 d... 2010-10-13 due-trials
Reported results 2007-003797-25 A randomized, double-blind, multi-center, vehicle-controlled, parallel group study to evaluate the efficacy and safety of diclofenac diethylamine 2.32% gel applied once or twice daily in subjects with... 2008-06-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-003973-16 A 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tolerability of repeated subcut... 2010-02-18 bad-data
Completed, but no date, and reported results 2007-004008-10 Evaluating the efficacy of Exjade® (deferasirox) in transfusion dependent chronic anaemias ( Myelodysplasia Syndrome, Beta-thalassaemia major patients) with chronic iron overload bad-data
Listed as ongoing, but also has a completion date and reported results 2007-004071-19 A phase III, randomized, double-blind, double-dummy, placebo-controlled, multicenter, 3-period incomplete block, multidose crossover study to determine the effect on lung function of indacaterol (150 ... 2008-12-30 bad-data
Reported results 2007-004122-24 An extension of the 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 0,5 mg and 0.5 mg administered orally once daily v... 2011-06-22 due-trials
Reported results 2007-004143-30 A phase III randomized, double-blind, placebo controlled, 2 period crossover, multicenter study to assess the effect of indacaterol (300 µg o.d.) on exercise endurance in patients with moderate to ... 2009-01-13 due-trials
Ongoing, reported early 2007-004316-31 A randomised, double-blind, vehicle controlled, single centre, parallel group, comparative study of the efficacy of penciclovir 10 mg/g (1%) cream in preventing the appearance of classical lesions in ... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-004367-22 An open-label, long-term safety and efficacy study of ACZ885 (anti-interleukin-1&#946; monoclonal antibody) administered for at least 6 months in patients with the following cryopyrin-associated peri... 2010-04-30 bad-data
Completed, reported early 2007-004391-39 A Phase I/II multi-center, open label study of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC) 2012-08-18 not-yet-due
Completed, but no date, and reported results 2007-004507-36 A multicenter, open label, 2 period cross-over study to evaluate the Pharmacokinetics of an 8 week continuous treatment with 1x300mg/d and 2x300mg/d TOBI® inhaled with the PARI eFlow® rapid in Cystic ... bad-data
Listed as ongoing, but also has a completion date 2007-004568-27 A Randomised, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/neu Positive Metastatic Breast Cancer 2012-08-01 bad-data
Completed, but no date, and reported results 2007-004608-11 A randomized, double-blind, placebo-controlled, parallel group study to investigate the safety and tolerability of 14-days treatment with an inhaled dose of QMF149 (500/800) in mild to moderate asthma... bad-data
Listed as ongoing, but also has a completion date and reported results 2007-004653-29 A randomized, multi-center, double-blind, placebo-controlled, parallel-group trial to explore the effects of 78 weeks omalizumab treatment as add on therapy on airway inflammation and remodeling in pa... 2011-11-21 bad-data
Reported results 2007-004669-17 A multi-center, open-label, Proof of Concept (PoC) study to evaluate the efficacy and tolerability of STI571 for the treatment of fibrosis in patients with systemic sclerosis 2010-01-13 due-trials
Reported results 2007-004684-22 An exploratory, double-blind, randomized, placebocontrolled, 2-way cross-over study to assess the effect of repeat-dose inhaled indacaterol maleate (300 mcg) on dynamic and static lung hyperinflation,... 2008-08-05 due-trials
Reported results 2007-004726-24 A multicenter, double-blind, randomized, parallel-group study to evaluate the safety, tolerability, and efficacy of once daily amlodipine/valsartan 5/80 mg as compared to amlodipine/valsartan 5/40 ... 2009-12-10 due-trials
Completed, but no date, and reported results 2007-004844-59 A two part, randomized, placebo controlled study to evaluate the pharmacokinetics and cardiovascular pharmacodynamics of AEB071 in combination with ritonavir in healthy volunteers bad-data
Reported results 2007-004845-14 A single-arm, multinational, two year study evaluating the efficacy and safety of lead-in telbivudine for 24 weeks with or without tenofovir treatment intensification in adult patients with HBeAg-posi... 2011-12-28 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-004877-24 A randomized, double-masked, multicenter, laser-controlled Phase III study assessing the efficacy and safety of ranibizumab (intravitreal injections) as adjunctive and mono-therapy in patients with vi... 2010-01-27 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-004888-22 A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed af... 2013-02-06 bad-data
Reported results 2007-004994-25 A multi-center, randomized, double-blind, placebo-controlled, crossover study in women with irritable bowel syndrome to evaluate feasibility and reproducibility of barostat assessments of colorectal s... 2009-04-23 due-trials
Reported results 2007-005088-82 A multi-centre, randomized, double-blind, placebo-controlled, two-period, crossover proof-of-concept study in male patients with Fragile X Syndrome to assess the efficacy, safety and tolerability of m... 2009-02-19 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-005256-16 A 54 week, randomized, double-blind, parallel-group, multicenter study evaluating the long-term gastrointestinal (GI) safety and tolerability of aliskiren (300 mg) compared to ramipril (10 mg) in pati... 2009-09-01 bad-data
Reported results 2007-005294-60 Multicenter, single-arm, single-stage, phase II trial to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tis... 2017-05-17 due-trials
Completed, but no date, and reported results 2007-005367-10 A Phase I/II, open-label, dose escalation trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of RAF265 (CHIR-265) administered orally to patients with locally advanced or metastatic ... bad-data
Listed as ongoing, but also has a completion date and reported results 2007-005383-27 A 3-year, multicenter, double-blind, randomized, placebo-controlled extension to CZOL446H2301E1 to evaluate the efficacy and long term safety of 6 and 9 years zoledronic acid treatment of postmenopaus... 2013-04-11 bad-data
Listed as ongoing, but also has a completion date 2007-005460-28 An open-label, multi-center, expanded access study of RAD001 in patients with metastatic carcinoma of the kidney who are intolerant of or have progressed despite any available vascular endothelial gro... 2014-03-11 bad-data
Reported results 2007-005468-28 A Phase III, randomized, double-blind, placebo controlled, multicenter, 3-period, 14 day crossover study to determine the 24-h lung function profile of indacaterol (300 μg o.d.) in patients with moder... 2008-07-31 due-trials
Completed, but no date, and reported results 2007-005681-13 A pilot, single-blind, forced-titration study to assess the hemodynamic and hormonal effects, safety and tolerability of the aldosterone synthase inhibitor LCI699 in patients with primary hyperaldoste... bad-data
Listed as ongoing, but also has a completion date and reported results 2007-006072-11 A Phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with paclitaxel and carboplatin as first-line treatment for locally advanced or metastatic (stage ... 2010-05-20 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-006189-14 A phase III, randomized, double-blind, triple-dummy, placebo controlled, multicenter, 5- period, single-dose complete block crossover study to determine the onset of action of indacaterol (150 and 300... 2008-09-06 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-006218-40 A phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and safety of Telbivudine (LdT) in Children and Adolescents with Chronic Hepatitis B Virus Infection 2012-03-08 bad-data
Completed, reported early 2007-006279-35 An open-label, multi-center, Phase I-Ib/II study of AUY922 administered as single agent and in combination with bortezomib with or without dexamethasone in adult patients with relapsed or refractory m... 2011-02-18 not-yet-due
Reported results 2007-006648-23 An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis 2010-06-04 due-trials
Reported results 2007-006741-40 A double blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, tolerability and immunogenicity of repeated s.c administrations of 100µg NIC002 vaccine in cigarette smokers wh... 2009-10-29 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-006997-27 A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC) 2014-10-14 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-007000-15 A randomized, double-blind, placebo-controlled, phase II study to evaluate efficacy and safety of deferasirox in non-transfusion-dependent thalassemia patients with iron overload 2012-06-13 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-007160-19 A double blind, randomized, placebo controlled, multicenter, dose finding study of oral AEB071 assessing Psoriasis Area and Severity Index (PASI) response as a function of dose and treatment duration... 2011-08-29 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-000077-38 A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell c... 2013-04-15 bad-data
Listed as ongoing, but also has a completion date 2008-000280-42 A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered to Patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia... 2017-08-24 bad-data
Ongoing, reported early 2008-000301-11 A 12-week treatment, multi-center, randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 µg o.d.) in patients with chronic obstructiv... not-yet-due
Reported results 2008-000357-35 An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinib 2014-08-13 due-trials
Ongoing 2008-000358-11 An open-label, multi-center, single-arm study to evaluate the efficacy of nilotinib in adult patients with metastatic or unresectable gastrointestinal stromal tumors in first line treatment not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-000411-15 A Phase Ib multicenter dose-determination study, with an adaptive, randomized, placebo-controlled, double-blind phase II, using various repeated IV doses of BHQ880 in combination with zoledronic acid ... 2011-12-09 bad-data
Reported results 2008-000498-40 A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching place... 2016-06-15 due-trials
Reported results 2008-000531-18 A 12 to 36-month extension to a 12-month, open-label, randomised, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus Neoral in c... 2012-07-30 due-trials
Reported results 2008-000581-23 A randomized, double-masked, placebo-controlled add on study to assess the efficacy of oral aliskiren 300 mg once daily for diabetic macular edema 2011-02-03 due-trials
Reported results 2008-000663-42 A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two do... 2009-02-26 due-trials
Completed, report not yet due 2008-000673-38 A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in Patients with Anthracycline- or Taxane-Exposed ErbB2-positive Metastatic B... 2018-03-22 not-yet-due
Reported results 2008-000790-38 A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of oral RSV604 in healthy adults experimentally infected with respiratory syncytial virus 2009-06-17 due-trials
Reported results 2008-000862-21 A 12 week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and hydrochlorothiazide 25 mg compared to aliskiren ... 2009-04-03 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-000901-13 A randomized, multi-center, double-blind, double-dummy, parallel-group, 8 week pilot study, to investigate the effect of QMF Twisthaler® (250/400 µg q.d. evening) compared to fluticasone propionate/sa... 2009-06-23 bad-data
Reported results 2008-001035-35 a double blind, double dummy, randomized, multicenter, parallel group study to evaluate the Effects of aliSkiren, ramipril and combination treatment on plasma Concentration of Angiotensin II in Patien... 2011-02-04 due-trials
Reported results 2008-001242-10 A 28 to 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren / amlodipine / and hydrochlorothiazide in patients with essential hyperte... 2009-10-05 due-trials
Reported results 2008-001243-18 A 28 week extension to a 24 week multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of vildagliptin (50 mg qd) versus placebo in patients with type 2 diabete... 2011-04-20 due-trials
Reported results 2008-001246-21 A multicenter, double-blind, randomized study to compare the efficacy of 24 weeks treatment with fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) versus metformin monotherapy (... 2010-02-10 due-trials
Listed as ongoing, but also has a completion date 2008-001252-52 A multicenter, randomized, double-blind, placebo controlled efficacy and safety trial of intravenous (i.v.) zoledronic acid, twice yearly compared to placebo in osteoporotic children treated with glu... 2018-03-05 bad-data
Reported results 2008-001305-42 An eight-week double-blind, multi-center, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren 75mg, 150mg and 300mg in elderly patients with essent... 2009-04-16 due-trials
Reported results 2008-001306-16 A 2 year extension to a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular ... 2011-07-07 due-trials
No trial status on register 2008-001429-32 A multi-center, open label, 24-month treatment study to establish the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of canakinumab (anti-IL-1 beta antibody) in patients with NO... bad-data
Listed as ongoing, but also has a completion date and reported results 2008-001609-40 An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with am... 2009-06-10 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-002039-34 An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al... 2010-12-03 bad-data
Reported results 2008-002096-27 A 24-month double-blind, randomized, multicenter, placebocontrolled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ver... 2011-06-21 due-trials
Ongoing 2008-002102-19 Estudio de pazopanib frente a sunitinib en el tratamiento de sujetos con carcinoma de células renales localmente avanzado y/o metastásico not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-002113-48 A randomized double-blind, placebo-controlled study of RAD001 in the treatment of Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) 2015-11-06 bad-data
Reported results 2008-002309-38 A phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with docetaxel in second-line treatment of patients with advanced or metastatic (stage IIIb/IV) no... 2010-12-20 due-trials
Reported results 2008-002318-22 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder from a Mod... 2011-05-06 due-trials
Reported results 2008-002628-27 Randomized, double-blind, placebo-controlled, multi-center, proof-of-concept study to assess the efficacy of AIN457 in patients with psoriatic arthritis 2010-12-22 due-trials
Reported results 2008-002631-33 Randomized, double-blind, placebo-controlled, multi-center, phase II, proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis 2011-05-12 due-trials
Completed, reported early 2008-002795-96 A single center, phase I, partially blinded, placebo-controlled, first-in-man study to evaluate the safety, tolerability and Proof of Mechanism (PoM) of a single administration of BFH772 in healthy vo... 2010-02-02 not-yet-due
Reported results 2008-002797-36 A twenty-four week, open-label, non-comparative, multicenter study to assess the efficacy and tolerability of an aliskiren-based treatment algorithm in patients with mild to moderate hypertension. 2009-08-19 due-trials
Completed, but no date, and reported results 2008-002848-41 A randomized, double-blind, placebo-controlled ascending dose study to evaluate the effect of APL180 on endothelial function in patients with familial hypercholesterolemia bad-data
Reported results 2008-002854-39 A double blind, placebo controlled, parallel group study with an open label reference arm to assess the effects of intravenously administered AIN457 on ozone induced neutrophilia compared to placebo a... 2009-11-24 due-trials
Reported results 2008-002898-12 An open label, Aclasta, re-treatment of relapsed patients with Paget´s disease of bone who participated in the CZOL446K2304 and CZOL446K2305 Core Registration studies 2012-03-14 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-002983-32 A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML) 2012-02-03 bad-data
Completed, but no date, and reported results 2008-002986-30 A phase Ib, open-label, multi-center dose-finding study of oral panobinostat (LBH589) in combination with ara-C and mitoxantrone as salvage therapy for refractory or relapsed acute myeloid leukemia bad-data
Listed as ongoing, but also has a completion date and reported results 2008-003016-35 A Phase II Study of Oral Panobinostat in Adult Patients with Relapsed/Refractory Classical Hodgkin’s Lymphoma after Failure of High-dose Chemotherapy with Autologous Stem Cell Transfusion and a Gemcit... 2013-08-12 bad-data
Reported results 2008-003139-19 A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose finding study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks treatment in... 2009-07-29 due-trials
Reported results 2008-003199-23 An 8 week, double-blind, randomized, parallel group, active-controlled study to evaluate the efficacy and safety of the combination of Aliskiren /Amlodipine / HCTZ in patients with moderate to seve... 2009-08-07 due-trials
Completed, but no date, and reported results 2008-003207-30 Ensayo abierto, no aleatorizado, multicéntrico, que evalúa la eficacia y seguridad de deferasirox (Exjade®) en pacientes con sobrecarga férrica después de un trasplante alogénico de progenitores hemat... bad-data
Completed, but no date, and reported results 2008-003230-22 Multicenter, open label, prospective study to evaluate the efficacy and safety of deferasirox 30 mg/kg/day for 52 weeks, in transfusion-dependent &amp;#946;-thalassemic patients with cardiac MRI T2*... bad-data
Not reported 2008-003883-20 An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection 2012-04-16 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-004096-21 A phase 1 open label/phase 2 randomized, double-blind, multicenter study investigating the combination of RAD001 and sorafenib (Nexavar®) in patients with advanced hepatocellular carcinoma 2010-10-14 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-004104-31 A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compar... 2015-10-05 bad-data
Ongoing 2008-004177-17 A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Ritux... not-yet-due
Reported results 2008-004242-83 A randomized, 32 week double-blind, parallel-group, multicenter study to compare the efficacy and safety of initiating treatment with combination (aliskiren/amlodipine) therapy in comparison with the ... 2010-04-14 due-trials
Reported results 2008-004412-12 A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as monotherapy in patients with type 2 diabetes 2010-10-18 due-trials
Completed, but no date, and reported results 2008-004467-19 An open-label, single center study of oral AMN 107 (nilotinib) in adult patients with imatinib - resistant or - intolerant chronic myeloid leukemia in chronic phase, accelerated phase or blast crisis... bad-data
Reported results 2008-004666-61 An adaptive dose-ranging, multi-center, single-blind, double-dummy, active-controlled trial to determine the target dose of canakinumab (ACZ885) in the treatment of acute flares in gout patients who a... 2009-08-09 due-trials
Listed as ongoing, but also has a completion date 2008-004672-50 A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or ... 2017-08-24 bad-data
Reported results 2008-004722-16 A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes 2011-06-02 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-004758-34 A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumor... 2014-10-23 bad-data
Reported results 2008-004764-39 A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder after Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Complet... 2011-10-06 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-004932-19 A phase III, open label, randomized, multicenter trial of Ofatumumab added to Chlorambucil vs. Chlorambucil Monotherapy in previously untreated patients with Chronic Lymphocytic Leukemia 2018-05-17 bad-data
Reported results 2008-005012-41 A multi-center, randomized, double-blind, placebo controlled clinical trial to evaluate the effect of 52 weeks treatment with vildagliptin on left ventricular function in patients with type 2 diabetes... 2012-08-13 due-trials
Reported results 2008-005065-64 A multicenter, double-blind, randomized, placebo-controlled, two-arm parallel-group study of BGG492 as monotherapy in individuals with refractory partial seizures undergoing inpatient evaluation for e... 2010-08-05 due-trials
Reported results 2008-005109-20 6-month, open-label, randomized, multicenter, prospective, controlled study to evaluate the efficacy, safety and tolerability of Everolimus in de novo renal transplant recipients participating in the ... 2013-03-21 due-trials
Reported results 2008-005146-23 A 12 week treatment, multi-center, randomized, parallel group, double blind, double dummy study to assess the superiority of indacaterol (150 μg o.d.) via a SDDPI in patients with moderate to severe C... 2015-10-09 due-trials
Reported results 2008-005168-15 A randomized, double-blind, two way cross-over, proof of concept study to compare the efficacy, safety, pharmacokinetics and pharmacodynamics of two-week oral administration of QAV680 versus placebo, ... 2009-10-07 due-trials
Reported results 2008-005216-40 An 8-week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and amlodipine 10 mg compared to amlodipine 10 mg in p... 2009-11-03 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-005320-81 A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1β monoclonal antibody in patients with active rheumatoid arthr... 2009-06-10 bad-data
Reported results 2008-005392-10 A multi-centre, randomized, double-blind, parallel group, active and placebo controlled, Proof of Concept study in patients with acute migraine to assess the efficacy, safety and tolerability of singl... 2010-08-24 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-005476-27 A randomized, double-blind, placebo controlled, single-dose study to assess the initial efficacy of canakinumab (ACZ885) with respect to the adapted ACR Pediatric 30 criteria in patients with Systemic... 2010-12-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-005479-82 A randomized, double-blind, placebo controlled, withdrawal study of flare prevention of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manif... 2011-09-15 bad-data
Reported results 2008-005500-10 An eight-week, randomized, double-blind, parallel-group, pilot study to evaluate the efficacy and safety of aliskiren 300 mg in comparison with valsartan 320 mg in patients with mild to moderate hyper... 2009-10-23 due-trials
Completed, reported early 2008-005506-40 A double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study, to evaluate the safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administrations of LD... 2010-08-19 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-005802-37 An 8 day open-label, multiple-dose, multi-center study to evaluate the safety/tolerability and pharmacokinetics of aliskiren in hypertensive pediatric and adolescent patients 6 – 17 years of age 2010-01-08 bad-data
Reported results 2008-005810-39 An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the aliskiren 300 mg plus hydrochlorothiazide 25 mg in hypertensive patients not adequately responding to ... 2009-08-26 due-trials
Listed as ongoing, but also has a completion date 2008-005811-16 A Phase III, Open Label, Randomized Trial of Ofatumumab added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia 2017-10-25 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-005870-11 A Phase II multi-center, non-randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma. 2013-04-04 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-005876-28 A 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled study to evaluate canakinumab (ACZ885) for prophylaxis of signs and symptoms of acute flares in chronic gout patien... 2010-02-04 bad-data
Reported results 2008-006097-15 A double-blind, randomized, placebo- controlled multi-center trial to compare the phosphate lowering efficacy of different doses of SBR759 to placebo 2010-08-16 due-trials
Reported results 2008-006156-22 A single-blind, multiple dose, placebo-controlled, double dummy study to investigate the pharmacodynamic and pharmacokinetic interaction between aliskiren and furosemide in patients with heart failure... 2011-08-16 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-006181-28 A single arm, multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancer 2014-12-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-006182-88 A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe 2016-11-07 bad-data
Completed, but no date, and reported results 2008-006270-15 A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy and tolerability of AFQ056 in reducing L-dopa induced dyskinesias in Parki... bad-data
Reported results 2008-006305-16 A randomized, open-label, multicenter, two-period crossover study to evaluate the 24 hour bronchodilator profile of Tiotropium Bromide Respimat® administered once daily versus twice daily in patients ... 2009-05-06 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-006311-21 A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis 2012-06-13 bad-data
Reported results 2008-006430-10 A multi-center, open label Phase II trial of TKI258 in FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer. 2011-03-02 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-006447-40 A 104 week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy of aliskiren on the progression of atherosclerosis in patients with coronary art... 2013-01-31 bad-data
Reported results 2008-006544-20 A randomized, double-blind, multi-center phase III study comparing everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in patients with advanced gastric cancer after... 2014-01-30 due-trials
Listed as ongoing, but also has a completion date 2008-006556-21 A randomized phase III, double-blind, placebo-controlled multicenter trial of Everolimus in combination with Trastuzumab and Paclitaxel, as first line therapy in women with HER2 positive locally advan... 2017-10-23 bad-data
Reported results 2008-006849-28 A randomized, double-blind, placebo-controlled, multi-center, two-period crossover study to investigate the bronchodilatory effect of 50µg NVA237 inhaled once daily in patients with Chronic Obstructiv... 2009-05-07 due-trials
Completed, reported early 2008-006931-11 A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of twice daily oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic r... 2014-10-21 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-006976-31 A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg ... 2010-03-17 bad-data
Completed, but no date, and reported results 2008-007015-32 A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with multip... bad-data
Listed as ongoing, but also has a completion date and reported results 2008-007054-35 A RANDOMIZED PHASE III STUDY OF IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIB 2014-07-25 bad-data
Reported results 2008-007337-49 A phase II, randomized, double-blind, placebo controlled, multi-center study to evaluate the effects of LCI699 on cortisol in patients with hypertension. 2009-08-12 due-trials
Reported results 2008-007338-23 A phase II, randomized, double-blind, placebo and active controlled, parallel group, multi-center, dose ranging study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks tr... 2009-10-13 due-trials
Reported results 2008-007348-32 An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin 2015-06-10 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-007467-17 An open-label, multi-center, 24-month extension study to evaluate the safety of ranibizumab as symptomatic treatment for visual impairment due to diabetic macular edema in patients who have complet... 2012-01-19 bad-data
Completed, but no date, and reported results 2008-007507-83 Once-a-day regimen or Steroid withdrawal in de novo kidney transplant recipients treated with everolimus, cyclosporin and steroids: a 12-month, prospective, randomized, multicenter, open-label study. ... bad-data
Reported results 2008-007525-39 A randomized, double-blind, placebo controlled, multicenter regimen finding study of subcutaneously administered AIN457, assessing Psoriasis Area and Severity Index (PASI) response in patients with mo... 2010-12-16 due-trials
Reported results 2008-007831-41 A twelve-week, randomized, double-blind, parallel group study to evaluate the prolonged efficacy and safety of aliskiren 300 mg compared to telmisartan 80 mg in mild to moderate hypertensive patients ... 2010-06-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-007944-33 A phase IIIb multicenter, 52 week treatment, randomized, blinded, double dummy, parallel group efficacy study comparing the effect of inhaled indacaterol 150 &amp;#956;g o.d. vs inhaled tiotropium ... 2012-07-05 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-008008-42 An open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations 2015-01-21 bad-data
Reported results 2008-008359-40 A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (ant... 2010-08-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-008394-63 A 52-week treatment, randomized, double-blind, placebo-controlled, with open label tiotropium, parallel-group study to assess the efficacy, safety and tolerability of NVA237 in patients with chronic o... 2011-04-28 bad-data
Reported results 2008-008447-26 A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg ... 2010-02-09 due-trials
Reported results 2008-008697-31 A randomized Phase III, double-blind, placebo-controlled multicenter trial of daily everolimus in combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over-expressing loca... 2015-06-11 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-008698-69 A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic... 2014-12-04 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-008712-98 13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Par... 2010-12-03 bad-data
Reported results 2008-008719-25 A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determi... 2011-05-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-008748-26 A phase IIIb randomized, double-blind, placebo controlled, 2 period crossover, multicenter study to assess the effect of indacaterol (150 μg o.d.) on exercise endurance in patients with moderate to se... 2010-01-14 bad-data
Reported results 2009-009858-24 A Randomized Study of the JAK Inhibitor INCB018424 Tablets Compared to Best Available Therapy in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essent... 2015-03-04 due-trials
Reported results 2009-009888-60 A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5, 1... 2010-06-21 due-trials
Reported results 2009-009889-13 Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration for the Treatment of Hyperglycemia in Metformin Monotherapy Treated Type 2 Diabetic Patients: a Randomized, Double-... 2010-09-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-009995-11 A randomized, adaptive-design dose finding study to assess the antiviral efficacy and safety of NIM811 administered in combination with Standard of Care (SOC) for 12 weeks in relapsed HCV-1 infecte... 2011-04-27 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-010170-38 A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People Aliskiren Prevention Of Later Life Outcomes (APOLLO) 2012-11-02 bad-data
Reported results 2009-010196-25 A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced Hepatocellular Carcinoma after ... 2013-10-15 due-trials
Reported results 2009-010198-19 A Phase 2 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ908 for weight reduction and reduced LDL ch... 2010-09-03 due-trials
Reported results 2009-010208-27 A 36-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic he... 2011-12-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-010236-18 A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the 6 months efficacy and safety of aliskiren therapy on top of standard therapy, on morbidity and mort... 2012-07-02 bad-data
Reported results 2009-010403-84 A one year, open label, multicenter trial of LBH589 alone or in combination with ESA in red blood cell transfusion-dependent LOW and INT-1 MDS patients being either refractory to ESA or with a low pro... 2012-07-18 due-trials
Ongoing 2009-010548-32 A phase Ib/IIb, open-label, multi-center study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza®) in adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic le... not-yet-due
Reported results 2009-010589-46 A multi-centre, randomized, double-blind, placebo controlled, multiple-dose, 4-way cross-over study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol sa... 2009-11-03 due-trials
Reported results 2009-010665-23 A 12-week treatment, multi-center, randomized, parallel group, blinded, double dummy study to compare the efficacy and safety of Indacaterol (150 &amp;#956;g o.d.) delivered via a SDDPI with Tiotro... 2010-03-25 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-010806-12 A multi-center, randomized, open label, controlled study to compare the Sustained Virological Response during treatment with Neoral or tacrolimus in maintenance liver transplant recipients treated ... 2013-05-01 bad-data
Completed, but no date, and reported results 2009-010825-37 Ensayo clínico de fase II, controlado, abierto, aleatorizado y multicéntrico, para comparar la eficacia y la seguridad de ranibizumab (inyección intravítrea) frente a fotocoagulación láser en paciente... bad-data
Listed as ongoing, but also has a completion date and reported results 2009-010875-26 A double-blind, placebo-controlled, randomized Phase 2 study of BHQ880, an anti-Dickkopf1 (DKK1) monoclonal antibody (mAb), in patients with untreated multiple myeloma and renal insufficiency 2013-05-02 bad-data
Completed, but no date, and reported results 2009-010937-38 A 16-week treatment, multicenter, randomized, double blind, placebo-controlled, parallel-group study to assess the effect of omalizumab on the expression of FcεRI receptors of blood basophils and dend... bad-data
Reported results 2009-011000-34 A 16-week multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of subcutaneous AIN457 followed by an extensio... 2011-03-04 due-trials
Reported results 2009-011007-23 A facilitated access open-label, non-randomized, multicenter, long-term safety and efficacy study in Chronic Kidney Disease patients treated with SBR759 who have completed previous SBR759 studies 2010-08-23 due-trials
Reported results 2009-011008-43 Early vs.delayed EVERolimus in de novo HEART transplant recipients: optimozation of the safety/efficacy profile (EVERHEART Study) 2014-01-27 due-trials
Reported results 2009-011056-21 An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in... 2015-05-29 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-011128-70 A randomized, double-blind, multicenter, phase III study to evaluate the efficacy and safety of pasireotide LAR in patients with Cushing’s disease 2016-12-21 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-011237-27 A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated wit... 2010-09-08 bad-data
Completed, but no date, and reported results 2009-011296-80 Efficacy of Rasilez® (Aliskiren) compared to ramipril in the treatment of moderate systolic hypertensive patients bad-data
Completed, but no date, and reported results 2009-011473-33 Etude prospective, multicentrique, randomisée, en ouvert, évaluant la progression de la fibrose rénale selon le profil de transition épithélio-mésenchymateuse chez des patients adultes transplantés ré... bad-data
Reported results 2009-011539-10 A randomized, multi-center, parallel group, double blind, study to assess the safety of QMF Twisthaler® (500/400μg) and mometasone furoate Twisthaler® (400μg) in adolescent and adult patients with per... 2011-05-06 due-trials
Reported results 2009-011571-71 A randomized, double-blind, multi-center, placebo-controlled, 3-treatment arm, parallel group study to evaluate the efficacy and safety of diclofenac diethylamine 2.32% gel applied twice or three time... 2009-12-14 due-trials
Reported results 2009-011590-32 A Multi-Center, Randomized, Double Blind, Placebo-Controlled, ‘add-on’ study to investigate the efficacy and safety of 24 weeks intravenous treatment with QAX576 in patients (≥18-75 years) with persis... 2012-04-10 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-011591-30 An open-label non-randomized extension study to evaluate the safety and tolerability of AIN457 (anti interleukin-17 monoclonal antibody) in patients with moderate to severe ankylosing spondylitis 2012-12-05 bad-data
Ongoing, reported early 2009-011621-14 A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’s disease not-yet-due
Listed as ongoing, but also has a completion date and reported results 2009-011622-34 An open label non-randomized extension study to evaluate the safety and tolerability of AIN457 (anti interleukin-17 monoclonal antibody) in patients with psoriatic arthritis 2012-11-07 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-011626-34 A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 w... 2012-04-26 bad-data
Reported results 2009-011743-39 A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safety a... 2011-08-26 due-trials
Reported results 2009-011888-37 A 1-year, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of zoledronic acid 5 mg (Aclasta®) on bone mineral density in patients with multiple ... 2012-06-20 due-trials
Reported results 2009-012057-38 A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arterial h... 2011-05-12 due-trials
Reported results 2009-012098-36 A multicenter, randomized, double-blided, placebo and positve controlled study to evaluate the anti-pruritic effect, safety and tolerability, systemic and skin exposure, after 2 weeks of treatment wit... 2011-07-13 due-trials
Completed, but no date, and reported results 2009-012196-10 A single-blind, double dummy, randomized, multi-dose, two sequence, crossover, study to investigate the Added effects of Renin Inhibitor (aliskiren 300 mg) on Albuminuria in non-diabetic nephropathy p... bad-data
Reported results 2009-012316-40 A 24-week open-label, multicenter, follow-up and extension study to CACZ885H2251, to assess safety, tolerability and efficacy of canakinumab (ACZ885) in patients with gout who are given canakinumab a... 2010-08-03 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-012394-35 A 90-week, multi-center, randomized, double-blind, placebo-controlled study in patients with mild Alzheimer s Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody respon... 2012-12-28 bad-data
Reported results 2009-012395-27 An open-label extension to a 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tole... 2011-06-21 due-trials
Reported results 2009-012417-22 A phase II, multi-center, non-randomized, open-label study of TKI258 in patients with relapsed or refractory multiple myeloma, who are with or without t(4;14) translocation 2013-02-12 due-trials
Listed as ongoing, but also has a completion date 2009-012418-38 A multi-center, randomized, double-blind, placebocontrolled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload 2018-02-27 bad-data
Listed as ongoing, but also has a completion date 2009-012518-39 A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded t... 2018-06-26 bad-data
Reported results 2009-012600-48 A randomized, partially-blinded, single-dose, 4-way crossover study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol maleate administered via the Conce... 2010-03-19 due-trials
Reported results 2009-012616-40 An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients with Evidence of Persistent Leukemia by RQ-... 2015-07-03 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-013074-41 A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican®) and early elimination of cyclosporine (Sandimmun Neoral®) in de novo heart transplant reci... 2014-11-17 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-013235-38 A multicenter, randomized, double-blind, placebocontrolled study, to assess the long term safety of 52 weeks treatment with QVA149 (110μg indacaterol / 50μg glycopyrrolate) in patients with moderate t... 2011-12-14 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-013256-69 A 52-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium ... 2012-08-11 bad-data
Ongoing, reported early 2009-013429-40 Randomized, double-blind, placebo-controlled trial to determine the capacity of VAK694 to elicit long term immune tolerance when combined with subcutaneous allergen immunotherapy for the treatment of ... not-yet-due
Completed, but no date, and reported results 2009-013504-32 A 26-week treatment, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety and tolerability of NVA237 in patients with chronic obstructive pulmonary disease... bad-data
Completed, reported early 2009-013665-26 A double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study to evaluate the efficacy, safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administrati... 2011-05-10 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2009-013667-19 A randomized, double-blind, placebo-controlled, parallel group study to evaluate AFQ056 in adult patients with Fragile X Syndrome 2013-08-14 bad-data
Reported results 2009-013686-26 A randomized, double-blind, placebo controlled, multicenter, 3-period crossover study to compare the effect of indacaterol (150μg o.d.) on inspiratory capacity to placebo in patients with moderate COP... 2011-01-19 due-trials
Completed, but no date, and reported results 2009-013763-19 Multicenter, randomized, blinded, placebo controlled, cross over, single dose study to assess the effect of indacaterol (150 �g) versus tiotropium (18 �g) on Inspiratory Capacity in moderate COPD pati... bad-data
Completed, but no date, and reported results 2009-013780-19 Estudio multicéntrico, aleatorizado, abierto, de 24 meses de duración, con dos grupos paralelos, para comparar la eficacia de everolimus en la mejora del perfil cardiovascular en el régimen con AMF vs... bad-data
Reported results 2009-013901-33 A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or... 2011-01-13 due-trials
Reported results 2009-014038-11 A randomized, double-blind, placebo-controlled, 2-period, cross-over study to assess the efficacy and safety of differing doses of NVA237 administered either once daily or twice daily, in patients wit... 2010-12-30 due-trials
Completed, but no date, and reported results 2009-014359-63 A double blind, randomized, parallel study to assess the effects of aliskiren/amlodipine and amlodipine monotherapy on ankle foot volume (AFV) in patients naïve to trial drugs with mild to moderate hy... bad-data
Reported results 2009-014391-22 An open label, multi-center, randomized, comparative Phase IIIb study to compare efficacy and safety of intravenous (i.v.) daptomycin with that of Semi-synthetic Penicillins (SSPs) or vancomycin in th... 2011-03-24 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-014392-51 A dose blinded extension study to the CBAF312A2201 study to evaluate long-term safety, tolerability and efficacy of BAF312 given orally once daily in patients with relapsing multiple sclerosis. 2016-10-10 bad-data
Completed, but no date, and reported results 2009-014562-26 “Estudio multicéntrico, aleatorizado, abierto de maximización de micofenolato sódico (MFS) versus micofenolato mofetilo (MMF) para minimizar la dosis de tacrolimus en pacientes trasplantados renales e... bad-data
Listed as ongoing, but also has a completion date and reported results 2009-014618-80 A multi center, randomized, double blind, placebo-controlled, study of the safety, tolerability, and the effects on arterial structure and function of ACZ885 in patients with clinically evident athero... 2014-02-05 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-014834-22 A 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with activ... 2011-02-24 bad-data
Reported results 2009-014835-19 A 24-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppressio... 2011-06-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-014846-26 A Phase III randomized, double blind, placebo controlled, multicenter study of panobinostat for maintenance of response in patients with Hodgkin’s lymphoma who are at risk for relapse after high dos... 2012-05-14 bad-data
Ongoing, reported early 2009-014854-14 A phase II, open-label, multicentre, 12 month study to evaluate the efficacy and safety of ranibizumab (0.5 mg) in patients with choroidal neovascularization secondary to pathological myopia (PM) not-yet-due
Reported results 2009-015017-48 A randomized, double blind, placebo and Naproxen controlled, multi-center, study to determine the safety, tolerability, pharmacokinetics and effect on pain of a single intra-articular administration o... 2011-07-28 due-trials
Reported results 2009-015018-23 A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated, not tolera... 2010-07-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-015407-47 A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy... 2012-03-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-015417-46 A Phase Ib/II, open label, multi-center study evaluating the safety and efficacy of BKM120 in combination with trastuzumab in patients with relapsing HER2 overexpressing breast cancer who have previou... 2014-04-07 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-015456-14 A partially blinded, prospective, randomized multicenter study evaluating efficacy, safety and tolerability of oral sotrastaurin plus standard or reduced exposure tacrolimus vs. myfortic plus tacrolim... 2012-08-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-015459-25 An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogen... 2014-07-01 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-015507-52 A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. 2015-07-30 bad-data
Reported results 2009-015508-24 A 38-week extension to a 24-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintaining uveitis suppression when reducing sys... 2011-07-15 due-trials
Reported results 2009-015509-38 A 34-week extension to a 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppressio... 2011-02-24 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-015514-21 Ensayo TEAM (eficacia de Tasigna en melanoma avanzado): Un estudio fase III, aleatorizado, abierto, multicéntrico, con dos grupos de tratamiento para comparar la eficacia de Tasigna® frente a dacarbaz... 2014-12-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-015628-27 A phase Ib/II, multi-center, open-label study to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer, that has p... 2013-09-11 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-015834-31 A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chro... 2015-05-21 bad-data
Reported results 2009-015918-22 A 24 months, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calcin... 2014-10-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-016590-15 A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of... 2015-06-24 bad-data
Reported results 2009-016604-23 A multi-center, double-blind, placebo-controlled, randomized study to compare the effect of a subcutaneous canakinumab administration to placebo in patients with Impaired Glucose Tolerance or patie... 2010-08-06 due-trials
Reported results 2009-016693-33 An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the single pill (SPC) combination of Aliskiren 300 mg / Amlodipine 10 mg in hypertensive patients not adeq... 2010-10-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-016722-13 A phase III, multicenter, randomized, parallel-group study to assess the efficacy and safety of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open-label octreotide LAR or lanreo... 2017-02-28 bad-data
Reported results 2009-016734-26 A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder after Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Patients Who success... 2012-03-19 due-trials
Completed, but no date, and reported results 2009-016735-36 Estudio de los efectos de ALiskiren o Losartán sobre los bioMARKadores del remodelado miocárdico. Estudio ALLMARK bad-data
Reported results 2009-016807-42 A randomized, double-blind, placebo controlled, multicenter dose ranging study of subcutaneously administered AIN457, assessing Psoriasis Area and Severity Index (PASI) response in patients with moder... 2011-02-14 due-trials
Ongoing, reported early 2009-016834-28 An open-label, multi-center, continued access trial of investigational drug ASA404 for patients in previous ASA404 clinical trials not-yet-due
Listed as ongoing, but also has a completion date and reported results 2009-016859-22 A one-year open-label, multicenter trial to assess efficacy, safety and tolerability of canakinumab (ACZ885) and the efficacy and safety of childhood vaccinations in patients aged 4 years or younger w... 2014-11-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-017028-22 A multicenter, randomized, double-blind, 8 week study to evaluate the dose response, efficacy and safety of aliskiren in pediatric hypertensive patients 6-17 years of age 2014-08-14 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-017029-20 A multicenter, double-blind, randomized, 52 week extension study to evaluate the long term safety, tolerability and efficacy of aliskiren compared to enalapril in pediatric hypertensive patients 6-17 ... 2015-08-13 bad-data
Completed, but no date, and reported results 2009-017148-15 A retrospective pharmacogenetic analysis of patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN) in clinical studies CCOX189A0117, CCOX189A2332, CCOX189A2369, CCOX189A0126, CC... bad-data
Listed as ongoing, but also has a completion date and reported results 2009-017234-51 A multicenter extension trial of subcutaneously administered AIN457 in patients with moderate to severe chronic plaque-type psoriasis 2016-12-22 bad-data
Reported results 2009-017267-41 A randomized, double-blind, parallel group study to compare the pharmacodynamics/efficacy, safety and pharmacokinetics of QAV680 versus placebo in patients with moderate persistent asthma 2010-09-02 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-017311-15 Estudio de extensión al estudio multicéntrico, aleatorizado, abierto y controlado CRAD001H2304, para evaluar la eficacia y seguridad a largo plazo de everolimus con control de la concentración en rece... 2013-05-03 bad-data
Reported results 2009-017503-29 A randomized, controlled extension study of CACZ885H2356 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tol... 2010-10-12 due-trials
Reported results 2009-017594-37 A multicenter, open-label 18 month study to evaluate the long-term safety and tolerability of valsartan in children 6 to 17 years of age with hypertension and with or without chronic kidney disease. 2015-09-10 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-017772-25 A 26-week treatment multi-center, randomized, doubleblind, parallel-group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 μg q.d.) i... 2012-02-13 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-017775-19 A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase 2014-07-07 bad-data
Completed, but no date, and reported results 2009-017802-35 A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not toler... bad-data
Reported results 2009-017961-52 A 12-week, multi-center, randomized, double-blind, placebo-controlled efficacy and safety study examining seizure frequency of BGG492 capsules administrated orally three times daily (TID) as adjunc... 2011-09-26 due-trials
Reported results 2009-018091-34 A multicenter open label phase II study to evaluate the safety and efficacy of deferasirox in combination with deferioxamine followed by transitioning to deferasirox monotherapy in β-thalassemia patie... 2014-06-06 due-trials
Completed, but no date, and reported results 2009-018117-40 Etude prospective, randomisée, comparant les profils glycémiques sur 72 hr obtenus par enregistrement continu du glucose (CSGM) chez des patients diabétiques de type 2 insuffisamment contrôlés par la ... bad-data
Listed as ongoing, but also has a completion date and reported results 2009-018167-26 An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension. 2014-04-16 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-018174-54 MERIDIAN: A 12-month prospective, open-label, randomized, multicenter, parallel-group study to evaluate the efficacy, safety and tolerability of a Myfortic®-based regimen in the conversion from a CNI ... 2010-07-06 bad-data
Completed, reported early 2010-018418-53 A non-randomized, open-label study to characterize the pharmacokinetics of Glivec/Gleevec® (imatinib mesylate) in pediatric (age range 1 to less than 4 years) patients with chronic myeloid leukemia (C... 2011-05-20 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2010-018419-14 A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec® (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with ref... 2015-07-01 bad-data
Reported results 2010-018481-22 A multi-center, randomized, double-blind, placebo-controlled, parallel group, repeated-dose study to evaluate the efficacy, safety, tolerability and pharmacokinetics of three different dosing regimens... 2010-07-12 due-trials
Reported results 2010-018597-20 A multi-center, randomized, double-blind, placebo- controlled, two-period cross-over study to assess the effect of 50µg inhaled NVA237 on exercise endurance in patients with moderate to severe COPD 2011-03-08 due-trials
Reported results 2010-018766-23 a 12-week, randomized, double-blind, placebo-controlled exploratory dose-titration study to assess the antiepileptic activity of BGG492 given orally three times daily (TID) as adjunctive treatment in ... 2011-01-31 due-trials
Reported results 2010-018780-42 Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Releapsed After Rituximab-Containing Therapy 2017-01-19 due-trials
Reported results 2010-018852-29 A 12-month, two-armed, randomized, double-masked, multicenter, Phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to Ranibizumab intravitreal injections vs. las... 2011-05-20 due-trials
Completed, but no date, and reported results 2010-018913-32 A controlled extension study of CACZ885H2357 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or in... bad-data
Reported results 2010-019028-30 A 3-month blinded, randomized, multicenter, placebo controlled study to evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus tox... 2011-05-17 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-019029-32 A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis 2011-10-13 bad-data
Reported results 2010-019200-23 A multi-center, prospective, open-label, 8-weeks study to investigate the efficacy, safety and pharmacokinetics of certoparin (3000 IU anti-Xa bolus, with the option to titrate dose) in the prophylaxi... 2011-03-28 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-019348-37 A phase 1 study of LDE225 in pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway 2014-10-03 bad-data
No trial status on register 2010-019353-18 A sequential, open-label, two-period study to assess the pharmacokinetics, safety and tolerability of two dose levels of AFQ056 in male, adolescent patients with Fragile X Syndrome (12 to 18 years inc... bad-data
Listed as ongoing, but also has a completion date and reported results 2010-019395-73 A 2-week single-blind, randomized, 3-arm proof of concept study of the effects of AIN457 (anti-IL17 antibody), ACZ885 (canakinumab, anti-IL1b antibody), or corticosteroids in patients with polymyalgia... 2013-01-29 bad-data
Reported results 2010-019418-25 An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias 2013-10-15 due-trials
Reported results 2010-019559-23 An open-label extension study of CACZ885H2356E1 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or... 2011-09-27 due-trials
Ongoing 2010-019577-16 A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first-line therapy in p... not-yet-due
Reported results 2010-019689-10 A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus 2013-02-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-019795-74 A 2 year randomized, single-masked, multicenter, controlled phase IIIb trial assessing the Efficacy and safety of 0.5 mg ranibizumab in two “treat and extend” treatment algorithms vs. 0.5 mg ranibizum... 2013-06-28 bad-data
Completed, but no date, and reported results 2010-019825-32 An exploratory, open label, non-randomized, within-patient multiple dose-escalation safety, tolerability, PK and efficacy trial of RAD001 (everolimus) in patients with Lymphangioleiomyomatosis. bad-data
Reported results 2010-019856-30 A randomized, double-blind, vehicle-controlled, multicenter trial of topically administered LDE225 cream [0.75% bid] to evaluate clearance of Basal Cell Carcinoma in adult patients with Nevoid Basa... 2010-07-22 due-trials
Reported results 2010-019883-36 A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) 2013-01-22 due-trials
Reported results 2010-019970-33 A multi-centre, double-blind, placebo controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of KRP203 in subjects with moderately active refractory ulcer... 2012-05-15 due-trials
Completed, but no date, and reported results 2010-019973-13 A multi-center, randomized, double-blind, active controlled study to assess efficacy, safety and tolerability of the anti-IL13 monoclonal antibody QAX576 in the treatment of perianal fistulas in patie... bad-data
Listed as ongoing, but also has a completion date and reported results 2010-020033-14 A multicentre, randomized, double-blind, placebocontrolled, parallel-group phase II study on efficacy and safety of DEB025 combined with peg-IFN alfa-2a and ribavirin in chronic hepatitis C genotype 1... 2013-05-09 bad-data
Reported results 2010-020034-26 A multicenter, randomized, open label, parallel-group phase IIB study on the efficacy and safety of oral regimens of DEB025 alone or in combination with ribavirin versus Standard of Care (peg-IFN alph... 2012-05-15 due-trials
Ongoing, reported early 2010-020060-38 An open-label extension study of CACZ885H2357E1 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2010-020061-24 An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 5-month follow-up and long-term treatment period in patients with active recurrent or chronic TNF-receptor a... 2014-06-20 bad-data
Reported results 2010-020116-11 A phase II, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in patients with advanced non-small-cell lung cancer who have received at least two lines of prior chemot... 2014-07-13 due-trials
Reported results 2010-020166-20 A randomized, double-blind, multiple-dose, placebo-controlled, parallel group study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of ACZ885 in patients w... 2011-06-03 due-trials
Reported results 2010-020177-16 A randomized, placebo- controlled, parallel group study to assess the efficacy, safety, and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma 2011-09-26 due-trials
Ongoing 2010-020399-41 A 1-year, multicenter, open-label extension to CZOL446H2337 to evaluate safety and efficacy of zoledronic acid twice yearly in osteoporotic children treated with glucocorticoids not-yet-due
Reported results 2010-020447-13 An open-label, multicenter phase II study to examine the efficacy and 2015-05-05 due-trials
Completed, but no date, and reported results 2010-020460-38 Etude prospective, randomisée, en ouvert évaluant le bénéfice clinique sur les hypoglycémies après 6 mois de l’addition de la vildagliptine versus celle d’un autre antidiabétique oral, chez des patien... bad-data
Ongoing 2010-020515-37 A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple ... not-yet-due
Reported results 2010-020684-20 A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin, with or without ... 2011-10-24 due-trials
Reported results 2010-020688-18 A randomized, double-blind, placebo-controlled, multipledose, exploratory proof of concept study to assess the safety, tolerability, efficacy, pharmacodynamics and 2013-04-26 due-trials
Listed as ongoing, but also has a completion date 2010-020807-57 Estudio Fase III, aleatorizado, multicéntrico y abierto, para evaluar eficacia y de seguridad del inhibidor de JAK INC424 (comprimidos), frente al mejor tratamiento de soporte en pacientes con policit... 2018-02-09 bad-data
Completed, but no date, and reported results 2010-020904-31 Estudio piloto, abierto, multicéntrico, de eficacia y seguridad del tratamiento con canakinumab durante 6 meses y seguimiento de hasta 6 meses, en pacientes con síndrome de Hiper-IgD activo. bad-data
Reported results 2010-020935-38 A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of diclofenac sodium topical gel 1% applied four times daily in subjects with acu... 2011-08-22 due-trials
Reported results 2010-020936-21 A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of diclofenac sodium topical gel 1% applied four times daily in subjects with acu... 2011-07-24 due-trials
Ongoing 2010-020965-26 A randomized, double blind, placebo controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephre... not-yet-due
Reported results 2010-021062-29 Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe car... 2013-11-18 due-trials
Reported results 2010-021097-11 A multi-center, randomized, double-blind placebo controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiri... 2011-11-21 due-trials
Reported results 2010-021137-32 A multi-center, double-blind, randomized, placebocontrolled, cross-over study to evaluate the efficacy, safety and tolerability of SAF312 in subjects with neurogenic detrusor overactivity due to spina... 2012-09-26 due-trials
Reported results 2010-021236-34 Pilot study to assess the difference in glycemic profiles between vildagliptin and glimepiride using CGM device 2011-03-18 due-trials
Reported results 2010-021239-15 Estudio multicéntrico, abierto para evaluar el uso clínico a largo plazo del tratamiento con AIN457 en pacientes que finalicen los ensayos clínicos en los que se investiga AIN457 para el tratamiento d... 2011-03-28 due-trials
Reported results 2010-021344-17 A non-randomized, multiple dose, three treatment period, open-label, single sequence, single group study to evaluate the pharmacokinetic effect of two doses of QTI571 (imatinib) on the co-administe... 2012-12-24 due-trials
Reported results 2010-021448-17 A multicenter, open-label, follow-up study to evaluate the long-term safety and tolerability of BGG492 TID as adjunctive therapy in patients with partial onset seizures completing double-blind, placeb... 2012-07-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-021533-31 A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD 2012-08-07 bad-data
Reported results 2010-021653-39 A randomized, double-blind, parallel group, single-dose study of the efficacy of lidocaine 8 mg + cetylpyridinium chloride (CPC) 2 mg fixed combination lozenges on sore throat pain intensity compared ... 2011-06-30 due-trials
Reported results 2010-021662-30 A 12 month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PDT i... 2012-08-17 due-trials
Reported results 2010-021723-27 An exploratory, randomized, double-blind, placebo controlled, multi-center study to assess the efficacy, safety and tolerability of a single and a repeated dose of oral 2013-05-14 due-trials
Reported results 2010-021960-14 An open-label extension study to CQTI571A2102 to evaluate the long-term safety, tolerability and efficacy of QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension 2014-03-27 due-trials
Reported results 2010-022015-19 A Phase II, single-arm study of orally administered BKM120 as second-line therapy in patients with advanced endometrial carcinoma 2014-02-14 due-trials
Completed, but no date, and reported results 2010-022029-13 A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with intravenous BHQ880, a fully human, anti-Dickkopf1 (DKK1) neutralizing antibody in previously untre... bad-data
Reported results 2010-022066-28 A 6-month multicenter, single-arm, open-label study to investigate changes in biomarkers after initiation of treatment with 0.5 mg fingolimod (FTY720) in patients with relapsing-remitting multiple scl... 2012-07-11 due-trials
Reported results 2010-022166-27 A multicenter, randomized, double-blind, placebo- controlled, cross-over, proof of concept study comparing the effects of both single dose and repeated dosing treatment for 2 weeks of BGG492 2012-01-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-022228-66 A randomized, double-blind, double-dummy, placebo controlled, multicenter study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, compared to placebo and etanercept,... 2013-07-07 bad-data
Reported results 2010-022273-34 A multi-centric, open-label, phase II study investigating the combination of Afinitor with paclitaxel and carboplatin in first line treatment of patients with advanced (stage IV) large cell lung cance... 2015-03-13 due-trials
Reported results 2010-022326-32 A multi-center, randomized, double-blind, placebo and active controlled, parallel group study to evaluate the dose response of AHU377 in combination with valsartan 320 mg after 8 week treatment in pat... 2011-12-03 due-trials
Ongoing 2010-022403-22 A proof-of concept, open-label, forced titration, multicenter study to assess the safety/tolerability and efficacy of 10-weeks treatment of LCI699 in patients with Cushing’s disease not-yet-due
Completed, but no date, and reported results 2010-022406-41 A 3-month, exploratory, non-randomized, multi-center, open label study to evaluate the reliability, safety and usability of the Transplantation Sensor System combined with Myfortic in adult kidney tra... bad-data
Listed as ongoing, but also has a completion date 2010-022583-13 An open-label, multi-center, expanded access study of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC). The EFFECTS STUDY: Everolimu... 2014-03-11 bad-data
Ongoing, reported early 2010-022616-39 RELIGHT - Ranibizumab treatment of diabetic macular oEdema with bimonthLy monItorinG after a pHase of initial Treatment. A UK, 18-month, prospective, open-label, multicenter, single-arm Phase IIIb stu... not-yet-due
Ongoing 2010-022629-14 A phase II, randomized double-blind study of efficacy and safety of two dose levels of LDE225 in patients with locally advanced or metastatic basal cell carcinoma not-yet-due
Listed as ongoing, but also has a completion date and reported results 2010-022638-96 A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome 2014-01-06 bad-data
Reported results 2010-022658-18 A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin in type 2 diabetes mellitus patients ≥ 70 years (drug-nai... 2012-03-14 due-trials
Ongoing, reported early 2010-022713-26 Localized gastrointestinal stromal tumors (GIST): an exploratory open-label, multicenter, single-arm phase II study to evaluate the efficacy of 2 years of adjuvant nilotinib treatment following at lea... not-yet-due
Reported results 2010-022721-14 A randomized, blinded, double-dummy, multi-center, placebo controlled, 3 period, cross-over study to assess the effect of QVA149 (110/50 µg o.d.) on exercise endurance in patients with moderate to sev... 2011-11-30 due-trials
Reported results 2010-022794-34 A randomized, double-blind, placebo-controlled, multi-center parallel group phase IV study to evaluate the efficacy and safety of Voltaren® Schmerzgel 1.16% gel in subjects with acute neck pain 2011-07-18 due-trials
Reported results 2010-022831-12 Etude de la valeur prédictive de la réversibilité de l’obstruction bronchique sur l’efficacité d’un traitement d’un mois par indacatérol (Onbrez Breezhaler) 150 µg une fois par jour chez des patients ... 2012-05-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-022838-85 A Phase III randomized, open-label study comparing GSK1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma 2016-12-16 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-022867-37 A randomized, double-blind, placebo-controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with peg-IFN alfa2a and ribavirin in chronic hepatitis C genotype 1 treatment-naïve... 2013-08-13 bad-data
Ongoing 2010-022970-14 A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction pa... not-yet-due
Reported results 2010-023023-19 A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta-1b... 2015-09-01 due-trials
Not reported 2010-023032-17 An open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors 2012-07-27 due-trials
Ongoing 2010-023055-29 A Phase Ib, open-label, dose-finding study of the JAK inhibitor INC424 tablets administered orally to patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-E... not-yet-due
Listed as ongoing, but also has a completion date 2010-023066-52 An open label, multicenter study investigating the safety and efficacy of ofatumumab therapy versus physicians' choice in patients with bulky fludarabine refractory chronic lymphocytic leukaemia (CLL) 2017-04-27 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-023183-40 A randomized, open-label phase II multicenter study evaluating the efficacy of oral Everolimus alone or in combination with Pasireotide LAR i.m. in advanced progressive pancreatic neuroendocrine tumor... 2015-02-19 bad-data
Ongoing, reported early 2010-023315-34 Etude ouverte, multicentrique, évaluant l’efficacité et la sécurité d’emploi clinique du Lucentis® (ranibizumab 0,5 mg) chez des patients Diabétiques présentant une atteinte visuelle due à un œdème ma... not-yet-due
Ongoing 2010-023412-13 A Phase II, open-label study to assess the safety and efficacy of oral MEK162 in adults with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS m... not-yet-due
Reported results 2010-023512-13 A randomized, double-blind, placebo-controlled, multi-center study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability and long-... 2013-04-24 due-trials
Reported results 2010-023621-37 A 26-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in patients... 2012-03-13 due-trials
Reported results 2010-023819-34 A Phase II, double-blind, randomized, Proof-of-Concept, dose-ranging trial evaluating the efficacy, safety and pharmacokinetics of oral LDE225 in treatment of adult patients with Nevoid Basal Cell Car... 2012-10-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-024011-14 An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway 2015-06-01 bad-data
Completed, but no date, and reported results 2010-024013-31 An open-label, intra-patient dose-escalation study to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of multiple infusions of BPS804 in adults with h... bad-data
Completed, but no date, and reported results 2010-024017-31 A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Mu... bad-data
Listed as ongoing, but also has a completion date and reported results 2010-024165-44 An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushing’s disease (Seascape) 2017-01-26 bad-data
Reported results 2010-024172-26 A randomized, double-blind, double-dummy, active controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares, for whom NSAIDs and/or colchi... 2015-05-19 due-trials
Reported results 2010-024173-39 A randomized, double-blind, active-controlled study of canakinumab (ACZ885) pre-filled syringes or reconstituted lyophilizate versus triamcinolone acetonide for treating acute gouty arthritis flares ... 2012-09-10 due-trials
Reported results 2010-024231-16 Etude prospective, multicentrique, randomisée, en ouvert, de phase 2, d'une durée de 12 semaines, évaluant la pharmacodynamie, l’efficacité et la tolérance de Simulect® chez des patients adultes trans... 2013-03-21 due-trials
Reported results 2010-024342-30 A randomized, double-blind, placebo-controlled multi-center study of BYM338 for treatment of cachexia in patients with stage IV non-small cell lung cancer or stage III/IV adenocarcinoma of the pancrea... 2014-04-24 due-trials
Ongoing 2010-024381-21 A 12-month, multicenter, open label, randomized, controlled study to evaluate the efficacy, tolerability and safety of early introduction of everolimus, reduced CNI, and early steroid elimination comp... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2010-024394-39 A Phase II study of orally administered BEZ235 monotherapy in patients with hormone receptor positive, HER2 negative, metastatic breast cancer, with or without PI3K activated pathway 2011-12-19 bad-data
Reported results 2010-024396-12 A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinoma 2011-12-16 due-trials
Reported results 2010-024473-39 An open-label, multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibros... 2017-02-09 due-trials
Reported results 2010-024516-34 A randomized, double-blind, placebo-controlled regimen finding study of efficacy, safety and tolerability of secukinumab at 12 weeks administered with an i.v. or s.c. loading regimen compared to place... 2013-12-30 due-trials
Completed, report not yet due 2010-024527-25 A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living don... 2017-10-10 not-yet-due
Reported results 2010-024529-18 A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in ... 2014-12-18 due-trials
Reported results 2011-000102-21 A randomized, double-blind, placebo- and active-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 1 year in pa... 2015-02-03 due-trials
Reported results 2011-000210-19 A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset... 2013-02-05 due-trials
Reported results 2011-000229-63 A multicenter, randomized, blinded, double-dummy, placebo controlled, 3-period cross-over study to evaluate the effect of QVA149 on patient reported dyspnea in moderate to severe chronic obstructive p... 2012-08-29 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-000266-35 A phase II, open-label, single-arm, non-randomized, multi-center study to evaluate the efficacy of oral TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or... 2014-06-26 bad-data
Reported results 2011-000275-13 A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with... 2015-06-11 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-000276-34 A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in ... 2014-10-21 bad-data
Not reported 2011-000365-12 A randomized, open-label, five period, crossover study to evaluate the single dose pharmacokinetics and food effect of two pediatric AFQ056 formulations in healthy adults 2011-07-05 due-trials
Ongoing, reported early 2011-000461-12 A randomized, double blind, placebo controlled, multi-centre study to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in chronic obstructive pulmonary disease patients... not-yet-due
Reported results 2011-000518-21 Cross-over study to assess the difference in fasting plasma glucose (FPG) between vildagliptin (Galvus®/Eucreas®) and sitagliptin (Januvia®/Janumet®) after two weeks (FPG-VISIT) 2012-06-06 due-trials
Reported results 2011-000631-92 A phase II, randomized, double-blind, placebo controlled, parallel design, dose ranging, multi-center trial of four levels of exposure of QGE031 s.c. for 16 weeks in subjects aged 18 years and older w... 2012-06-13 due-trials
Reported results 2011-000767-27 A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to severe c... 2013-05-04 due-trials
Completed, but no date 2011-000770-60 “An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists” bad-data
Reported results 2011-000833-35 A multicenter, double blind, randomized, parallel group, placebo-controlled study to evaluate the hemodynamic responses to intravenous RLX030 infusion in subjects with acute heart failure. 2013-01-17 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-000860-90 A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) wh... 2017-10-25 bad-data
Completed, reported early 2011-000917-38 A first–in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multiple ... 2014-02-13 not-yet-due
Reported results 2011-000947-26 Multi-center, randomized, evaluator-blind, 2013-08-29 due-trials
Reported results 2011-000960-93 A 12-week treatment, randomized, blinded, double-dummy, parallel-group study to assess the efficacy, safety, and tolerability of NVA237 (50 μg o.d.) compared to tiotropium (18 μg o.d.) in patients wit... 2013-01-17 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-001019-30 A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implan... 2013-06-19 bad-data
Reported results 2011-001020-38 A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implan... 2014-01-21 due-trials
Listed as ongoing, but also has a completion date 2011-001062-18 A randomized, placebo-controlled, dose-ranging, multi-centre trial of QAW039 (1-450 mg p.o.), to investigate the effect on FEV1 and ACQ in patients with moderate-to-severe, persistent, allergic asthma... 2013-11-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-001077-13 A multicenter, randomized, comparative study of different deferasirox administration regimens on gastrointestinal (GI) tolerability in low or intermediate (int-1) risk myelodysplastic syndrome (MDS) p... 2012-09-14 bad-data
Reported results 2011-001092-39 A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias 2013-02-21 due-trials
Ongoing, reported early 2011-001161-41 A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small c... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2011-001220-38 A multicenter, 12 week, randomized, double-blind, placebo-controlled biomarker study of secukinumab (AIN457) in rheumatoid arthritis patients followed by an open label extension 2014-02-13 bad-data
Reported results 2011-001230-42 A multicenter, randomized, double blind, placebo controlled, phase II trial evaluating the safety and efficacy of TKI258 combined with fulvestrant, in postmenopausal patients with HER2- and HR+ breast... 2015-04-03 due-trials
Reported results 2011-001243-67 An open-label proof-of-concept study with a double-masked, dose-ranging component to assess the effects of AIN457 in patients with noninfectious uveitis 2013-09-12 due-trials
Reported results 2011-001280-49 « GRACE : Gilenya® - Réponse Au Coping - Evaluation » Etude multicentrique de phase IV, prospective, en ouvert, d'une durée de 4 mois, visant à comparer la réponse à l’initiation du fingolimod (Gileny... 2013-06-29 due-trials
Reported results 2011-001342-15 A 36-week open-label extension study of CACZ885H2361 on the safety and tolerability of canakinumab 150 mg s.c. pre-filled syringe (PFS) in treating acute gouty arthritis flares in frequently flaring p... 2013-05-09 due-trials
Ongoing 2011-001437-16 A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis not-yet-due
Listed as ongoing, but also has a completion date and reported results 2011-001442-15 A 32-week, patient- and rater-blinded, randomized, multi-center, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from pr... 2012-11-29 bad-data
Completed, reported early 2011-001465-41 A randomized, open label intra-patient dose escalation study with an untreated reference group to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of multiple infusions of BPS8... 2012-12-04 not-yet-due
Reported results 2011-001539-21 A 2-arm, prospective, randomized, controlled, open-label, 12 month Phase III trial to evaluate the efficacy of Everolimus in combination with a centre specific standard immunosuppressive regimen consi... 2017-01-05 due-trials
Reported results 2011-001588-37 A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the renal hemodynamic effects of RLX030 at a dose of 30 μg/kg/day or placebo infused for 24 hours in subje... 2012-12-20 due-trials
Reported results 2011-001617-14 An adaptive multicentre, randomized, partially doubleblind, placebo controlled study to assess the safety, PK and PD/efficacy of RLX030 in women with pre-eclampsia 2014-08-13 due-trials
Reported results 2011-001629-25 An open label extension study to evaluate the safety, tolerability and efficacy of AIN457 in patients with relapsing-remitting multiple sclerosis 2014-01-22 due-trials
Reported results 2011-001692-39 A 21-week, multicenter, open label study to evaluate the safety and tolerability profile of the combination of a SSRI or SNRI antidepressive therapy with oral fingolimod in the treatment of RRMS patie... 2013-09-02 due-trials
Reported results 2011-001725-24 DOVIGIST: Phase II trial to evaluate the efficacy and safety of Dovitinib (TKI258) in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib 2014-07-31 due-trials
Ongoing, reported early 2011-001824-39 A randomized, double-blind, double-dummy, placebo-controlled, 3-period crossover study to evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of orally inhaled indacaterol adminis... not-yet-due
Reported results 2011-001825-25 A multi-centre, randomized, double-blind, double-dummy, multiple-dose, crossover study to evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of orally inhaled indacaterol adminis... 2012-05-22 due-trials
Reported results 2011-001884-39 A phase II study of orally administered BEZ235 monotherapy in patients with metastatic or unresectable malignant PEComa 2013-04-24 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-001952-12 An open-label study to evaluate the long-term safety, tolerability and efficacy of AFQ056 in adult patients with Fragile X Syndrome 2014-09-10 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-002000-32 A single arm, open-label, multicenter, Phase IV trial to 2014-01-13 bad-data
Reported results 2011-002073-30 12-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkin... 2012-09-14 due-trials
Reported results 2011-002074-23 13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in pat... 2013-04-24 due-trials
Reported results 2011-002112-84 A randomized, double-blind, placebo controlled, parallel group, proof of concept study evaluating the efficacy,safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with... 2013-08-28 due-trials
Reported results 2011-002350-31 A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intra... 2015-04-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-002379-40 An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome 2014-09-17 bad-data
Completed, but no date, and reported results 2011-002400-32 A dose-finding phase Ib study followed by an open-label, randomized phase II study of BEZ235 plus paclitaxel in patients with HER2 negative, inoperable locally advanced or metastatic breast cancer bad-data
Listed as ongoing, but also has a completion date and reported results 2011-002510-36 A randomized, double-blind, double dummy, multicenter study to assess the safety, tolerability and long-term efficacy of intravenous (10 mg/kg) and subcutaneous (300 mg) secukinumab in subjects with m... 2013-04-24 bad-data
Ongoing 2011-002569-39 A phase IB/II, open label, multicenter study of INC280 administered orally in combination with gefitinib in adult patients with EGFR mutated, c-MET-amplified non-small cell lung cancer who have progre... not-yet-due
Reported results 2011-002570-23 An open-label, single-arm, multi-center phase II study to evaluate the efficacy and safety of AUY922 in combination with trastuzumab standard therapy as second-line treatment in patients with HER2-pos... 2013-05-29 due-trials
Completed, but no date 2011-002731-26 An open-label, multi-center, expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist. bad-data
Reported results 2011-002859-34 A 24-month, phase IIIb, open-label, randomized, activecontrolled, 3-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen with... 2015-06-25 due-trials
Completed, but no date, and reported results 2011-002866-19 A 3-month, multicenter, randomized, open label study to evaluate the impact of early vs delayed introductioN of EVERolimus on WOUND healing in de novo kidney transplant recipients (NEVERWOUND study) bad-data
Ongoing 2011-002872-17 Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymu... not-yet-due
Ongoing 2011-002887-26 A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI ... not-yet-due
Reported results 2011-002969-38 A 6-month, multicenter, randomized, controlled parallel group study to evaluate the effect of physical training on fatigue in patients with relapsing-remitting multiple sclerosis treated with fingolim... 2014-07-14 due-trials
Not reported 2011-003065-15 PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients with Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib 2017-07-03 due-trials
Ongoing, reported early 2011-003066-32 A randomized double-blind multiple-dose placebo-controlled trial to establish the efficacy of QBX258 (combination of VAK694 and QAX576) in asthma that is inadequately controlled with inhaled corticost... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2011-003069-14 A 24-month, multi-center, single arm, prospective study to evaluate renal function, efficacy, safety and tolerability of everolimus in combination with reduced exposure cyclosporine or tacrolimus in p... 2016-06-01 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-003117-41 A randomized, double-blind, placebo controlled, multiple dose study to evaluate the safety, tolerability, and efficacy of intravenous administration of secukinumab (AIN457) in patients with asthma not... 2015-01-30 bad-data
Completed, but no date 2011-003118-17 A 12 month, multi-center, open-label, randomized, controlled study to evaluate efficacy/safety and evolution of renal function of everolimus in co-exposure with tacrolimus in de novo liver transplant ... bad-data
Ongoing 2011-003254-90 A randomised, active-controlled, open-label, multiple-dose, proof-of-concept study of intravitreal LFG316 in patients with active non-infectious intermediate-, posterior-, or panuveitis requiring syst... not-yet-due
Ongoing 2011-003392-10 An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 in Noonan syndrome hypertrophic cardiomyopathy. not-yet-due
Reported results 2011-003414-17 An open-label extension study of CACZ885H2356E2 and CACZ885H2357E2 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated... 2013-05-22 due-trials
Reported results 2011-003416-23 An open label, single arm trial to evaluate patients with metastatic renal cell carcinoma treated with everolimus after failure of first line therapy with sunitinib or pazopanib 2016-04-01 due-trials
Completed, but no date, and reported results 2011-003484-30 A multi-centre, open-label, non-randomised, parallel group clinical trial to assess the efficacy of fingolimod in naïve patients versus fingolimod in patients previously treated with interferons or gl... bad-data
Listed as ongoing, but also has a completion date 2011-003559-21 A Retrospective Pharmacogenetic Analysis of Hepatitis C Patients treated with Alisporivir (DEB025) Alone or in Combination with Peg-IFN2a and/or Ribavirin 2012-11-07 bad-data
Not reported 2011-003573-28 A Phase III Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 when Administered to Adult and Elderly... 2015-05-04 due-trials
Completed, but no date, and reported results 2011-003602-25 A Phase Ib/randomized phase II study of BEZ235 and trastuzumab versus lapatinib and capecitabine in patients with HER2-positive locally advanced or metastatic breast cancer who failed prior to trastuz... bad-data
Not reported 2011-003603-37 Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 when Administered to Adult and Elderly S... 2015-04-02 due-trials
Ongoing 2011-003712-23 A 5-year study to compare the durability of glycemic control of a combination regimen with vildagliptin & metformin versus standard-of-care monotherapy with metformin, initiated in treatment-naive pat... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2011-003732-31 A randomized, double-blind, parallel-group, 26-week study comparing the efficacy and safety of indacaterol (Onbrez® Breezhaler® 150 mcg o.d.) with salmeterol/fluticasone propionate (Seretide® Accuhale... 2014-02-13 bad-data
Reported results 2011-003795-36 Multi-center, open-label, prospective, randomized, parallel group study investigating a tacrolimus Hexal® based regimen versus a Prograf® based regimen in de novo renal transplant recipients 2015-08-20 due-trials
Reported results 2011-003818-16 A randomized, open-label, cross-over study to evaluate patient preferences for Eucreas® versus Victoza® as add-on to Metformin in Type 2 Diabetes mellitus patients who did not have adequate glycaemic ... 2012-10-17 due-trials
Listed as ongoing, but also has a completion date 2011-004160-30 A multicenter, randomized, active-controlled study to assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis 2014-10-10 bad-data
Completed, but no date, and reported results 2011-004185-14 A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of intraseasonal specific short-term immunotherapy with depigmented glutaraldehyde... bad-data
Completed, but no date, and reported results 2011-004216-31 A phase II, multi-centre, randomized, double blind, placebo-controlled study to determine the mode of action of omalizumab in patients with chronic idiopathic urticaria (CIU) who remain symptomatic wi... bad-data
No trial status on register 2011-004217-17 A single-arm, open-label study of the Palatability and Tolerability of Exjade Taken with Meals, with Different Liquids or Crushed and Added to Food bad-data
Reported results 2011-004254-25 A randomized, double-blind, placebo-controlled, multicenter, 28-week treatment study with an 8 week follow-up period to investigate the impact of subcutaneous Omalizumab on quality of life measures as... 2014-05-09 due-trials
Reported results 2011-004378-27 An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias 2013-11-04 due-trials
Listed as ongoing, but also has a completion date 2011-004411-22 A multicenter, 52 to 104 week extension study to evaluate the long term growth and development of pediatric hypertensive patients 6 – 17 years of age treated previously with aliskiren 2017-08-03 bad-data
Reported results 2011-004653-31 A multicenter, single-arm trial evaluating the safety and efficacy of DEB025/Alisporivir in combination with pegylated interferon-?2a and ribavirin (peg-IFN?2a/RBV) in protease inhibitor treatment fai... 2012-04-30 due-trials
Other 2011-004867-65 Sequential, two-period study to assess the pharmacokinetics, safety & tolerability of single and multiple oral doses of AFQ056 in patients with FXS (Fragile X syndrome) aged 5-11 years (Cohort 1) and ... not-yet-due
Reported results 2011-004870-26 A 26-week treatment, multicenter, randomized, parallel group, blinded study to assess the efficacy and safety of QVA149 (110/50 µg q.d.) in patients with moderate to severe chronic obstructive pulmona... 2013-04-02 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-004959-39 A 24-month, phase IIIb, randomized, double-masked, multicenter study assessing the efficacy and safety of two treatment regimens of 0.5 mg ranibizumab intravitreal injections guided by functional and/... 2015-09-30 bad-data
Ongoing, reported early 2011-004966-13 A double-blind, placebo-controlled, study examining the not-yet-due
Reported results 2011-005045-13 An open-label, multi-center, 6-month extension study comparing the long-term efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implant i... 2014-10-07 due-trials
Ongoing, reported early 2011-005066-38 A UK open-label, multicentre, exploratory Phase II study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibr... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2011-005085-37 A randomized, double blind placebo-controlled study to assess the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of single and multiple ascending doses of QBW251 in healthy su... 2015-11-20 bad-data
Reported results 2011-005100-14 A randomized, double-blind, double-dummy, 4-week treatment, parallel-group study to evaluate the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in adul... 2013-07-05 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-005154-57 An open-label extension study to assess efficacy, safety and tolerability of canakinumab and the efficacy and safety of childhood vaccinations in patients with Cryopyrin Associated Periodic Syndromes ... 2015-10-13 bad-data
Reported results 2011-005238-21 12 month, multi-center, open-label, prospective, randomized, parallel group study investigating a standard regimen in de novo kidney transplant patients versus a Certican® based regimen either in comb... 2016-03-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-005280-24 A double-blind, randomized, multicenter, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients wit... 2016-09-01 bad-data
Reported results 2011-005297-36 An 8-week randomized, open label, multi-center study to evaluate the efficacy and safety of oral aliskiren 300 mg once daily under light meal versus fasted condition in patients with hypertension 2012-11-16 due-trials
Ongoing, reported early 2011-005316-28 A multi-center, randomized, double-blind, parallel group, placebo controlled, study in patients with non-chronic migraine to assess the efficacy, safety and tolerability of BID oral doses of BGG492 in... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2011-005499-41 A double blind, double dummy, randomised, multi-centre study to assess the tolerability and efficacy profile of vildagliptin compared to gliclazide as dual therapy with metformin in Muslim patients wi... 2013-09-05 bad-data
Listed as ongoing, but also has a completion date 2011-005524-17 A phase III randomized, double-blind placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast can... 2017-05-03 bad-data
Reported results 2011-005535-68 A randomized, double-blind, placebo controlled study to assess efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia Syndrome 2014-05-28 due-trials
Completed, report not yet due 2011-005542-35 Multicenter randomized open-label three-arms controlled 12 months clinical proof of concept study to evaluate efficacy and safety of Ranibizumab alone or in combination with laser photocoagulation vs.... 2017-12-05 not-yet-due
Reported results 2011-005577-23 A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of diclofenac potassium 25 mg in subjects with acute joint pain 2013-01-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-005673-23 A 12-week multi-center, randomized, double-blind, parallel-group study to assess the efficacy, safety and tolerability of the co-administration of NVA237 + indacaterol once daily vs. indacaterol once ... 2013-01-08 bad-data
Ongoing 2011-005677-23 A two-year, double-blind, randomized, multicenter, active controlled Core Phase study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once ... not-yet-due
No trial status on register 2011-005852-33 An open-label, single-arm study to evaluate the efficacy, safety and PK of artemether-lumefantrine Dispersible Tablet in the treatment of acute uncomplicated Plasmodium falciparum malaria in infants <... bad-data
Ongoing 2011-005875-17 A Phase Ib/II, multicenter, open-label, dose escalation study of LGX818 in combination with MEK162 in adult patients with BRAF V600 - dependent advanced solid tumors not-yet-due
Listed as ongoing, but also has a completion date and reported results 2011-005932-24 A randomized, double-blind, placebo controlled, phase II/III study of BKM120 plus paclitaxel in patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or without PI3... 2015-06-01 bad-data
Reported results 2011-005991-40 A 6 Week, Randomized, Multicenter, Double-blind, Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension, With or Without ... 2017-01-24 due-trials
Completed, reported early 2011-006017-34 A phase Ib dose escalation/randomized phase II, multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma 2016-05-09 not-yet-due
Completed, but no date 2011-006043-30 An open-label, multiple-dose, two-treatment period study to evaluate the effect of oral BAF312 on the pharmacokinetices and pharmacodynamics of a monophasic oral contraceptive in healthy female volunt... bad-data
Reported results 2011-006050-91 A study to compare the efficacy and safety of once daily QVA149 vs. the once daily concurrent administration of QAB149 plus NVA237 in patients with moderate to severe chronic obstructive pulmonary dis... 2012-12-19 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-006057-28 A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, t... 2016-10-24 bad-data
Reported results 2011-006058-94 A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term efficac... 2015-05-11 due-trials
Ongoing 2011-006087-49 A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subjects ... not-yet-due
Other 2011-006088-23 A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib to the BRAF inhibitor vemurafenib in subjects with unresectable (s... not-yet-due
Reported results 2011-006111-62 A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With ... 2013-11-26 due-trials
Reported results 2011-006118-15 Multicentric cross-over trial to assess the glycemic profiles on 8 weeks of vildagliptin and sitagliptin treatment, each, in type-2 diabetic patients with a pre-existing cardiovascular disease pre-tre... 2014-09-08 due-trials
Reported results 2011-006131-38 A multi-centre 3-year follow-up study to assess the durability of sustained virologic response in alisporivir treated chronic hepatitis C patients 2015-05-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-006132-24 A multi-centre 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored alisporivir studies for chronic hepatitis C pati... 2014-01-23 bad-data
Ongoing 2012-000046-35 A randomized, double-blind, placebo-controlled phase III multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 16 weeks and to assess the long term efficac... not-yet-due
Listed as ongoing, but also has a completion date 2012-000073-23 An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine t... 2014-09-01 bad-data
Completed, but no date, and reported results 2012-000137-39 Etude nationale multicentrique, randomisée, en ouvert, évaluant l’efficacité et la tolérance de l’évérolimus associé au mycophénolate sodique , en comparaison à un traitement standard associant tacrol... bad-data
Reported results 2012-000218-12 A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Va... 2016-04-25 due-trials
Reported results 2012-000236-26 An exploratory study to investigate the haemodynamic effects of serelaxin in patients with compensated cirrhosis and portal hypertension 2014-12-19 due-trials
No trial status on register 2012-000299-40 A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg evero... bad-data
Completed, reported early 2012-000305-76 A phase Ib/II open-label, multi-center study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors 2015-04-01 not-yet-due
Reported results 2012-000520-18 A multicenter, randomized, double-blind, placebo controlled, 12-week treatment, parallel-group study to assess the efficacy, safety and pharmacokinetics of indacaterol acetate (75 and 150 μg o.d.) in ... 2013-07-05 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-000533-39 A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 2 years in subject... 2017-06-26 bad-data
Completed, reported early 2012-000562-37 A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects 2014-03-04 not-yet-due
Ongoing 2012-000650-64 An open label, multi-center, efficacy and safety study of deferasirox in iron overloaded patients with non-transfusion dependent thalassemia (THETIS) not-yet-due
Reported results 2012-000653-32 A 1-week, open-label, multi-center study to explore conduction abnormalities during first dose administration of fingolimod in patients with relapsing-remitting multiple sclerosis (START) 2016-12-12 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-000675-16 A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) 2015-07-30 bad-data
Reported results 2012-000677-23 A Phase II, multi-center, open-label, neoadjuvant, randomized study of weekly paclitaxel with or without LCL161 in patients with triple negative breast cancer 2014-09-18 due-trials
Reported results 2012-000738-21 NeoPHOEBE: Pi3k inhibition in Her2 OverExpressing Breast cancEr A phase II, randomized, parallel cohort, two stage, double-blind, placebo-controlled study of neoadjuvant trastuzumab versus trastuzumab... 2015-02-18 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-000769-19 Randomized phase II study of BEZ235 or everolimus in advanced pancreatic neuroendocrine tumors 2014-08-19 bad-data
Reported results 2012-000802-32 An open label, 52-week, safety and tolerability extension to a randomized, double-blind, placebo controlled study of LCQ908 in subjects with Familial Chylomicronemia Syndrome 2015-05-20 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-000835-18 Open-label, single-arm extension study to the double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally onc... 2015-06-22 bad-data
No trial status on register 2012-000855-15 An open label, randomized, three period, single-dose, crossover study to determine the bioavailability of 300 mg aliskiren mini-tablets relative to the 300 mg aliskiren market tablet under fasted cond... bad-data
Completed, but no date, and reported results 2012-000872-40 A pilot study to assess the efficacy and safety of LCQ908 alone and in combination with fenofibrate or Lovaza® in patients with severe hypertriglyceridemia bad-data
Reported results 2012-000983-27 A single-dose, open-label parallel-group study to assess the pharmacokinetics of LCZ696 in subjects with hepatic impairment compared to matched healthy subjects 2013-01-12 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-000985-39 A multicenter, double-blind and open label, 2 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate to... 2017-05-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-001050-25 A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment 2015-11-04 bad-data
Completed, but no date, and reported results 2012-001099-13 Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors bad-data
Reported results 2012-001143-46 A randomized open-label study to compare safety and efficacy of vildagliptin versus NPH insulin add-on to glimepiride in patients with type 2 diabetes mellitus that do not reach adequate glycemic cont... 2013-10-10 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-001172-12 A randomized, double-blind, 12-week treatment, parallel-group study to evaluate the efficacy and safety of QMF149 (150 µg/160 µg o.d.) compared with salmeterol xinafoate/fluticasone propionate (50 µg/... 2013-09-25 bad-data
Ongoing 2012-001266-15 COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutatio... not-yet-due
No trial status on register 2012-001333-14 A randomized, investigator-blinded, multicenter, parallel group study to compare efficacy, safety and tolerability of Coartem® dispersible tablet formulation vs. Coartem® 6-dose crushed tablet in the ... bad-data
Reported results 2012-001389-14 A randomized, double-blind, placebo-controlled three-period incomplete cross over study to compare the 2013-10-02 due-trials
Completed, but no date, and reported results 2012-001427-12 A multicenter, randomized, double-blind, placebo-controlled study of the safety, tolerability and effects on arterial structure and function of ACZ885 in patients with intermittent claudication bad-data
Other 2012-001499-12 Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects with Advanced BRAF V60... not-yet-due
Completed, but no date, and reported results 2012-001534-34 A multi-center, intra-patient dose escalation phase II study to evaluate the preliminary efficacy, safety and pharmacokinetics of pasireotide (SOM230) subcutaneous (s.c.) followed by pasireotide LAR i... bad-data
Listed as ongoing, but also has a completion date and reported results 2012-001565-33 An open-label, crossover, interventional Phase IV study to compare the ease of use of tobramycin inhalation powder with tobramycin inhalation solution and nebulized colistimethate for the treatment of... 2015-10-20 bad-data
Reported results 2012-001632-64 An open label, three-period, single sequence study to evaluate the pharmacokinetic drug-drug interaction between LCZ696 and sildenafil in subjects with mild to moderate hypertension 2013-01-30 due-trials
Ongoing, reported early 2012-001945-42 A multicenter, double blind, randomized, parallel group, placebo-controlled study to evaluate the effects of intravenous serelaxin infusion on micro- and macrovascular function in patients with corona... not-yet-due
Ongoing, reported early 2012-001961-33 A phase I/II, multicenter, open-label dose finding study of oral CFG920 in patients with metastatic castration-resistant prostate cancer not-yet-due
Completed, reported early 2012-001962-13 A phase Ib/II open-label, multi-center study of the combination of BYL719 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors 2017-06-01 not-yet-due
Reported results 2012-001998-93 A multi-center, randomized, double-blind, 52-week study to assess the safety of QVA149 compared to QAB149 in patients with Chronic Obstructive Pulmonary Disease (COPD) who have moderate to severe airf... 2014-06-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-002057-38 A placebo and active controlled study to assess the long-term safety of once daily QVA149 for 52 weeks in Chronic Obstructive Pulmonary Disease (COPD) patients with moderate to severe airflow limitati... 2015-02-05 bad-data
Ongoing 2012-002074-31 A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK) not-yet-due
Completed, report not yet due 2012-002208-41 An open-label phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma 2017-07-20 not-yet-due
Other 2012-002250-23 Phase Ib dose finding study of abiraterone acetate plus BEZ235 or BKM120 in patients with castration-resistant prostate cancer not-yet-due
Listed as ongoing, but also has a completion date and reported results 2012-002298-69 A Multi-Center, Randomized, Double Blind, Placebo and Active-Controlled study with exploratory dose-ranging, to investigate the efficacy and safety of 16 weeks treatment with subcutaneous QGE031 in as... 2016-01-21 bad-data
Ongoing 2012-002540-25 An open label, multi-center imatinib roll-over protocol for patients who have completed a previous Novartis sponsored imatinib study and are judged by the investigator to benefit from continued imatin... not-yet-due
Listed as ongoing, but also has a completion date 2012-002571-34 A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastat... 2017-09-08 bad-data
Reported results 2012-002606-40 A randomized, double-blind, parallel group study to evaluate metabolic effects of LCZ696 and amlodipine in obese hypertensive subjects 2013-07-29 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-002609-22 A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in autoinjectors to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolera... 2016-10-27 bad-data
Reported results 2012-002637-11 A 6 months, randomized, multicenter, parallel-group, open-label study to evaluate the effect of an individualized patient support program on treatment satisfaction in Fingolimod (FTY720)-treated patie... 2013-02-25 due-trials
Reported results 2012-002760-27 A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis 2015-05-14 due-trials
Reported results 2012-002854-21 A 26-week multi-center randomized double-blind study to compare efficacy and safety of NVA237 versus placebo as an add-on to maintenance therapy with fixed-dose combination salmeterol/fluticasone prop... 2013-03-13 due-trials
Not reported 2012-002859-42 A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis 2016-08-04 due-trials
Reported results 2012-002899-14 A randomized, double-blind, active-controlled, multicenter, 52-week study to evaluate the safety and efficacy of an LCZ696 regimen on arterial stiffness through assessment of central blood pressure in... 2015-04-08 due-trials
Completed, report not yet due 2012-002916-16 A multi-center, randomized, open-label, Phase IV study to investigate the management of pasireotide-induced hyperglycemia with incretin based therapy or insulin in adult patients with Cushing’s diseas... 2018-03-26 not-yet-due
Reported results 2012-002968-27 A 48-week, double-blind, randomized, multi-center, parallelgroup study comparing structural changes in the retina and evolution of visual function after immediate versus delayed treatment with fingoli... 2014-05-07 due-trials
Not reported 2012-003010-14 A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction pa... 2014-03-24 due-trials
Listed as ongoing, but also has a completion date 2012-003011-58 A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction... 2013-07-29 bad-data
Completed, but no date, and reported results 2012-003054-92 An open-label, multi-arm, non-comparative safety and tolerability study of canakinumab (ACZ885) in patients with active Systemic Juvenile Idiopathic Arthritis (SJIA) bad-data
Ongoing 2012-003056-36 A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progre... not-yet-due
Ongoing 2012-003065-17 An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive HER2 negative metastatic or locally advan... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2012-003066-40 A Phase III, multi-center, open-label, randomized, controlled study of the efficacy and safety of oral LDE225 versus temozolomide in patients with Hh-pathway activated relapsed medulloblastoma 2016-10-05 bad-data
Ongoing 2012-003186-18 A phase II, single arm, open label study of treatment-free remission after achieving sustained MR4.5 on nilotinib not-yet-due
Reported results 2012-003346-32 A 12-week treatment, multi-center, randomized, double-blind, parallel group, placebo and active controlled study to assess the efficacy, safety, and tolerability of QVA149 (indacaterol maleate /glycop... 2014-02-28 due-trials
Reported results 2012-003347-30 A 12-week treatment, multi-center, randomized, double-blind, parallel group, placebo and active controlled study to assess the efficacy, safety, and tolerability of QVA149 (indacaterol maleate /glycop... 2014-02-28 due-trials
Not reported 2012-003348-63 A randomized, placebo-controlled trial of BPS804 on safety and tolerability in patients with late-stage chronic kidney disease 2013-07-25 due-trials
Reported results 2012-003350-84 A randomized, double-blind, placebo- and comparator-controlled study evaluating the effect of multiple doses of QGE031 compared to omalizumab in asthma induced by allergen bronchial provocation 2013-10-28 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-003370-10 A randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with bullous pemphigo... 2015-03-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-003432-24 A phase II, multicenter, single-arm study of oral LDK378 in adult patients with ALK-activated non-small cell lung cancer previously treated with chemotherapy and crizotinib 2016-01-27 bad-data
Listed as ongoing, but also has a completion date 2012-003474-36 A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naïve adult patients with ALK-activated non-small cell lung cancer 2018-01-22 bad-data
Reported results 2012-003532-23 A 48 week extension to CTBM100C2401, a single arm open-label, multicenter, phase IV trial, to assess long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis 2014-11-18 due-trials
Ongoing 2012-003593-51 The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastati... not-yet-due
Ongoing, reported early 2012-003689-41 A Phase IV multicentre, open label study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with everolimus (RAD001) in combination with exem... not-yet-due
Ongoing 2012-003757-28 A three-arm, randomized, open label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen rece... not-yet-due
Ongoing 2012-003902-28 An open label, multi-center nilotinib roll-over protocol for patients who have completed a previous Novartis-sponsored nilotinib study and are judged by the investigator to benefit from continued nil... not-yet-due
Reported results 2012-003995-38 A double-blind, placebo-controlled, study examining the effect of orally administered QAW039 (450 mg QD) on FEV1 and ACQ in non-atopic, asthmatic patients with a baseline, pre-bronchodilator FEV1 of 4... 2016-02-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-004019-29 A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple scl... 2015-04-17 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-004022-21 A Phase II multi-center, open label, randomized study to assess safety and efficacy of two different schedules of oral LDE225 in adult patients with relapsed/refractory or untreated elderly patients w... 2015-05-26 bad-data
Listed as ongoing, but also has a completion date 2012-004023-20 A Phase Ib/II, open-label, multi-center, dose-finding study to assess the safety and efficacy of the oral combination of LDE225 and INC424 (Ruxolitinib) in patients with myelofibrosis 2018-04-10 bad-data
Reported results 2012-004024-38 A 4-week, randomized, double-blind, multi-center, vehicle-controlled, parallel group study to assess the efficacy and safety of diclofenac diethylamine 2.32% gel for the relief of signs and symptoms i... 2014-05-05 due-trials
Ongoing 2012-004092-40 A single-arm, multicenter, nilotinib treatment-free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease ... not-yet-due
Listed as ongoing, but also has a completion date 2012-004104-35 A phase IB/II, multicenter, open label, study of LEE011 in combination with MEK162 in adult patients with NRAS mutant melanoma 2018-02-22 bad-data
Reported results 2012-004185-17 A multicenter, open-label, randomized, 3-arm, phase II profiling trial of pharmacokinetics, pharmacodynamics and safety of DEB025/Alisporivir in combination with ribavirin therapy in chronic hepatit... 2015-03-24 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-004228-40 A phase I, multi-center, open-label study of LEE011 in patients with malignant rhabdoid tumors and neuroblastoma 2017-06-29 bad-data
Ongoing 2012-004439-22 A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term efficac... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2012-004551-36 A phase Ib/II, multicenter, study of LEE011 in combination with LGX818 in adult patients with BRAF mutant melanoma 2015-04-13 bad-data
Ongoing 2012-004707-12 An open-label, multi-center everolimus roll-over protocol for patients who have completed a previous Novartis-sponsored everolimus study and are judged by the investigator to benefit from continued ev... not-yet-due
Reported results 2012-004798-17 Phase II, Multi-center, Open-label Study of Single-agent LGX818 Followed by a Rational Combination With Agents After Progression on LGX818, in Adult Patients With Locally Advanced or Metastatic BRAF V... 2015-03-23 due-trials
Reported results 2012-004854-27 A 26 week, randomized, active-controlled safety study of double-blind formoterol fumarate in free combination with an inhaled corticosteroid versus an inhaled corticosteroid in adolescent and adult pa... 2016-05-10 due-trials
Listed as ongoing, but also has a completion date 2012-004942-14 A randomized, double-blind, 104-weeks treatment study to evaluate the efficacy, safety, tolerability and pharmacokinetics of telbivudine oral solution and tablets in children and adolescents with comp... 2017-01-06 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-004966-16 A 52-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) with s... 2015-09-15 bad-data
Reported results 2012-005000-17 A randomized, double-blind, placebo-controlled, parallel-group proof of concept study to evaluate the effect of AFQ056 in obsessive compulsive disorder (OCD) patients resistant to Selective Serotonin ... 2015-03-20 due-trials
Completed, but no date, and reported results 2012-005087-10 A 12-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in COPD pat... bad-data
Not reported 2012-005102-22 A 12-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in COPD pat... 2013-10-23 due-trials
Ongoing 2012-005124-15 A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia chromosome-positive CML after two different durations of con... not-yet-due
Reported results 2012-005183-94 Etude multicentrique, randomisée, contrôlée, en ouvert d'une durée de 24 semaines, comparant la stratégie metformine/vildagliptine + insuline basale versus metformine/sulfamide + insuline basale chez ... 2015-02-23 due-trials
Ongoing 2012-005252-41 An open-label multi-center single agent panobinostat rollover protocol for patients who have completed a previous Novartis-sponsored panobinostat study and are judged by the investigator to benefit fr... not-yet-due
Reported results 2012-005321-78 A randomized, double-blind, placebo-controlled, parallel group study evaluating efficacy and safety of QAW039 in the treatment of patients with moderate to severe atopic dermatitis 2014-11-12 due-trials
Completed, but no date 2012-005397-63 An open-label, multi-center, expanded access study of RAD001 in patients with angiomyolipoma associated with tuberous sclerosis complex (TSC) bad-data
Listed as ongoing, but also has a completion date and reported results 2012-005412-25 A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy u... 2016-11-02 bad-data
Reported results 2012-005413-40 A randomized, double-blind, placebo-controlled, multicenter, 2017-01-03 due-trials
Reported results 2012-005417-38 A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to vas... 2015-11-11 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-005418-20 A 12-month, randomized, double-masked, sham-controlled, multicenter 2015-09-09 bad-data
Listed as ongoing, but also has a completion date 2012-005461-13 A phase Ib/II trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with estrogen receptor positive Her2 negative locally advanced or metastat... 2016-12-02 bad-data
Not reported 2012-005507-40 An open-label, single arm study to provide access to fingolimod to MS patients who completed fingolimod phase IIIb studies and who benefited from treatment with fingolimod or do not have suitable alte... 2014-02-13 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-005541-21 A dose-finding phase Ib study followed by a randomized, double-blind phase II study of carboplatin and paclitaxel with or without buparlisib in patients with previously untreated metastatic non-small ... 2014-06-13 bad-data
Reported results 2012-005615-92 A two part, double blind, placebo controlled, study to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of multiple doses of QBM076 in patients with COPD 2015-06-12 due-trials
Reported results 2012-005624-15 A phase Ib/II, open-label study of LJM716 in combination with BYL719 compared to taxane or irinotecan in patients with previously treated esophageal squamous cell carcinoma 2016-06-03 due-trials
Ongoing 2012-005637-36 A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have bee... not-yet-due
Reported results 2012-005720-15 A randomized, double-blind, active-controlled, parallel group, 52-week study to evaluate the effect of LCZ696 compared to olmesartan on regional aortic stiffness in subjects with essential hypertensio... 2015-06-05 due-trials
Not reported 2012-005793-63 A multi-center, randomized, double-blind, double-dummy, parallel-group 2014-03-24 due-trials
Ongoing 2013-000200-41 A multi-center, open label, non-controlled phase II study to evaluate efficacy and safety of oral nilotinib in pediatric patients with newly diagnosed Ph+ chronic myelogenous leukemia (CML) in chronic... not-yet-due
Completed, report not yet due 2013-000250-22 A single dose, double-blind, placebo-controlled, parallel study to assess the pharmacodynamics, pharmacokinetics and safety and tolerability of VAY736 in patients with primary Sjögren’s syndrome 2018-02-07 not-yet-due
Completed, but no date 2013-000256-18 A single-arm, open label, multi-center phase II study investigating oral everolimus tablets with dose titration in pediatric patients with relapsed or refractory Hodgkin lymphoma bad-data
Ongoing 2013-000267-84 An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued p... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2013-000281-11 A phase Ib/II, open-label, multicenter study of AEB071 and MEK162 in adult patients with metastatic uveal melanoma 2015-05-15 bad-data
Ongoing 2013-000319-26 A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-smal... not-yet-due
Listed as ongoing, but also has a completion date 2013-000322-66 A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor... 2018-01-17 bad-data
Reported results 2013-000642-20 A Randomized, Blinded, Placebo-Controlled, Dose Finding 2017-01-25 due-trials
Completed, reported early 2013-000699-14 A Phase Ib/II, open-label, multicenter study of INC280 in combination with buparlisib in adult patients with recurrent glioblastoma. 2016-12-23 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2013-000705-23 A randomized, double-blind, placebo-controlled, multicenter, parallel group, dose-finding, pivotal, phase IIb/III study to evaluate the efficacy, safety and tolerability of intravenous BYM338 at 52 we... 2016-01-06 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-000744-26 Phase II multicenter randomized, double blind, placebo controlled study assessing the efficacy of buparlisib (BKM120) plus paclitaxel vs. placebo plus paclitaxel in patients with platinum pre-treated ... 2017-03-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-000833-11 A Phase Ib/II study of docetaxel with or without buparlisib as second line therapy for patients with advanced or metastatic squamous non-small cell lung cancer 2015-08-04 bad-data
Reported results 2013-000944-25 A three year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in subjects with active rheumatoid arthritis 2015-05-11 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-000981-12 An open-label, phase II, randomized, pilot study to assess the effect in term of erythroid improvement of deferasirox combined with erythropoietin compared to erythropoietin alone in patients with low... 2017-03-22 bad-data
Completed, reported early 2013-001018-14 A phase Ib, open-label study of oral BGJ398 in combination with oral BYL719 in adult patients with select advanced solid tumors 2016-08-23 not-yet-due
Completed, report not yet due 2013-001089-40 An extension study to evaluate the sustainability of clinical benefits, safety and tolerability of secukinumab in patients with active Ankylosing Spondylitis 2018-03-16 not-yet-due
Listed as ongoing, but also has a completion date 2013-001090-24 A randomized, double-blind, placebo-controlled phase III multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long-term safety, tolerability and efficacy up to 3 ... 2017-12-11 bad-data
Completed, but no date 2013-001100-10 An open-label, multi-center protocol to provide QTI571 to PAH patients who participated in one of the extension studies and are judged by the investigator to benefit from continued QTI571 treatment bad-data
Ongoing 2013-001176-38 A 2-part phase III randomized, open label, multicenter study of LGX818 plus MEK162 versus vemurafenib and LGX818 monotherapy in patients with unresectable or metastatic BRAF V600 mutant melanoma not-yet-due
Completed, but no date, and reported results 2013-001191-38 Multicentric, randomized, open-label, controlled study, of 12 months of follow-up to assess the effect in renal function of a immunosuppressive treatment based on tacrolimus minimization in combinati... bad-data
Other 2013-001217-33 A randomized, partial-blind, placebo-controlled trial evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of VAY736 in the treatment of patients with pemphigus vulgaris not-yet-due
Other 2013-001219-57 A phase Ib/II, multicenter, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer not-yet-due
Listed as ongoing, but also has a completion date 2013-001241-13 A three-year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active psoriatic arthritis 2018-01-11 bad-data
Completed, reported early 2013-001265-16 An Open-Label, Single-arm, Phase Ib/II study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR inhibitor) in Patients with CD79-mutant or ABC subtype Diffuse Large B-Cell Lymphoma 2016-06-01 not-yet-due
Listed as ongoing, but also has a completion date 2013-001370-20 OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects with Pemphigus Vulgaris 2016-12-01 bad-data
Completed, but no date, and reported results 2013-001421-55 An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases. bad-data
Reported results 2013-001477-25 A randomized, double-blind, placebo-controlled, multicenter cross-over study to assess the effects of a 3 week therapy each with QVA149 versus placebo on pulmonary function and average physical activi... 2015-02-11 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-001498-25 A multicenter, randomized, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure 2017-01-27 bad-data
Not reported 2013-001562-42 A randomized, double-blind, parallel group, active-controlled study to compare the systolic blood pressure lowering efficacy of aliskiren, ramipril and a combination of aliskiren and amlodipine, with ... 2015-03-31 due-trials
Not reported 2013-001643-30 An 8-week randomized, double-blind, placebo-controlled factorial study to evaluate the efficacy and safety of LCZ696 alone and in combination with amlodipine in patients with essential hypertension 2014-06-24 due-trials
Ongoing 2013-001705-87 A Phase II, Open-label, Study in Subjects with BRAF V600EMutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Tram... not-yet-due
Ongoing 2013-001747-31 A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patien... not-yet-due
Reported results 2013-001783-36 A randomized 8-week double-blind, parallel-group, active-controlled, multicenter study to evaluate efficacy and safety of LCZ696 200 mg in comparison with olmesartan 20 mg in essential hypertensive pa... 2014-08-14 due-trials
Reported results 2013-001799-39 A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active dermatomyositis. 2016-02-17 due-trials
Reported results 2013-001835-33 A multicenter, randomized, double-blind, parallel group study to assess the safety and tolerability of initiating LCZ696 in heart failure patients comparing two titration regimens. 2014-08-05 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-001855-11 Secukinumab In patients with moderate to severe active, chronic plaque psoriasis who have failed on TNFα antaGoNists: A clinical Trial EvalUating Treatment REsults 2016-07-12 bad-data
Completed, reported early 2013-001862-41 A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HE... 2017-07-08 not-yet-due
Completed, reported early 2013-001986-18 A phase Ib/II, open-label, multi-center, dose escalation study of MEK162 in combination with panitumumab in adult patients with mutant RAS or wild-type RAS metastatic colorectal cancer 2016-01-25 not-yet-due
Reported results 2013-002088-25 A randomized, double-blind, placebo controlled multiple dose study of subcutaneous ACZ885 for the treatment of abdominal aortic aneurysm 2015-10-21 due-trials
Ongoing 2013-002170-49 A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease not-yet-due
Other 2013-002200-13 A Phase 2, multicenter, open-label study of BGJ398 in patients with recurrent resectable or unresectable Glioblastoma not-yet-due
Not reported 2013-002201-66 An exploratory, randomized, double-blind, placebo-controlled study to investigate the effect of BYM338 on muscle in patients requiring prolonged mechanical ventilation 2014-04-04 due-trials
Reported results 2013-002266-40 A randomized, double-blind, placebo-controlled, multicenter, exploratory evaluation of surrogate markers of cardiovascular risk in patients with active chronic plaque-type psoriasis treated for 52 wee... 2016-04-21 due-trials
Not reported 2013-002306-31 An open-label, long term (52 week) extension study to evaluate the safety, tolerability, and efficacy of treatment with LCZ696 monotherapy and LCZ696 in combination with amlodipine in patients with es... 2014-06-24 due-trials
Completed, but no date 2013-002324-16 A randomized, partially blind, placebo-controlled, proof-of-concept study to assess the effect of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relaps... bad-data
Reported results 2013-002431-15 A 12-month, phase IV, randomized, open label, multicenter study to compare efficacy of 0.5 mg ranibizumab PRN compared to 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stabil... 2017-05-29 due-trials
Reported results 2013-002483-84 Multicenter, randomized, blinded, two-period cross-over study to assess the effect of glycopyrronium (44 µg QD) versus tiotropium (18 µg QD) on morning symptoms and pulmonary function in patients with... 2014-10-28 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-002513-35 A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients. 2017-04-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-002588-24 A randomized pre-surgical pharmacodynamics study to assess the biological activity of LEE011 plus letrozole versus single agent letrozole in primary breast cancer 2014-09-10 bad-data
Reported results 2013-002608-15 A two-part placebo-controlled study to evaluate the safety, tolerability and 2016-04-13 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-002626-23 A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen, in... 2015-11-19 bad-data
Reported results 2013-002660-17 Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis 2015-12-02 due-trials
Not reported 2013-002664-10 A randomized, double-blind, parallel group, 52-week study evaluating the efficacy, safety and 2014-12-18 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-002781-39 Prospective, Double-Blind, Multicenter Study Evaluating the Safety of Repeat Doses of IV Serelaxin in Subjects with Chronic Heart Failure 2015-09-23 bad-data
Reported results 2013-002812-28 A single arm, multicenter, phase IIa study to explore the efficacy and safety of ruxolitinib (INC424) in regularly transfused patients with thalassemia 2016-04-12 due-trials
Reported results 2013-002847-28 Multicenter, open-label, dose escalation study to evaluate safety, tolerability and pharmacokinetics of RLX030 in addition to standard of care in pediatric patients from birth to <18 years of age, hos... 2017-04-03 due-trials
Completed, but no date, and reported results 2013-002850-54 A 24 month open-label, multicenter, phase IIIb study of the efficacy and safety of Lucentis® (ranibizumab 0,5mg) in diabetic patients with visual impairment due to macular edema evaluating a treatment... bad-data
Ongoing 2013-003084-61 A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast can... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2013-003086-34 A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index ... 2017-05-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-003127-11 A prospective, multicenter, 12-week, randomized open-label study to evaluate the efficacy and safety of glycopyrronium (50 micrograms o.d.) or indacaterol maleate and glycopyrronium bromide fixed-dose... 2016-04-29 bad-data
Completed, reported early 2013-003129-27 Phase Ib/II multicenter study of buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma multiforme (GBM) 2016-07-07 not-yet-due
Other 2013-003205-25 A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia not-yet-due
Completed, but no date, and reported results 2013-003333-15 A 12 months, prospective, multicenter, open-label, single arm interventional study assessing the safety and tolerability of 0.5 mg ranibizumab in mono/bilateral wet AMD patients in eyes with BCVA belo... bad-data
Completed, but no date, and reported results 2013-003334-33 A 12-month, open-label, interventional, multicentre study to investigate the current criteria driving re-treatment with ranibizumab upon relapse in patients with visual impairment due to choroidal neo... bad-data
Reported results 2013-003431-29 A multicenter medical safety follow-up study for patients with partial onset seizures who received more than 28 days of total exposure to BGG492 in studies CBGG492A2207 and/or CBGG492A2212. 2015-09-21 due-trials
Reported results 2013-003434-32 A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekin... 2016-06-28 due-trials
Ongoing 2013-003439-31 A 24-week, double blind treatment and 24-week follow-up, randomised, multicenter, placebo-controlled, phase IIa/IIb study to evaluate the safety and efficacy of i.v. bimagrumab on total lean body mass... not-yet-due
Listed as ongoing, but also has a completion date 2013-003452-21 BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain 2018-02-14 bad-data
Not reported 2013-003493-27 A randomized, double-blind, placebo-controlled study to 2014-06-30 due-trials
Ongoing 2013-003583-31 Randomized, open label, multicenter phase IIIb study evaluating the efficacy and safety of ruxolitinib versus best available therapy in patients with polycythemia vera who are hydroxyurea resistant or... not-yet-due
Other 2013-003595-12 A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors not-yet-due
Other 2013-003596-35 An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subject... not-yet-due
Reported results 2013-003683-31 An open-label, multi-center, extension study to evaluate the long-term safety of subcutaneous 240mg QGE031 given every 4 weeks for 52 weeks in allergic asthma patients who completed study CQGE031B2201 2016-03-22 due-trials
Ongoing, reported early 2013-003751-38 A multicenter, open-label, randomized, 2-arm, phase II trial of pharmacodynamics, pharmacokinetics and safety of two dose regimens of DEB025/alisporivir in combination with ribavirin therapy in chro... not-yet-due
Ongoing 2013-003785-14 A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK-3475 in Subjects with Advanced Renal Cell Carcinoma not-yet-due
Ongoing 2013-003795-13 Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301 not-yet-due
Completed, report not yet due 2013-004002-25 A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in autoinjectors, to demonstrate efficacy at 24 weeks and to assess the long term safety, tolera... 2018-03-28 not-yet-due
Completed, but no date 2013-004139-62 A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of everolimus plus letrozole in the firs... bad-data
Reported results 2013-004167-32 A randomized, open-label, multicenter, two arm, phase II study to investigate the benefits of an improved deferasirox formulation (film-coated tablet) 2016-02-24 due-trials
Reported results 2013-004223-37 A randomized, multicenter, open-label, cross-over study to assess lung function and patient preference after a 4 week treatment each with QVA149 vs. tiotropium in patients with stable chronic obstruct... 2015-01-12 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-004291-35 A randomized, double-blind, placebo controlled study of canakinumab in patients with Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), with subsequent randomized withdrawal/ dosing frequency reducti... 2017-07-04 bad-data
Completed, but no date, and reported results 2013-004325-91 Multicenter, prospective, open-label, controlled, randomized, parallel groups study to evaluate the renal function of adult liver transplant recipients treated with two everolimus-based immunosuppress... bad-data
Ongoing 2013-004461-13 A randomized, double-blind, placebo-controlled, two-period crossover study to assess the effect of inhaled QVA149 on global and regional lung function and gas exchange in patients with moderate to sev... not-yet-due
Other 2013-004482-14 A phase I/II, multicenter, open-label study of EGFRmut–TKI EGF816,administered orally in adult patients with EGFRmut solid malignancies not-yet-due
Other 2013-004552-38 A Phase II, Multi-center, Open-label Study of sequential LGX818/MEK162 combination followed by a Rational Combination With targeted agents After Progression, to overcome resistance in Adult Patients W... not-yet-due
Ongoing 2013-004587-65 A phase Ib/II study of LEE011 in combination with fulvestrant and BYL719 or BKM120 in the treatment of postmenopausal women with hormone receptor positive, HER2 negative locally recurrent or advanced ... not-yet-due
Ongoing 2013-004739-55 A randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients with iron o... not-yet-due
Ongoing 2013-004766-34 A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LC... not-yet-due
Listed as ongoing, but also has a completion date 2013-004808-19 A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary Sjög... 2018-06-29 bad-data
Reported results 2013-004816-22 The ReTreatment Trial: A phase II, open-label, single-arm study of re-treating myelofibrosis patients with ruxolitinib/Jakavi after treatment interruption due to loss of response and/or adverse event 2015-02-02 due-trials
Completed, report not yet due 2013-004867-29 An open-label canakinumab (ACZ885) dose reduction or dose interval prolongation efficacy and safety study in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) 2017-09-25 not-yet-due
Completed, reported early 2013-004959-21 A phase Ib/II, multi-center, study of oral LGH447 in combination with oral BYL719 in patients with relapsed and refractory multiple myeloma 2015-10-28 not-yet-due
Not reported 2013-005014-34 A phase II, single arm, open-label, multicenter, study of oral LGX818 in patients with BRAF V600 mutant advanced non-small cell lung cancer that have progressed during or after at least one prior chem... 2014-05-12 due-trials
Ongoing 2013-005085-19 A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are int... not-yet-due
Completed, but no date 2013-005333-21 A multiple-dose, double-blind, placebo-controlled, parallel study to assess the efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis bad-data
Completed, report not yet due 2013-005540-28 A phase Ib/II, multicenter study of LJM716 in combination with cetuximab in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma 2014-07-03 not-yet-due
Reported results 2013-005573-51 A 12-week, multicenter, cross-over, placebo-controlled, double-blind study to determine the impact of QVA149 (indacaterol/glycopyrronium) 85/43 µg on nocturnal oxygen levels in Chronic Obstructive Pul... 2016-06-22 due-trials
Listed as ongoing, but also has a completion date 2013-005575-41 A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading regimen to assess efficacy, safety, and tolerab... 2018-01-02 bad-data
Reported results 2013-005576-18 A randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of CNP520 in healthy elderly subje... 2016-03-11 due-trials
Completed, reported early 2014-000316-34 A phase I/II multicenter, open-label study of CLR457 administered orally 2015-11-12 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2014-000368-17 An open label, multi-center, extension study to evaluate long-term safety and tolerability of dovitinib in patients with solid tumors, who continue to receive treatment with dovitinib (TKI258) in Nova... 2016-11-28 bad-data
Listed as ongoing, but also has a completion date 2014-000428-12 A randomized, blinded, placebo-controlled, phase II trial of LEE011 in patients with relapsed, refractory, incurable teratoma with recent progression 2018-02-21 bad-data
Ongoing 2014-000578-20 A phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) metastatic to the... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2014-000579-20 A phase Ib, open-label, multicenter, dose escalation and expansion study, to evaluate the safety, pharmacokinetics and activity of INC280 in combination with cetuximab in c-MET positive CRC and HNSCC ... 2017-01-20 bad-data
Ongoing 2014-000726-37 A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer not-yet-due
Not reported 2014-001085-10 A phase IV, prospective, open label, uncontrolled, European study in patients with neovascular age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching from intravitrea... 2017-05-31 due-trials
Completed, but no date, and reported results 2014-001182-27 A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until study ... bad-data
Reported results 2014-001204-21 An 8 week open-label interventional multicenter study to evaluate the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥ 6 years of age, chronically infected with Pseud... 2017-04-10 due-trials
Completed, but no date 2014-001220-30 An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab in C... bad-data
Ongoing 2014-001241-24 Long-term, open-label, multicenter study assessing long-term cardiovascular risks in patients treated with fingolimod not-yet-due
Listed as ongoing, but also has a completion date 2014-001309-42 An open-label, multi-center, Expanded Treatment Protocol (ETP) of ruxolitinib in patients with Polycythemia Vera who are Hydroxyurea resistant or intolerant and for whom no treatment alternatives are ... 2017-12-29 bad-data
Reported results 2014-001530-28 A randomized, double blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics and efficacy of multiple doses of QBW251 in patients with COPD. 2017-01-23 due-trials
Completed, but no date 2014-001639-35 A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until study ... bad-data
Other 2014-001673-14 Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CAR T-Cell Therapy not-yet-due
Ongoing 2014-001795-53 A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone rece... not-yet-due
Ongoing 2014-001931-36 A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the trea... not-yet-due
Completed, report not yet due 2014-001971-30 A multicenter study to evaluate safety and tolerability in patients with chronic heart failure and reduced ejection fraction from PARADIGM-HF receiving open label LCZ696 2017-12-27 not-yet-due
Completed, but no date, and reported results 2014-001974-32 A randomized, double-blind, multicenter study to assess the efficacy and safety of 16 weeks secukinumab dosage interval shortening (2-weekly 300 mg s.c.) in comparison to continued standard treatment ... bad-data
Completed, report not yet due 2014-002041-22 An Open Label Continuation Study of the Oral AKT Inhibitor 2018-06-18 not-yet-due
Ongoing 2014-002053-19 An open-label multi-part first-in-human study of oral LMI070 in infants with Type 1 spinal muscular atrophy not-yet-due
Reported results 2014-002150-39 A multi-center, randomized, double-blind, placebo controlled, study to evaluate the efficacy and safety of CSJ148 compared to placebo to prevent human cytomegalovirus (HCMV) replication in stem cell t... 2016-12-07 due-trials
Completed, but no date, and reported results 2014-002212-16 Exploratory study on the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers in patients with moderate to severe plaque-type psoriasis treated with subcutaneous secukinumab (300... bad-data
Reported results 2014-002599-95 A Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Administ... 2016-01-13 due-trials
Ongoing 2014-002630-31 A phase IIIb multicenter, open-label, single arm study to evaluate the efficacy and safety of pasireotide in patients not-yet-due
Completed, reported early 2014-002826-11 A phase Ib/II multi-center, open label, dose escalation study of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant KRAS wild-type metastatic colorectal cancer harboring Wnt pathway mutatio... 2017-07-10 not-yet-due
Other 2014-002854-37 A 12-months, randomized, VA-assessor blinded, multicenter, controlled phase IV trial to investigate non-inferiority of two treatment algorithms (discretion of the investigator vs. pro re nata) of 0.5 ... not-yet-due
Completed, but no date, and reported results 2014-002865-31 A 24-week, multicenter, proSpective, open-label stUdy to evaluate the efficacy in terms of non-inferiority with respect to PASI 90 response rate and the safety PRofile of sEcukinuMab 300 mg in Cw6-neg... bad-data
Ongoing 2014-002872-95 A French open-label extension study of canakinumab in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) who participated in the international phase III study CACZ885G2301E1 not-yet-due
Other 2014-002929-35 A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and KLB expression not-yet-due
Reported results 2014-002972-95 Phase 3b, Open label, Uncontrolled, Single-arm, Single-centre Study to Evaluate the Safety of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Healthy Adults from 18 to 50 Year... 2015-04-24 due-trials
Completed, but no date 2014-003032-39 A phase Ib/II study of the ALK inhibitor ceritinib in combination with the CDK4/6 inhibitor LEE011 in patients with ALK-positive Non-small Cell Lung Cancer bad-data
Listed as ongoing, but also has a completion date and reported results 2014-003041-10 RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of RAnibizumab compared with laser therapy for the treatment of INfants BOrn prematurely With retinopathy of prematurit... 2017-12-14 bad-data
Ongoing 2014-003060-20 A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not-yet-due
Reported results 2014-003155-57 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled study to investigate the efficacy and safety of 52 weeks treatment with QGE031 s.c. in Asthma Patients not adequately controlled by medium-... 2016-03-07 due-trials
Listed as ongoing, but also has a completion date 2014-003239-21 An open-label, multi-center, expanded treatment protocol of oral panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and relapsed and refractory multiple myeloma 2017-05-15 bad-data
Ongoing 2014-003482-25 A 28 week, randomized, double-blind, placebo-controlled, multi-center, parallel group dose range finding study to assess the effect of monthly doses of bimagrumab 70, 210, and 700 mg on skeletal muscl... not-yet-due
Ongoing 2014-003527-22 An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study and are judged by the investigator to be... not-yet-due
Other 2014-003604-75 A Phase Ib/II, open-label, multicenter study of oral HDM201 in combination with oral LEE011 in adult patients with liposarcoma not-yet-due
Listed as ongoing, but also has a completion date and reported results 2014-003613-28 A randomized, vehicle controlled, active comparator, parallel group study to evaluate safety, tolerability and preliminary efficacy of topical LFX453 formulations in patients with actinic keratosis. 2016-01-27 bad-data
Completed, but no date, and reported results 2014-003666-25 A 52-week, single-arm study to evaluate psoriasis severity and its psychosocial impact using the Simplified Psoriasis Index at 16 weeks, as well as long-term safety, tolerability and efficacy of secuk... bad-data
Other 2014-003731-20 A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult pa... not-yet-due
Listed as ongoing, but also has a completion date 2014-003849-10 A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab (150 mg) in pre-filled syringe, with or without loading regimen, to demonstrate efficacy, safety... 2017-12-19 bad-data
Ongoing 2014-003850-15 A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) not-yet-due
Other 2014-003876-22 An open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CDZ17... not-yet-due
Ongoing 2014-003929-17 Open label multicenter Phase I/II study of the safety and efficacy of PDR001 administered to patients with advanced malignancies not-yet-due
Ongoing 2014-004048-36 RAINBOW extension study: an extension study to evaluate the long term efficacy and safety of RAnibizumab compared with laser therapy for the treatment of INfants BOrn prematurely With retinopathy of p... not-yet-due
Ongoing 2014-004092-23 A Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing’s dise... not-yet-due
No trial status on register 2014-004248-36 A phase 3, Observed-Blind, Randomized, Multi-center Study to Evaluate Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico. bad-data
No trial status on register 2014-004477-16 A phase 3, multi-center, open-label study to evaluate immunogenicity and safety of Novartis Meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy subjects from 2 to 75 years of age in India. bad-data
Reported results 2014-004616-12 A randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CDZ173 in patients with primary Sjögren’s syndrome 2017-05-17 due-trials
Reported results 2014-004680-21 A randomized, double-blinded, single-center, placebo controlled, cross-over study to assess the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) on cardiac function in patients with chr... 2017-05-15 due-trials
Reported results 2014-004731-39 A randomized, double-blind, placebo controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, dose relation, pharmacokinetics and pharmacodynamics of CJM112 in moderate ... 2016-11-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-004818-28 A randomized, double-blind, parallel group, 26-week study evaluating the efficacy, safety and tolerability of NVA237 given once or twice daily, in patients with moderate and severe chronic obstructive... 2016-11-16 bad-data
Ongoing 2014-004915-35 A randomized, double blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of inhaled QBW276 in patients with cystic fibrosis not-yet-due
Listed as ongoing, but also has a completion date 2014-004928-21 A randomized, double blind, placebo-controlled, multi-center, Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations 2017-10-23 bad-data
Listed as ongoing, but also has a completion date and reported results 2014-004972-49 A randomized, open label, controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of LFG316 in patients with transplant associate... 2017-06-30 bad-data
No trial status on register 2014-005075-88 A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1Mon... bad-data
Completed, but no date, and reported results 2014-005258-20 A 24-week, randomized, controlled, multicenter, open-label study with blinded assessment of the efficacy of subcutaneous secukinumab compared to Fumaderm® in adults with moderate to severe plaque psor... bad-data
Ongoing 2014-005338-74 An open-label proof of concept study to assess the efficacy, safety and pharmacokinetics of LFG316, an anti-C5 monoclonal antibody in patients with paroxysmal nocturnal hemoglobinuria (PNH) not-yet-due
Listed as ongoing, but also has a completion date and reported results 2014-005339-15 Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 wee... 2017-05-22 bad-data
No trial status on register 2014-005392-90 A Phase IV, Open-Label, Multi-Center Study to Evaluate the Safety and the 1-year Persistence of Antibody Response Among Children Who Received 4 Doses of the Novartis MenACWY Conjugate Vaccine at 2, 4,... bad-data
Completed, but no date, and reported results 2014-005424-97 A phase IV, multicenter, single-arm and open-label study to explore the impact on quality of life of omalizumab (Xolair®) in patients with chronic spontaneous urticaria (CSU) who remain symptomatic de... bad-data
Listed as ongoing, but also has a completion date and reported results 2014-005559-16 A multicenter, randomized, double-blind, placebo and active-controlled phase 2b dose-finding study of QGE031 as add-on therapy to investigate the efficacy and safety in patients with Chronic Spontaneo... 2017-06-12 bad-data
No trial status on register 2014-005568-14 A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine... bad-data
Other 2014-005663-32 A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous secukinumab compared to placebo and etanercept (in a single blinded arm) after twel... not-yet-due
Ongoing 2015-000050-38 A Phase III, randomized, double-blind, placebo controlled multi-center study of subcutaneous secukinumab (150 mg and 300 mg) in prefilled syringe to demonstrate efficacy (including inhibition of struc... not-yet-due
Listed as ongoing, but also has a completion date 2015-000097-35 A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily evaluate the safety, tolerability, pharmacokinetics and efficacy of CFZ533 in patients with moderate... 2017-04-19 bad-data
Completed, reported early 2015-000114-22 A 26-week, randomized, double blind, parallel-group multicenter study to assess the efficacy and safety of QVA149 (110/50 ?g o.d.) vs tiotropium (18 ?g o.d.) + salmeterol/fluticasone propionate FDC (5... 2017-07-18 not-yet-due
Ongoing 2015-000179-29 A randomized phase II study of MCS110 combined with carboplatin and gemcitabine in advanced Triple Negative Breast Cancer (TNBC) not-yet-due
Ongoing 2015-000340-42 SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advan... not-yet-due
Ongoing 2015-000449-21 A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies not-yet-due
Ongoing 2015-000454-38 A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progress... not-yet-due
Ongoing 2015-000471-27 A 24 week off drug extension, parallel group, study assessing durability of effect on skeletal muscle strength not-yet-due
Not reported 2015-000590-12 A 24-month multi-center, open-label, randomized, controlled study to evaluate the evolution of renal function in maintenance liver transplant recipients receiving either RAD001 (everolimus) plus reduc... 2015-10-05 due-trials
Ongoing 2015-000617-43 MONALEESA-3: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2-ne... not-yet-due
Ongoing 2015-000814-23 A Phase II, open label, multi-center, multi-arm study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of anaplastic lymphoma k... not-yet-due
Completed, report not yet due 2015-000925-36 A 12-month randomized, multiple dose, open-label, study evaluating safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of an anti-CD40 monoclonal antibody, CFZ533, in combinat... 2017-11-29 not-yet-due
Ongoing 2015-000968-34 A Phase IV single arm, multicenter, open-label study assessing deep molecular response in adult patients with newly diagnosed Philadelphia chromosome positive CML in chronic phase after two years of t... not-yet-due
Ongoing 2015-001106-33 A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active non-radiographic axial spondyloa... not-yet-due
Ongoing 2015-001241-84 A phase Ib/II, open-label, multicenter trial with oral cMET inhibitor INC280 alone and in combination with erlotinib versus platinum/pemetrexed in adult patients with EGFR mutated, cMET-amplified, loc... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2015-001411-12 Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tolerability of intravenous BYM338 in patients with sporadic inclusion body myositis 2017-02-13 bad-data
Ongoing 2015-001564-19 A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethaso... not-yet-due
Ongoing 2015-001590-41 A multi-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and efficacy of tropifexor (LJN452) in patients with primary biliary cholangitis not-yet-due
Completed, reported early 2015-001890-42 A randomized, sponsor open, site and subject double-blind, parallel group, placebo-controlled study to evaluate the safety and efficacy of LHW090 after 4 weeks treatment in patients with resistant hyp... 2018-08-17 not-yet-due
Ongoing 2015-001922-40 An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investiga... not-yet-due
Ongoing 2015-002354-12 A phase I-Ib/II, open-label, multi-center study of the safety and efficacy of MBG453 as single agent and in combination with PDR001 in adult patients with advanced malignancies not-yet-due
Ongoing 2015-002394-38 A 52-week, multicenter study to assess the time course of response to secukinumab on joint inflammation using Power Doppler ultrasonography in patients with active psoriatic arthritis not-yet-due
Ongoing 2015-002423-26 A randomized, multicenter Study to evaluate the Effect of secukinumab 300 mg s.c. administered during 52 Weeks to patients suffering from new-onset moderate to severe plaque Psoriasis as early Interve... not-yet-due
Other 2015-002529-21 AA multicenter randomized 52 week treatment double-blind, triple dummy parallel group study to assess the efficacy and safety of QMF149 compared to mometasone furoate in patients with asthma not-yet-due
Ongoing 2015-002553-35 A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma... not-yet-due
Ongoing, reported early 2015-002673-38 A multicenter, randomized, double-blind, crossover placebo-controlled Phase II study to assess the effect of serelaxin versus placebo on high sensitivity cardiac troponin I (hs-cTnI) release in patien... not-yet-due
Ongoing 2015-002715-15 A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s ... not-yet-due
Listed as ongoing, but also has a completion date 2015-002898-37 A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 we... 2018-07-09 bad-data
Ongoing 2015-002899-25 A multicenter, randomized, 52-week, double-blind, parallelgroup, active controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthma not-yet-due
Completed, but no date 2015-003008-22 A Phase III, Randomized, Single Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Administer... bad-data
Ongoing 2015-003040-39 A randomized, blinded, parallel group, multi-center dose-finding study, to assess the efficacy, safety and tolerability of different doses of tobramycin inhalation powder in patients with Non-Cystic F... not-yet-due
Other 2015-003166-91 A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapse... not-yet-due
Ongoing 2015-003172-67 A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma... not-yet-due
Ongoing 2015-003192-30 A double blind, randomized placebo controlled crossover multiple dose not-yet-due
Listed as ongoing, but also has a completion date 2015-003266-87 A multicenter, randomized, open label, parallel group study comparing pre-discharge and posT-discharge tReatment initiation with LCZ696 in heArt failure patieNtS with reduced ejectIon-fracTion hospIta... 2018-06-20 bad-data
No trial status on register 2015-003490-15 An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Peri... bad-data
No trial status on register 2015-003491-69 An Open Label Study to Assess the Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada bad-data
No trial status on register 2015-003522-13 A 6 Month Phase 2, Multi-Center, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Treatment With Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant... bad-data
No trial status on register 2015-003527-57 An Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever bad-data
No trial status on register 2015-003528-29 A Multicenter, Open-label, Randomized, Two Arm Study to Investigate the Efficacy and Safety of a Therapy Avoiding Intraoperative Steroids in Combination With Basiliximab, Cyclosporine/Cyclosporine Mic... bad-data
No trial status on register 2015-003531-35 1 Year, Open-label Multicenter Evaluation of Efficacy, Safety of Deferasirox in Patients MDS, Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. bad-data
No trial status on register 2015-003532-12 An Open Label Trial Evaluating Cardiac T2* in Beta-thalassemia Patients on Deferasirox (ICL670) Treatment for 18 Months bad-data
No trial status on register 2015-003533-10 A Randomized, Open-label, Multicenter Study to Evaluate the Effect of Xolair (Omalizumab) as Add-on Therapy to Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing Compared to... bad-data
No trial status on register 2015-003534-27 A 24 Week, Open Label, Multi-center Evaluation of Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Ast... bad-data
No trial status on register 2015-003535-35 A 4-year Extension to a Phase II a Multicenter Study Evaluating Long-term Safety, Tolerability, Pharmacokinetics and Effects on Liver Iron Concentration of Repeated Doses of 10 mg/kg/Day of Deferasiro... bad-data
No trial status on register 2015-003536-12 An Extension Study to CIGE025B1301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite Cu... bad-data
No trial status on register 2015-003538-28 A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years) Wi... bad-data
No trial status on register 2015-003539-37 An international, multicenter, randomized, open-label, parallel efficacy, and safety trial of intravenous zoledronic acid compared to intravenous pamidronate in children with severe osteogenesis imper... bad-data
Ongoing 2015-003614-24 A phase I dose finding study of oral LTT462 in adult patients with advanced solid tumors harboring MAPK pathway alterations not-yet-due
Ongoing 2015-003636-13 An open label, multicenter, extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria patients who completed study CQGE03... not-yet-due
Completed, report not yet due 2015-003701-42 An open-label, prospective, non-randomized, multicenter study to evaluate clear skin effect on health related quality of life outcomes at 16 and 52 weeks in patients with moderate to severe plaque pso... 2018-03-28 not-yet-due
No trial status on register 2015-003736-13 A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia bad-data
Not reported 2015-003763-11 A 12-week, open-label, parallel-cohort study to evaluate the efficacy, safety and tolerability of canakinumab in pediatric IVIG-naïve or refractory patients with active Kawasaki disease 2017-01-26 due-trials
Completed, but no date, and reported results 2015-003775-30 A phase II pilot study to assess the presence of molecular factors predictive for hematologic response in myelodysplastic syndrome patients receiving deferasirox therapy in hematological centers in Be... bad-data
Other 2015-004015-20 Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or rela... not-yet-due
Ongoing 2015-004206-42 A Phase I/Ib open-label, multi-center, dose escalation study of GWN323 (anti-GITR) as a single agent and in combination with PDR001 (anti-PD-1) in patients with advanced solid tumors and lymphomas not-yet-due
Other 2015-004207-22 Multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled stud... not-yet-due
Ongoing 2015-004436-34 A Multicenter, Placebo-Controlled, Single Dose Study in Acute Episodic and Chronic Cluster Headache to Evaluate the Safety and Efficacy of SOM230 subcutaneous (s.c.) not-yet-due
Not reported 2015-004440-19 A 30-month multicenter, phase 2b/3, randomized, open label trial to evaluate the efficacy and safety of clofazimine administered orally in addition to background regimen compared to background regimen... 2016-12-23 due-trials
No trial status on register 2015-004441-17 A Multicenter, Open-label, Single-arm, Two-step Study to Evaluate the Safety and Single-dose Pharmacokinetics of Famciclovir and Multiple-dose Safety After Administration of Famciclovir Oral Pediatric... bad-data
No trial status on register 2015-004442-25 A multicenter, open-label, single-arm, two-step study to evaluate the safety and single-dose pharmacokinetics of famciclovir and multiple-dose safety after administration of famciclovir oral pediatric... bad-data
No trial status on register 2015-004443-40 A Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis bad-data
No trial status on register 2015-004444-19 An open-label, behavioral-treatment-controlled evaluation of the effects of extended release methylphenidate (Ritalin® LA) on the frequency of cytogenetic abnormalities in children 6 - 12 years of age... bad-data
No trial status on register 2015-004445-10 A Multicenter, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Valsartan in Japanese Pediatric Patients 6 to 14 Years of Age. bad-data
No trial status on register 2015-004461-85 A cluster randomized, single-centre, controlled, parallel,12-month prospective study and additional 12-month follow-up in Africa of malaria incidence in a community setting following systematic treatm... bad-data
No trial status on register 2015-004464-11 Randomized, Double Blind, Double Dummy, Placebo Controlled Trial to Compare the Effectiveness of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Asthmatic Children (5-<12 Years) With Acute Bronchi... bad-data
No trial status on register 2015-004465-87 A 24-week Prospective Open-label Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures bad-data
Ongoing 2015-004477-32 A randomized, double-blind, active control, multicenter study to evaluate the efficacy at week 52 of subcutaneously administered secukinumab monotherapy compared with subcutaneously administered adali... not-yet-due
No trial status on register 2015-004484-37 A Multicentre, Randomized, Double-blind, Placebo Controlled, Parallel-group Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Efficacy, Safety and Tolerability of TR... bad-data
Ongoing 2015-004570-15 A two part randomized, double-blind, parallel-group, placebo-controlled study to evaluate the renal safety, tolerability and pharmacokinetics of LHW090 in patients with moderately impaired renal funct... not-yet-due
Ongoing 2015-004575-74 A randomized, double-blind, placebo-controlled multicenter study of Secukinumab (AIN457) to examine the clinical efficacy and the NSAID-sparing effect of Secukinumab over 16 weeks in patients with ank... not-yet-due
Ongoing 2015-004620-60 A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and not-yet-due
Ongoing 2015-004632-35 A randomized, double-blind, active-controlled study to assess the effect of LCZ696 compared with enalapril to improve exercise capacity in patients with heart failure with reduced ejection fraction (H... not-yet-due
Ongoing 2015-005019-34 A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors not-yet-due
Ongoing 2015-005021-39 A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab in prefilled syringes, to compare efficacy at 16 weeks with placebo and to assess safety and tol... not-yet-due
Listed as ongoing, but also has a completion date 2015-005170-38 A multicenter, randomized, double-blind, placebo-controlled, 52-weeks study to demonstrate the efficacy, safety and tolerability of subcutaneous secukinumAb injections with 2 mL pre-fiLLed syringes (3... 2018-06-08 bad-data
Ongoing 2015-005215-33 A randomized, double-blind, placebo controlled, 2- part, adaptive design, multicenter 12-week study to assess safety, tolerability and efficacy of LJN452 in patients with non-alcoholic steatohepatitis... not-yet-due
Ongoing 2015-005417-76 A phase Ib/II, open-label, multi-center study of INC280 in combination with PDR001 or PDR001 single agent in advanced hepatocellular carcinoma not-yet-due
Ongoing 2015-005418-31 A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis not-yet-due
Ongoing 2015-005419-33 A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis not-yet-due
Reported results 2015-005564-41 An open label study to evaluate the safety and efficacy of 12 week treatment with CFZ533 in patients with Graves' 2017-04-24 due-trials
Completed, report not yet due 2015-005565-23 A multicenter, randomized, double-blind, placebo-controlled 3-period complete cross-over study to assess the bronchodilator effects and safety of glycopyrronium bromide (NVA237) (25 µg and 50 µg o.d.)... 2017-12-29 not-yet-due
Ongoing 2015-005738-23 A phase II, patient and investigator-blinded, randomized, placebo-controlled study to evaluate efficacy, safety and tolerability of BAF312 in patients with stroke due to intracerebral hemorrhage (ICH) not-yet-due
Ongoing 2015-005806-12 A phase I/II, open-label, multi-center study of the safety and efficacy of BLZ945 as single agent and in combination with PDR001 in adults patients with advanced solid tumors not-yet-due
Ongoing 2016-000186-23 Open-label, multicenter, single arm, phase III study to collect additional safety and efficacy data with deferasirox film-coated tablets in patients completing study CICL670F2201 not-yet-due
Ongoing 2016-000210-29 A Phase Ib/II, open label, multicenter study of MCS110 in combination with PDR001 in patients with advanced malignancies not-yet-due
No trial status on register 2016-000246-62 A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients With Haemoglobinopathies, Myelodysplastic Syndromes (MDS) or Other Anaemias Treated With Exjade® (Deferasiro... bad-data
No trial status on register 2016-000248-32 A randomized, open-label, single center, phase I, cross-over study to evaluate the pharmacokinetic comparability of deferasirox new tablet formulation with the reference dispersible formulation in hea... bad-data
Ongoing 2016-000280-16 A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with ... not-yet-due
Ongoing 2016-000281-39 A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 in reducing 24-hour average pain intensity score in patients with painful diabetic neuropathy (EMPAD... not-yet-due
Ongoing 2016-000293-37 An open-label, multi-center rollover protocol for patients not-yet-due
No trial status on register 2016-000307-93 A randomized, open label, single center, phase I, two way, cross-over study to evaluate the pharmacokinetic comparability of deferasirox new granule formulation with the reference dispersible formulat... bad-data
No trial status on register 2016-000308-28 A randomized, open label, six sequences, cross-over study in healthy Japanese subjects to evaluate the pharmacokinetic comparability of deferasirox granule formulation with the reference dispersible t... bad-data
Completed, report not yet due 2016-000404-28 5, 6 or 7 year follow-up control after the SCHEDULE study (SCANDINAVIAN HEART TRANSPLANT EVEROLIMUS DE NOVO STUDY WITH EARLY CNI AVOIDANCE) (Protocol: CRAD001ANO02, EudraCT no.: 2009-013074-41) 2017-09-25 not-yet-due
Other 2016-000468-41 An open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 in patients with APDS/PASLI (Activated Phosphoinositide 3-kinase D... not-yet-due
Ongoing 2016-000472-22 A multi-center, randomized, 12-week treatment, double blind study to assess the efficacy and safety of QMF149 (150/80 microgram) compared with MF Twisthaler® (200 microgram) in adult and adolescent pa... not-yet-due
Completed, report not yet due 2016-000473-20 A prospective evaluation of natriuretic peptide based referral of CHF patients in primary care 2018-03-16 not-yet-due
Ongoing 2016-000524-25 A randomized, double-blind, placebo controlled, not-yet-due
Ongoing 2016-000814-31 MAXIMISE (Managing AXIal Manifestations in Psoriatic Arthritis with SEcukinumab), a randomized, double-blind, placebo-controlled, multicenter, 52 week study to assess the efficacy and safety of secuki... not-yet-due
Ongoing 2016-000972-91 A randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab to demonstrate efficacy in the treatment of enthesitis at the Achilles tendon up to 1 year in adult patient... not-yet-due
Ongoing 2016-001254-17 A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejec... not-yet-due
Ongoing 2016-001255-49 A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety, and tolerability of ACZ885 (canakinumab) in patients with pulmonary sarcoi... not-yet-due
Ongoing 2016-001387-12 A randomized, subject and investigator-blind, placebo-controlled study of CLR325 in chronic stable heart failure patients. not-yet-due
Ongoing 2016-001411-20 Long-term, open label, multicenter, extension study to evaluate the safety and tolerability of QCC374 in patients with PAH not-yet-due
No trial status on register 2016-001444-20 An Open-label, Single-arm, Multicenter, Phase IV, 52-week Study to Evaluate the Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients with Chronic Hepatitis B bad-data
Other 2016-001560-11 A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncon... not-yet-due
No trial status on register 2016-001561-88 A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation bad-data
No trial status on register 2016-001563-36 A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1) bad-data
Ongoing 2016-001671-79 A randomized, multicenter 28 week study to compare the efficacy and safety of combining Cosentyx (Secukinumab) (4-weekly, 300 mg s.c.) with a lifestyle intervention to Cosentyx therapy alone in adult ... not-yet-due
No trial status on register 2016-001840-20 A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using ... bad-data
Ongoing 2016-001860-12 A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies not-yet-due
Other 2016-001991-31 Expanded treatment protocol for relapsed/refractory pediatric/young adult acute lymphoblastic leukemia patients to be treated with CTL019. not-yet-due
Other 2016-002101-19 A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety and tolerability of ACZ885 (canakinumab) in pediatric and young adult patie... not-yet-due
Ongoing 2016-002113-21 A multicenter, randomized, double-blind, active-controlled, 2 week treatment, parallel-group study to assess the efficacy and safety of indacaterol acetate delivered via the Concept1 inhalation device... not-yet-due
Ongoing 2016-002154-20 A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk pat... not-yet-due
Ongoing 2016-002211-18 A 12-week double-blind, randomized, multicenter study comparing the efficacy and safety of once monthly subcutaneous 140 mg AMG 334 against placebo in adult episodic migraine patients who have failed ... not-yet-due
No trial status on register 2016-002273-35 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomati... bad-data
No trial status on register 2016-002282-61 Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet (Jupiter) bad-data
Ongoing 2016-002461-66 A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosin... not-yet-due
Ongoing 2016-002492-95 A randomized, subject and investigator blinded, placebo controlled, multi-center study in parallel groups to assess the efficacy and safety of CJM112 in patients with moderate to severe inflammatory a... not-yet-due
Ongoing 2016-002522-36 An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoraci... not-yet-due
Ongoing 2016-002529-12 A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis not-yet-due
Ongoing 2016-002556-24 A national phase IIIb, multi-center, open label study for women and men with hormone-receptor positive, HER2-negative locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in c... not-yet-due
No trial status on register 2016-002583-14 A Randomized, Open-label, Multi-center, Phase II Study to Evaluate the Safety and Efficacy of Deferasirox (ICL670) 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients Wi... bad-data
Ongoing 2016-002584-33 A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transpl... not-yet-due
Ongoing 2016-002794-35 A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patient... not-yet-due
Ongoing 2016-002814-29 SOAR Trial, A two-part study: Interventional phase II single-arm trial to assess efficacy and safety of Eltrombopag combined with cyclosporine as first line therapy in patients with severe acquired ap... not-yet-due
Ongoing 2016-002833-31 A randomized, patient and investigator blinded, placebo-controlled, multicenter study to assess the safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with non-alcoholic steatoh... not-yet-due
Ongoing 2016-002868-14 A randomized, double-blind, dose-finding study to evaluate the change in weight after 24 weeks treatment with 8 doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks ... not-yet-due
Ongoing 2016-002976-28 A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease (AD... not-yet-due
Ongoing 2016-002977-37 An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the Investigator to benefit from continued trea... not-yet-due
Listed as ongoing, but also has a completion date 2016-003084-19 A multi-center, randomized, double-blind, parallel-group dose-finding study to assess the effect of 3 doses of LIK066 compared to placebo or empagliflozin in type 2 diabetes mellitus patients with hea... 2018-06-06 bad-data
Completed, report not yet due 2016-003085-32 A multi-center, prospective, randomized, double-blind study to assess the impact of sacubitril/valsartan vs. enalapril on daily physical activity using a wrist worn actigraphy device in adult chronic ... 2018-04-11 not-yet-due
Ongoing 2016-003292-22 A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of ianalumab doses administered subcutaneously in patients with moderate to seve... not-yet-due
Ongoing 2016-003410-28 A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individuali... not-yet-due
Ongoing 2016-003418-28 A randomized, placebo-controlled, patient and investigator blinded, single dose, Proof of Concept study investigating the safety, tolerability and preliminary efficacy of intra-articular LNA043 in reg... not-yet-due
Ongoing 2016-003467-19 COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women wit... not-yet-due
Ongoing 2016-003552-75 A multicenter phase II, open label, single arm study to evaluate the efficacy and safety of ruxolitinib in the treatment of anemic myelofibrosis patients not-yet-due
Ongoing 2016-003592-21 Evaluation of the eFfect of early Initiation of secukinumab in systemic treatment-naïve patients with moderate to severe plaque psoriasis Requiring Systemic Treatment (FIRST) not-yet-due
Ongoing 2016-003761-26 A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis-re... not-yet-due
Ongoing 2016-004052-30 A randomized, placebo-controlled, patient and investigator blinded, Proof of Concept study investigating the safety, tolerability and preliminary efficacy of multiple intra-articular LNA043 injections... not-yet-due
No trial status on register 2016-004315-13 Multicentric, Open-label, Randomized, Parallel-group Study to Evaluate the Efficacy and Safety of Omalizumab in a 12-MonthPeriod, in Patients with Severe IgE-mediated Asthma Inadequately Controlled wi... bad-data
No trial status on register 2016-004318-82 Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles bad-data
No trial status on register 2016-004321-16 A study of the effects of Coartem, Malarone and artesunate-mefloquine on auditory function in patients 12 years of age or older with acute uncomplicated P. falciparum malaria bad-data
No trial status on register 2016-004322-42 Efficacy and safety of long-term treatment with ICL670 in beta-thalassemia patients with transfusional hemosiderosis bad-data
No trial status on register 2016-004323-23 An open-label, randomized, single dose, two period, crossover study to determine the bioequivalence between valsartan 160 mg pediatric final market image (FMI) formulation (solution) and clinical serv... bad-data
Other 2016-004432-38 A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogeneic stem cell t... not-yet-due
Ongoing 2016-004440-12 An open-label, multi–center, Phase IIIb study to assess the safety and efficacy of midostaurin (PKC412) in patients 18 years of age or older with newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (A... not-yet-due
Ongoing 2016-004586-67 A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR)... not-yet-due
Ongoing 2016-005144-42 An open-label, multi-center, long-term safety follow-up, roll-over study in patients who have completed a prior Novartis-sponsored capmatinib (INC280) study and are judged by the investigator to benef... not-yet-due
Ongoing 2016-005164-34 A randomized, double-blind, double dummy, active-controlled, 3-period complete cross-over study to assess the bronchodilator effect and safety of two doses of QVM149 compared to a fixed dose combinati... not-yet-due
Ongoing 2017-000136-34 A multicenter, partially-blinded, randomized, 24-week, parallel-group, non-inferiority, open-label active controlled study to compare the efficacy and safety of QVM149 with a free triple combination o... not-yet-due
Ongoing 2017-000205-21 A randomized, subject- and investigator-blinded, placebo-controlled, multi-center, multiple dose study to assess the efficacy and safety of CJM112 in patients with inadequately controlled moderate to ... not-yet-due
Other 2017-000241-49 A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma not-yet-due
Ongoing 2017-000401-21 SKIPPAIN (Speed of onset of SecuKinumab-Induced relief from Pain in Patients with Axial SpoNdyloarthritis) not-yet-due
Completed, report not yet due 2017-000644-17 A randomized, double-blind, repeat dose cross-over study to assess the bronchodilator effects of once daily QVM149 following morning or evening dosing for 14 days compared to placebo in patients with ... 2018-02-24 not-yet-due
Ongoing 2017-000679-10 A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to asses... not-yet-due
Ongoing 2017-000706-37 A Patient and Investigator-blinded, randomized, placebo controlled study of LLG783 in patients with peripheral artery disease (PAD) and intermittent claudication. not-yet-due
Ongoing 2017-000708-10 A prospective international multicenter phase II study to evaluate the efficacy, safety and quality of life of oral daily pazopanib in patients with advanced and/or metastatic renal cell carcinoma aft... not-yet-due
Ongoing 2017-000736-33 A randomized, subject and investigator blinded, placebo-controlled, parallel group study to investigate whether AFQ056 reduces cocaine use in patients diagnosed with Cocaine Use Disorder (CUD). not-yet-due
Ongoing 2017-000888-33 An open label, single arm, multiple dose study to assess efficacy, safety, pharmacokinetics and pharmacodynamics of LNP023 when administered in addition to Standard of Care (SoC) in patients with paro... not-yet-due
Ongoing 2017-000891-27 An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients not-yet-due
Ongoing 2017-001272-40 A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthm... not-yet-due
Other 2017-001273-16 A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthm... not-yet-due
Ongoing 2017-001555-32 A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete res... not-yet-due
Ongoing 2017-001593-42 A 24-week randomized, multicenter, single blinded, international not-yet-due
No trial status on register 2017-001678-40 An extension study of safety of canakinumab in Japanese patients with periodic fever syndromes bad-data
No trial status on register 2017-001765-25 An Investigation of the Safety and Efficacy of Elidel® 1% Cream in Atopic Disease Modification, Assessed in a 3-year Randomized Doubleblind Vehicle Controlled Phase to Evaluate Effects on Atopic Derma... bad-data
No trial status on register 2017-001766-25 An open label, 52 week, multicenter study, of long term management to evaluate effectiveness, tolerability and safety of pimecrolimus cream 1% in pediatric patients with mild to moderate atopic dermat... bad-data
No trial status on register 2017-001799-41 A 26-week randomized, double-blind, placebo-controlled, multi-center study to evaluate the effect of omalizumab on markers of asthma impairment in patients with persistent allergic asthma bad-data
No trial status on register 2017-001803-57 A randomized, study in healthy subjects to determine the bioavailability of 200 mg LCZ696 mini-tablet compared to the 200 mg LCZ696 final market image tablet bad-data
No trial status on register 2017-001804-31 Ph3 trial of Glivec in CML-CP patients previously untreated with IFN-alfa bad-data
No trial status on register 2017-001805-34 Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia bad-data
Ongoing 2017-001987-39 An open label, multi-center roll-over study to assess long-term safety in patients who are ongoing or have completed a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (tra... not-yet-due
Ongoing 2017-002046-71 A 12-week randomized, patient and investigator blinded, placebo-controlled, parallel group study to investigate the efficacy of LIK066 in obese patients with non-alcoholic steatohepatitis (NASH) not-yet-due
Ongoing 2017-002113-64 Controlled trial on the short-term effects of sacubitril/valsartan therapy on cardiac oxygen consumption and efficiency of cardiac work in patients with NYHA II-III heart failure and reduced systolic ... not-yet-due
Ongoing 2017-002176-75 A randomized, double blind, placebo controlled multicenter dose ranging study to assess the safety and efficacy of multiple oral ZPL389 doses in patients with moderate to severe Atopic Dermatitis (ZES... not-yet-due
Ongoing 2017-002292-26 A randomized, controlled, evaluator-blinded, multicenter, study to evaluate LYS228 pharmacokinetics, clinical response, safety and tolerability in patients with complicated urinary tract infection not-yet-due
Listed as ongoing, but also has a completion date 2017-002741-29 A multicenter, randomized, open-label, active-controlled, dose-range finding study to assess the pharmacodynamic parameters, safety and tolerability of MAA868 and its effect on thrombogenesis biomarke... 2018-07-25 bad-data
Ongoing 2017-002840-34 An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are... not-yet-due
Completed, report not yet due 2017-002925-39 A multicenter, randomized, open-label, blinded endpoint evaluation, active-controlled Phase 2 study to compare the efficacy and safety of s.c. MAA868 versus s.c. enoxaparin in adult patients undergoin... 2018-07-09 not-yet-due
Ongoing 2017-003099-30 A randomized, double-blind, placebo-controlled, parallel group, Phase II, 24-week study investigating the efficacy, safety and tolerability of AIN457 in patients with active overuse tendinopathy refra... not-yet-due
Ongoing 2017-003230-93 A randomized, placebo-controlled, patient and investigator blinded study investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of multiple doses of CFZ533 in patients with ... not-yet-due
Ongoing 2017-003540-21 A phase III, randomized, double-blind study of chemotherapy with daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation plus midostaurin (PKC412) o... not-yet-due
Ongoing 2017-003607-22 A 12 month, partially-blinded, active-controlled, multicenter, not-yet-due
Ongoing 2017-003960-11 A Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabet... not-yet-due
Completed, but no date 2017-003998-34 A Randomized, Open-label, Phase III Study of single agent Nazartinib Versus Investigator’s choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients with locally advanced or metastatic Non-S... bad-data
Ongoing 2017-004011-39 A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UIC... not-yet-due
No trial status on register 2017-004082-27 An extension study of eltrombopag in pediatric patients with chronic immune (idiopathic) thrombocytopenia purpura (ITP) bad-data
Other 2017-004207-52 A multicenter, randomized, double-blind, placebo-controlled phase 2b dose-finding study to investigate the efficacy and safety of ligelizumab (QGE031) in adolescent patients with Chronic Spontaneous U... not-yet-due
Ongoing 2017-004742-23 A Two-Year, Three-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diab... not-yet-due
Ongoing 2017-004865-28 A phase II open-label, randomized, three-arm, multicenter study of LAG525 given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or seco... not-yet-due
Ongoing 2018-000168-27 Open-label, phase IIIb study of dabrafenib in COMBInation with trametinib in the Adjuvant treatment of stage III BRAF V600 mutation-positive melanoma after complete resection to evaluate the impact on... not-yet-due
No trial status on register 2018-000422-55 A Phase I/II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric patients with grade II-IV acute graft vs. host disease after allogeneic hematopoietic stem ... bad-data